The genetic and functional basis of three inherited cutaneous and gastrointestinal diseases in humans by Brooke, Matthew A
The genetic and functional basis of three inherited cutaneous and
gastrointestinal diseases in humans
Brooke, Matthew A
 
 
 
 
 
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/7932
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
 1 
 
 
The genetic and functional 
basis of three inherited 
cutaneous and gastro-
intestinal diseases in humans 
 
Matthew A. Brooke 
 
 
Supervisor: Professor David Kelsell 
 
A Thesis submitted for the degree of PhD 
 
 
Centre for Cutaneous Research, Blizard Institute  
Barts & The London School of Medicine & Dentistry,  
Queen Mary, University of London 
  
 2 
 
 
 
I, Matthew Alexander Brooke, hereby declare that the work presented in this 
thesis is my own, unless otherwise stated, and is in accordance with the University 
of London’s regulations for the degree of PhD 
 
 
 
 
Matthew Alexander Brooke 
  
 3 
 
Abstract 
 
This thesis describes investigations into the genetic basis and pathophysiology of three 
distinct inherited diseases in humans, two of which are strongly associated to the function of 
the ectodomain sheddase enzyme ADAM17.  
The first of these is a novel inherited syndrome of neonatal onset inflammatory skin and 
bowel disease, which is associated in a consanguineous family with homozygous loss-of-
function mutations in ADAM17. This thesis describes investigations of the expression and 
function of ADAM17 – and downstream proteins it regulates – in an individual affected by 
this disease. This is accompanied by genetic investigations into other individuals suspected of 
suffering from the same syndrome. 
The second investigated disease is Tylosis with Oesophageal Cancer (TOC), an inherited 
cutaneous disease which represents the only known syndrome of familial oesophageal 
cancer susceptibility. This disease was associated to dominantly inherited mutations in the 
Rhomboid protein iRHOM2. This work describes investigations of immortalised keratinocyte 
cell lines and tissues derived from TOC-affected individuals, and illustrates that the 
pathogenesis of TOC is characterised by increased iRHOM2-dependent activation and activity 
of ADAM17, and upregulation of the shedding of ADAM17 substrates, particularly in the 
EGFR ligand family, accompanied by increased desmosome turnover and transglutaminase 1 
activity. This pattern of upregulation results in attendant increases in growth factor 
signalling, proliferation and motility in TOC keratinocytes, dependent on ADAM17.  
The third focus of this thesis is a life-threatening inherited gastrointestinal disease 
(accompanied by severe extraintestinal complications) whose symptoms correspond to 
Cryptogenic Multifocal Ulcerative Stenosing Enteritis. This work describes the identification 
of mutations in cytosolic phospholipase A2-α (cPLA2α) – an enzyme responsible for 
arachidonic acid production, the first step in the eicosanoid synthesis pathway – as 
associated with this condition in a single affected family. The expression and function of 
cPLA2α in this disease was investigated, using platelet aggregation stimulated by a 
downstream product of cPLA2α (Thromboxane A2) as a model. 
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1. Introduction 
This thesis will focus on understanding the pathophysiology of three distinct, rare, inherited 
conditions, which affect the skin and the epithelium of the gastrointestinal tract. The genes 
affected in each of these three conditions encode proteins involved either directly or 
indirectly in the generation of soluble mediators that play key roles in intercellular 
communication.  
Intercellular communication is a hallmark of and requirement for the maintenance of 
multicellular life. In addition to nervous transmission over long distances, and direct cell-cell 
interactions mediated by intercellular junction complexes, much intercellular communication 
is facilitated by the release, detection of, and response to a vast array of cell-derived soluble 
mediators. These include broad families of molecules such as growth factors, cytokines, 
chemokines and hormones, which can be small-molecular, peptide, lipid or phospholipid in 
nature, and have been shown to regulate vast numbers of diverse processes required for 
multicellular life. Due to the importance of these various intercellular mediators, regulation 
of their release can be considered to be of the utmost importance to the control of 
metabolism. As illustrated by the three conditions examined in this thesis, perturbation of 
physiological processes involved in the synthesis and release of these extracellular mediators 
can have wide-ranging effects on human health. 
To provide the necessary background for the results that will be presented in later chapters, 
this introduction will describe the structure of the skin and gastrointestinal epithelium, the 
importance of intercellular signalling pathways, the structures and functions of proteins 
involved in the regulation of various relevant intercellular signalling pathways, the 
importance of these pathways in epithelial development and homeostasis, and genetic 
techniques for investigating inherited diseases of the skin and gastrointestinal tract.  
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1.1 The skin and gastrointestinal tract, and EGFR signalling 
1.1.1 The epidermis 
The skin is the largest organ in the body; covering almost the entirety of the outer surface of 
the human body, it provides an essential defensive layer, protecting against physical and 
chemical damage, infectious agents and allergens. Beyond its protective role, the skin has 
other important functions in preventing water loss and regulating body temperature. On a 
gross scale, the skin is made up of three broad layers: the outermost is the epidermis, below 
which lies the dermis, with subcutaneous tissue (the hypodermis) below that.  
The epidermis represents the outermost layer of the skin, and consists of a specialised, multi-
layered stratified epithelium. It is made up primarily of specialised epidermal cells called 
keratinocytes, which are organised into defined basal, spinous and granular layers, topped by 
an outermost cornified layer (the stratum corneum), which provides the specific epidermal 
barrier function (Madison, 2003). The general structure of the epidermis is illustrated in 
figure 1.1. Keratinocytes in the epidermis are accompanied by three other cells types: 
pigment-producing melanocytes; Merkel cells, which have a role in mechanoreception; and 
Langerhans cells, which have an immune function and act as antigen-presenting cells.  
Proliferation of keratinocytes in the epidermis occurs exclusively predominantly in the basal 
layer, where epidermal stem cells reside. Here, stem cells give rise to a population known as 
transit-amplifying cells, which can in turn proliferate to give rise to daughter cells that can 
exit the cell cycle and begin the process of terminal differentiation (Jensen et alet al., 1999). 
Keratinocytes differentiate following a set pattern as they rise through the different 
epidermal layers, maturing eventually into corneocytes – the flattened, dead cells of the 
stratum corneum, whose plasma membrane has been entirely replaced by an insoluble 
cornified envelope (Proksch et alet al., 2008). In the uppermost skin layer, corneocytes are 
surrounded by an extracellular lipid matrix – roughly comprised (by weight) of around 45-
50% ceramides, 25% cholesterol, 10-15% free fatty acids and 5% other lipids  (Madison, 
2003) – which form the permeability barrier that characterises the stratum corneum. The 
lipids that make up the permeability barrier originate from lamellar granules, tiny 
membrane-bound organelles (visible only through electron microscopy) that are prominent 
 22 
 
in the granular layer of the epidermis. These fuse with the plasma membrane of 
keratinocytes late in the process of terminal differentiation, discharging their lipid contents 
into the extracellular space (Madison, 2003).  
 
Figure 1.1: The structure of the epidermis. An illustration of the organisation of the interfollicular 
epidermis, showing the major keratinocyte layers.  
 
The formation of the stratum corneum represents perhaps the most important stage in the 
formation of an effective epidermal barrier. Key to this process is the formation of the 
cornified envelope, an insoluble protein structure which replaces the plasma membrane of 
terminally differentiating keratinocytes, and facilitates the attachment of insoluble lipids 
during stratum corneum formation. Important in this process are the transglutaminase 
(TGM) enzymes TGM1 and TGM3, which function to cross-link structural component proteins 
of the cornified envelope (Franzke et alet al., 2012), such as, involucrin, loricrin, small 
proline-rich proteins and filaggrin (Hitomi, 2005), the last of which is also involved in 
aggregating keratinocytes’ keratin filaments into bundles, facilitating the collapse of the cell 
into its flattened corneocyte shape (Palmer et alet al., 2006). TGM1 has also been shown to 
be important in forming an ester link between involucrin (present in the cornified envelope) 
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and extracellular long-chain hydroxyceramides that make up part of the extracellular lipid 
matrix of the stratum corneum (Nemes et alet al., 1999).   
 
 
1.1.2 The small intestinal epithelium 
In contrast to the highly stratified nature of the epidermis, the lumen of the gastrointestinal 
tract is lined by a specialised simple columnar epithelium only one cell thick, whose primary 
role is the absorption and digestion of nutrients, as well as in protection from intestinal 
pathogens. This epithelium is characterised by a very high level of turnover, and has been 
described as the most vigorously self-renewing tissue in the adult human body (van der Flier 
and Clevers, 2009).  
As it is not stratified, proliferation and migration of cells in the gut epithelium is 
fundamentally different from that seen in the skin. The luminal surface of the intestine is 
organised into large tubular structures known as villi, a pattern of organisation which serves 
to vastly increase the surface area of the gastrointestinal tract available for nutrient 
absorption. At the base of the villi are specialised structures known as crypts of Lieberkühn, 
epithelial invasions into the underlying connective tissue, in which intestinal stem cells 
reside, and where all cell proliferation takes place (van der Flier and Clevers, 2009). The 
structure of the intestinal epithelium is illustrated in figure 1.3. In the crypts, intestinal stem 
cells generate transit amplifying cells, which divide 4-5 times before terminally differentiating 
into one of four specialised intestinal epithelial cell types. Differentiated epithelial cells then 
migrate upward along the luminal surface of a villus until they reach the tip, whereupon they 
undergo apoptosis and are shed into the intestinal lumen (Hall et alet al., 1994). Of the four 
cell types that make up the epithelium, over 80% are enterocytes, highly polarised cells 
which express a ‘brush border’ of microvilli at their apical surface, and are responsible for 
water and nutrient absorption (van der Flier and Clevers, 2009).  Goblet cells are responsible 
for the secretion of intestinal mucus (important in physical and chemical defence of the 
intestinal epithelium, and the effective movement of gut contents) in response to a variety of 
stimuli. The proportion of goblet cells in the intestinal epithelium increases over the length of 
the gastrointestinal tract, from around 4% in the duodenum, to 16% in the descending colon 
(van der Flier and Clevers, 2009). Enteroendocrine cells represent a diverse class of cells (up 
to 15 sub-types have been described) which coordinate gut function through the secretion of 
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specific peptide hormones (Rehfeld, 2004). Lastly, Paneth cells play a role in the innate 
immune system of the intestine; they are unique both in their relative longevity (at least 
three weeks, much longer than any other intestinal epithelial cell type) and in that they do 
not migrate out of the crypt of Lieberkühn, instead residing in the base of the crypt, where 
they secrete antimicrobial peptides, defensins and lysozymes (Crosnier et alet al., 2006). 
 
Figure 1.2: The structure of the intestinal epithelium. An illustration (not to scale) of the general 
structure of the intestinal epithelium, showing a single villus and a crypt of Lieberkühn. The four 
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major cell types of the epithelium are shown, as well as a representation of the location of 
intestinal stem cells.  
 
 
 
1.1.3 The Epidermal Growth Factor Receptor (EGFR) family, and its ligands 
Due to their protective functions and near-constant exposure to potential damage, a high 
rate of cell turnover is a feature of many epithelial tissues, and is especially prominent in 
both the skin and the gastrointestinal epithelium. Among the numerous signalling pathways 
involved in the growth and homeostasis of these tissues, signalling through the epidermal 
growth factor receptor (EGFR) plays a particularly prominent role.  
The EGFR is a member of the closely related, four-member family of receptor tyrosine 
kinases (RTKs) known as the ErbB family. The ErbB RTKs are a group of receptors which are 
activated by the binding of specific peptide ligands, with the exception of ErbB2, which has 
no specific ligand but functions as the preferred dimerisation partner of the of the other 
three members of the family (Agus et alet al., 2002). The peptide ErbB ligands are a seven-
member family (henceforth referred to as the EGFR ligand family), that consists of epidermal 
growth factor (EGF), heparin-binding EGF (HB-EGF), transforming growth factor-α (TGFα), 
amphiregulin, betacellulin, epigen and epiregulin – all of which can bind to the EGFR (ErbB1) 
(Hynes and Lane, 2005) with varying degrees of specificity. In addition, there exist four 
members of the neuregulin family, which bind to the ErbB3 and ErbB4 receptors to varying 
degrees (Chang et alet al., 1997, Carraway et alet al., 1997, Zhang et alet al., 1997, Harari et 
alet al., 1999). EGF, TGFα and amphiregulin have been shown to bind exclusively to the EGFR 
(ErbB1), whilst HB-EGF, betacellulin and epiregulin show dual specificity for the EGFR and the 
closely related ErbB4 (Hynes and Lane, 2005). Ligand binding to the EGFR and its related 
ErbB-family receptor tyrosine kinases results in receptor homo- or heterodimerisation, 
autophosphorylation, and downstream activation of a variety of diverse signalling pathways, 
prominently including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 
3-kinase (PI3K)-AKT pathways (Yarden and Sliwkowski, 2001), making signalling through the 
EGFR among the most important signalling pathways in vertebrates. As well as multiple roles 
in development, responses to EGFR signalling in normal physiology include cell division, 
differentiation, motility, adhesion and death (Yarden and Sliwkowski, 2001), whilst 
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dysregulation of the pathway is unsurprisingly associated with dysplasia and cancer (Salomon 
et alet al., 1995). 
As activation of the EGFR in requires ligand binding, the release of EGFR ligands from 
synthesising cells is of crucial importance in the signalling pathway, and represents a 
significant opportunity for the regulation of EGFR signalling. All members of the EGFR ligand 
family of growth factors are synthesised as membrane bound pro-ligands, which require 
proteolytic cleavage in a juxtamembrane region to release their extracellular ‘ectodomain’, 
which can then function as an active ErbB ligand. This process is known as ectodomain 
shedding, with the enzymes responsible for pro-ligand cleavage referred to as ectodomain 
sheddases. The importance of ectodomain shedding will be discussed in section 1.2.  
 
1.1.4 EGFR signalling in the epidermis and small intestinal epithelium 
Signalling through the EGFR represents a particularly important pathway in the development 
and maintenance of the skin. In the epidermis, the EGFR is expressed most prominently in 
proliferating basal keratinocytes, and to a lesser degree in suprabasal cells undergoing 
differentiation. EGFR ligands are autocrine and paracrine growth factors for keratinocytes, 
and play a central role in the regulation of keratinocyte proliferation, survival and 
differentiation (Schneider et alet al., 2008, Coffey et alet al., 1987, Cook et alet al., 1991, Stoll 
et alet al., 1997, Piepkorn et alet al., 1998). Signalling through the EGFR is essential for 
normal epidermal development and morphogenesis, as illustrated by the phenotype 
observed in Egfr knockout mice, which die perinatally, and display severe epithelial defects 
(Sibilia and Wagner, 1995, Miettinen et alet al., 1995). In vitro, keratinocytes express 
significant levels of amphiregulin, as well as much lower levels of TGFα and HB-EGF (Pastore 
et alet al., 2008), illustrating the relevance of EGFR ligand shedding in keratinocyte growth. 
Analysis of mice who which lack expression of the key ectodomain sheddase ADAM17 
(responsible for the shedding of multiple EGFR ligands, to be discussed in detail in section 
1.2) in their keratinocytes has suggested that EGFR-ligand dependent signalling is required 
for normal epidermal differentiation and barrier maintenance, meaning that any disruption 
of EGFR ligand shedding in the epidermis could be expected to adversely affect normal skin 
barrier function. 
Signalling through the EGFR is also known to play an important role in epithelial wound 
healing – particularly in the early phase response to wounding – by increasing keratinocyte 
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proliferation and migration (Barrientos et alet al., 2008). The importance of this response is 
illustrated in Egfr-null mouse skin grafts, where lesions heal at a slower rate compared to 
controls (Repertinger et alet al., 2004). Shedding of EGFR ligands is required for keratinocyte 
migration during wound healing and is immediately induced upon wounding (Tokumaru et 
alet al., 2000), with factors upregulated in wounded skin including amphiregulin, TGFα and 
HB-EGF; but not EGF or betacellulin (Barrientos et alet al., 2008). In particular, TGFα is 
responsible for approximately 80% of keratinocyte migration activity during wound healing 
(Li et alet al., 2006) and also promotes proliferation (Cha et alet al., 1996); whilst HB-EGF 
promotes re-epithelialisation (Hashimoto et alet al., 1994) and accelerates cutaneous wound 
healing when applied topically (Tolino et alet al., 2011, Shirakata et alet al., 2005).  
Bearing these factors in mind, EGFR signalling would be expected to have a significant 
function in skin homeostasis, a role which is well illustrated by the epidermal side effects that 
are a common consequence of treatment with EGFR-inhibiting chemotherapeutics in cancer 
patients. These side effects include papulopustular rashes of the face and trunk, periungual 
inflammation, and xerotic (dry), scaly skin (Lacouture, 2006). Although the effect of EGFR 
inhibition is well described, relatively little is understood of the precise contribution of EGFR 
signalling to epidermal homeostasis; however, shedding of EGFR ligands by ectodomain 
sheddases would be expected to be a key regulatory step in this process in the skin. Recently, 
the first example of an inherited human disease associated with loss-of-function missense 
mutations in the EGFR gene has been identified, which was characterised by inflammatory 
skin disease that resembled that seen in patients treated with EGFR-inhibiting drugs, as well 
as bowel and lung inflammation (Campbell et alet al., 2014).  
Within the crypts of the intestinal epithelium, the primary driver of proliferation is 
considered to be the highly conserved Wnt-β-catenin signalling pathway, activity of which 
has been shown to be necessary for the maintenance of progenitor cell compartments in the 
crypt (Ireland et alet al., 2004). However, EGFR signalling has also been shown to be of key 
importance in both the development and repair of the gut epithelium. Mouse knockouts of 
Egfr have severely deleterious effects on the development of numerous epithelial tissues, 
with the intestinal epithelium particularly affected, showing fewer, shorter villi and reduced 
proliferation, though all cell types do develop (Miettinen et alet al., 1995). The intestines of 
Egfr-null mice are fragile and strongly susceptible to damage, with numerous intestinal 
haemorrhages and disintegration of the villi becoming apparent a few days after birth. This is 
consistent with a particular role for EGFR signalling in the response to damage, and in 
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regeneration of the intestinal epithelium after injury. The EGFR is expressed on enterocytes, 
where its activation following intestinal mucosal injury induces repair mechanisms, reduces 
inflammation and promotes cell survival (McElroy et alet al., 2012, Dvorak et alet al., 2002). 
Similarly, enterocyte proliferation is stimulated via the EGFR following resection of the small 
intestine, one of the most potent stimuli for enterocyte proliferation (Sheng et alet al., 2006). 
So-called ‘transactivation’ of the EGFR (to be discussed in detail in section 1.2.6) also 
underlies the gastro-protective effects of prostaglandins, lipid mediators known to play key 
roles in gastro-intestinal defence and regeneration (Pai et alet al., 2002). A requirement for 
EGFR signalling in response to gastrointestinal injury is highly conserved, with EGFR pathway 
activation required for enterocyte proliferation and gut remodelling following infection in 
Drosophila (Buchon et alet al., 2010). 
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1.2 Ectodomain Shedding and ADAM17 
 
1.2.1 Ectodomain shedding in intercellular signalling 
As described previously, the release of peptide intercellular mediators (such as EGFR ligands) 
in vertebrates is frequently accomplished through the process of ectodomain shedding, in 
which the membrane bound precursor of an intercellular mediator (such as a pro-cytokine) 
undergoes proteolytic cleavage in a juxtamembrane region by one or more specific enzymes, 
resulting in the release of a soluble extracellular domain (Blobel, 2005); this is illustrated 
simply in figure 1.3, A.  
Most prominent among the enzymes involved in this process are members of the 
membrane-anchored ADAM (A Disintegrin And Metalloprotease) family, which appear to be 
responsible for the majority of known ectodomain shedding events (Huovila et alet al., 
2005). The prototype ADAM protease involved in ectodomain shedding – and the first to be 
discovered to be involved in this process – is known as ADAM17 (Edwards et alet al., 2008). 
Much of the research described in this report concerns the activity of this protein, and thus it 
will be discussed in greater detail than the other members of its family in the following 
sections.  
 
1.2.2 The structure of the ADAM ectodomain sheddases 
The ADAMs are multi-domain transmembrane proteins, and constitute one major family 
within a larger super-family of zinc-based metalloproteases (‘metzincins’)(Stocker and Bode, 
1995), whose members also include the well-known family of matrix metalloproteases 
(MMPs) and lesser studied protease groups such as reprolysins and astacins (Edwards et alet 
al., 2008). Active members of the metzincin super-family contain a highly conserved 
HEXXHXXGXXH…M motif (Bode et alet al., 1993), in which three histidine residues bind a zinc 
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ion, accompanied by an invariant methionine residue in the active site, and a catalytic 
glutamate residue. Though much research has focussed on the function of the ADAM’s 
catalytically active metalloprotease domain, full length ADAM proteins contain several more 
distinct domains (illustrated in Figure 1.3, B), including a cytoplasmic tail, a cysteine-rich 
domain, a disintegrin domain, and at their N-terminus an inhibitory pro-peptide, which 
blocks access to the active metalloprotease in inactive pro-ADAMs. Each of these domains 
has distinct functions to regulate an ADAM’s activity.  
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Figure 1.3: Ectodomain shedding and the structure of an ADAM. A: A simplified illustration of 
ectodomain shedding. A membrane tethered precursor (yellow) is cleaved in a juxtamembrane 
region by the actions of a protease (purple). B: The structure of a typical ADAM metallopotease, 
illustrating the major domains. Note that the EGF-like domain is absent in both of the broad 
spectrum sheddases ADAM17 and ADAM10. ADAM structure inspired in part by Murphy (Murphy, 
2008)  
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Intracellularly, the length and complexity of an ADAM’s cytoplasmic domain varies greatly 
between different members of the family, ranging from 11 (ADAM11) up to 291 (ADAM19) 
residues (Seals and Courtneidge, 2003); these domains mediate interactions of the ADAM 
with specific intracellular partners to control trafficking of the protein and modulation of its 
activity. For example, a region of ADAM10’s cytoplasmic domain rich in proline has been 
found to be important for the correct basolateral localisation of this protease in polarised 
epithelium, allowing for the cleavage of the ADAM10 substrate E-Cadherin to promote cell 
migration (Wild-Bode et alet al., 2006). Several ADAM cytoplasmic domains contain putative 
binding sites for proteins containing SH3 domains – such as for example the endocytosis-
associated, SH3-carrying protein PACSIN3, which has been shown to interact with several 
ADAMs (though not ADAM17) (Mori et alet al., 2003), and may regulate their sub-cellular 
localisation. Additionally, the cytoplasmic regions can contain potential sites for kinase 
phosphorylation (serine, threonine or tyrosine residues), allowing for kinase-based control of 
their activity; for example, ADAM17 is able to be phosphorylated by the MAP kinase ERK on 
Threonine (Thr)-735, with this phosphorylation required for successful trafficking of Pro-
ADAM17 from the endoplasmic reticulum (Soond et alet al., 2005).  
At the immediate extracellular side of several ADAM’s transmembrane domain lies an 
epithelial growth factor (EGF)-like repeat region (though this is absent in the key sheddases 
ADAM10 and ADAM17), followed by a cysteine-rich domain. This cysteine-rich region is 
thought to influence interactions of an ADAM its substrates (and other proteins). For 
example, the ADAM10 cysteine-rich domain has been shown to regulate of the availability of 
Ephrin-A5 (an ADAM10 substrate) to its active site (Janes et alet al., 2005), whilst the 
cysteine-rich domain of ADAM17 is required for the shedding of the IL-1 receptor, but not of 
TNFα (Reddy et alet al., 2000). 
The ADAM disintegrin domain is named due to its resemblance to true disintegrin proteins, 
snake venom constituents that prevent blood clotting by direct binding to integrins, and 
inhibition of integrin-mediated platelet-fibrinogen adhesion (Gould et alet al., 1990). As 
suggested by their close resemblance to true disintegrins, studies using both recombinant 
ADAM disintegrin domains and full length ADAMs have shown that these domains can 
interact directly with integrins, and can thereby influence cell adhesion either positively or 
negatively (Edwards et alet al., 2008). These interactions have been found to be important in 
fertility (reviewed by Evans [(Evans, 2001)]), and may have a role to play in promoting 
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migration or metastasis in cancer (to be discussed below, but also reviewed by Arribas 
([Arribas et alet al., 2006)]). 
Key to the functioning of the ADAMs is their N-terminal pro-domain, a structure present in 
inactive pro-ADAMs, which inhibits the function of the metalloprotease domain until it is 
removed as part of an ADAM’s maturation. The pro-domain functions by means of a 
‘cysteine-switch’ mechanism (Loechel et alet al., 2000), a feature shared in common with the 
inhibitory pro-domains of the MMPs (Roghani et alet al., 1999). This system is dependent on 
the binding of a cysteine residue in the pro-domain to the catalytic zinc ion in the active site 
of the metalloprotease domain (Becherer and Blobel, 2003). This serves not only to prevent 
catalytic activity, but positions the pro-domain so as to completely block the entrance to the 
active site. Removal of the pro-domain during ADAM maturation is accomplished by the 
actions of pro-protein convertase enzymes such as furin (Schlondorff et alet al., 2000), and 
takes place intracellularly in the secretory pathway following the transit of the pro-protein 
from the ER into the Golgi apparatus (Murphy, 2008). Regulation of pro-domain removal 
from an ADAM is therefore expected to play an important role in regulating the activity of 
the protease. 
 
1.2.3 The functions and substrates of the  ADAM ectodomain sheddases  
Although their roles in ectodomain shedding are far better known, the first ADAMs to be 
discovered in mammals (Adam1 and 2) are the constituents of the heterodimeric, testis-
restricted mouse sperm protein fertilin, (and are thus alternatively named fertilin-α and -β). 
As such, the first role uncovered for mammalian ADAMs was their involvement in fertility, 
specifically in the correct function of sperm. The precise contributions of various ADAMs in 
sperm function remain relatively unclear; however, they are thought to be involved in the 
binding of the sperm to the zona pellucida (the outermost layer of an unfertilised oocyte) 
(Ikawa et alet al., 2010, Linder and Heinlein, 1997). As such, fertilin-β knockout mice are 
infertile (Cho et alet al., 1998). While much of the study of the ADAMs’ role in fertility has 
been carried out in mice (and is reviewed as part of a general examination of fertilisation by 
Ikawa et alet al. ([Ikawa et alet al., 2010)]), ADAMs are also expected to play important roles 
in fertility in humans. A significant number of the numerous ADAMs expressed in humans (3 
catalytically active and 4 inactive) are expressed only in the testis, and have involvement in 
spermatogenesis, sperm function and fertility, as in mice. However, how the situation in 
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rodents with regard to ADAM function in fertility reflects that in humans remains confusing, 
as many important, testis-specific rodent ADAM genes (including Adam1 and Adam3) are 
represented only as pseudogenes in humans (Jury et alet al., 1997, Frayne and Hall, 1998, 
Puente and Lopez-Otin, 2004). 
Humans encode 21 distinct ADAMs, of which 13 contain the intact metalloprotease domain 
and active site required for proteolytic activity (Edwards et alet al., 2008). Aside from the 
testis-related members of the family, two further active ADAMs (8 and 28) are expressed 
primarily in haematopoietic cells, and one more (33) shows a very restricted tissue 
expression, meaning only six catalytically active ADAMs (ADAM9, 10, 12, 15, 17, and 19) are 
broadly expressed in somatic tissue (Edwards et alet al., 2008). Despite ADAMs’ role in 
fertility being the first elucidated, their best-known function remains their key involvement 
in in ectodomain shedding. Though some catalytically active members of the family have only 
a single (or indeed no known) substrate, the majority of the ADAM proteases have been 
shown to cleave a wide variety of substrates in vitro, with ADAM10 and ADAM17 notable for 
the high number and variety of their targets. Even when restricting a list to notable 
examples, ADAM17 – the first of the ADAMs to be implicated as an ectodomain sheddase – is 
still known to cleave multiple cytokines, receptors, growth factors, intracellular signalling 
molecules and cell adhesion molecules, among others. A by-no-means comprehensive list of 
selected significant ADAM substrates can be found in Table 1.1, whilst a much more 
complete list is given by Edwards et alet al (Edwards et al., 2008). In particular, the wide 
range of substrates proteolytically cleaved by ADAM10 and ADAM17 make these enzymes 
pivotal in controlling a wide range of cellular processes, including inflammation, cell 
adhesion, growth and wound repair, among many more. 
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ADAM Substrates 
ADAM9 
Amyloid precursor protein (APP) (Koike et alet al., 1999); EGF (Peduto et alet al., 
2005); Heparin Binding-Epidermal Growth Factor (HB-EGF) (Izumi et alet al., 
1998);  
Delta-like ligand 1 (Dyczynska et alet al., 2007); Laminin (Mazzocca et alet al., 
2005) 
ADAM10 
EGF (Sahin et alet al., 2004); Betacellulin (Sahin et alet al., 2004); 
APP (Slack et alet al., 2001); Notch-1 (Pan and Rubin, 1997);  
E-, N- and VE-Cadherins (Reiss et alet al., 2006, Maretzky et alet al., 2005, Schulz 
et alet al., 2008); Desmoglein 2 (Bech-Serra et alet al., 2006); RANKL (Hikita et alet 
al., 2006);  
Delta-like ligand 1 (Six et alet al., 2003); Collagen XVII (Franzke et alet al., 2004);  
ErbB2 (Liu et alet al., 2006); Ephrin A5 (Janes et alet al., 2005);  
CD23 (Moss and Rasmussen, 2007); CD44 (Nagano and Saya, 2004) 
ADAM12 HB-EGF (Asakura et alet al., 2002); Fibronectin (Roy et alet al., 2004);  Delta-like ligand 1 (Dyczynska et alet al., 2007) 
ADAM15 HB-EGF (Hart et alet al., 2005); Amphiregulin (Schafer et alet al., 2004);  E-Cadherin (Najy et alet al., 2008) 
ADAM17 
Tumour Necrosis Factor-α (TNFα) (Black et alet al., 1997, Moss et alet al., 1997);
Transforming Growth Factor-α (TGFα) (Peschon et alet al., 1998, Sahin et alet al., 
2004);  
Amphiregulin (Gschwind et alet al., 2003, Sahin et alet al., 2004);  
HB-EGF (Sahin et alet al., 2004); Neuregulin (Yokozeki et alet al., 2007);  
Epigen (Sahin and Blobel, 2007); TNF receptors I and II (Reddy et alet al., 2000);  
IL-6 receptor (Chalaris et alet al., 2007); IL-1 receptor II (Reddy et alet al., 2000);  
ErbB4 (Rio et alet al., 2000, Maatta et alet al., 2006); Notch1 (Brou et alet al., 
2000);  
L-selectin (Peschon et alet al., 1998); VCAM1 (Garton et alet al., 2003, Singh et 
alet al., 2005); Desmoglein 2 (Bech-Serra et alet al., 2006); CD40 (Contin et alet 
al., 2003);  
CD44 (Nagano and Saya, 2004); VEGF receptor 2 (Swendeman et alet al., 2008) 
ADAM19 Neuregulin (Yokozeki et alet al., 2007); RANKL (Chesneau et alet al., 2003) HB-EGF (Horiuchi et alet al., 2005) 
 
Table 1.1: Selected substrates of the widely expressed, catalytically active ADAMs 
 
 
It is particularly notable that, among its wide variety of substrates, ADAM17 is responsible 
for the shedding of numerous members of the EGFR ligand family, making ADAM17 
(alongside ADAM10) a key upstream regulator of the EGFR signalling pathway. Of the known 
ligands of the ErbB receptor family, two (betacellulin and EGF) are shed primarily by 
ADAM10, whilst the remaining five (HB-EGF, TGFα, amphiregulin, epiregulin and epigen) are 
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shed primarily by ADAM17 (Sahin and Blobel, 2007, Sahin et alet al., 2004). Though other 
ADAMs share the ability to cleave some EGFR ligands in vitro, it appears that ADAM10 and 17 
are responsible for the majority of their shedding in vivo, as demonstrated by the severe 
phenotypes seen in Adam10 and Adam17 knockout mice (to be discussed in detail in section 
1.2.7). 
1.2.4 ADAM17 in inflammatory processes 
The ectodomain sheddase function of ADAM17 was first discovered due to ability of the 
enzyme to cleave and release the pro-inflammatory cytokine TNFα (Black et alet al., 1997, 
Moss et alet al., 1997). Not only was this discovery pivotal in the understanding of the 
regulation of the release of TNFα – a cytokine whose paracrine signalling effects make it a 
key component of the inflammatory and innate immune responses – but it also represented 
the first association of an ADAM protein with ectodomain shedding events. Increased TNFα 
shedding has been implicated in the pathogenesis of a large number of inflammatory 
conditions, including (but not limited to): rheumatoid arthritis (Vinay and Kwon, 2011, 
Aggarwal et alet al., 2012); cardiovascular disease (Feldman et alet al., 2000); Alzheimer’s 
disease (Swardfager et alet al., 2010); Parkinson’s disease (Nagatsu and Sawada, 2005); a 
variety of lung diseases including chronic obstructive pulmonary disease (COPD)(Lundblad et 
alet al., 2005); and numerous types of cancer (to be discussed in greater detail in section 
1.2.8), making the regulation of its shedding of fundamental importance to the 
understanding a large number of well-known and prevalent conditions. TNFα cleavage 
remains the best known function of ADAM17, and as such the enzyme is still frequently 
referred to in literature as TACE (TNFα Converting Enzyme). Subsequent to its discovery as 
the sheddase for this well-known cytokine, ADAM17 has emerged as an enzyme with an 
unusually broad and varied range of substrates, as illustrated in Table 1.1.  
Even bearing its well-known function as the TNFα sheddase in mind, ADAM17 cannot be 
considered to be an exclusively pro-inflammatory enzyme. For example, in the regulation of 
inflammation, it is interesting to note that not only does ADAM17 regulate shedding of TNFα, 
but also of its receptors TNFR-I and –II (Reddy et alet al., 2000). ADAM17-mediated shedding 
of TNFRs serves to reduce the susceptibility of a given cell to TNFα stimulation, both by 
directly reducing cell surface TNFR numbers and by producing soluble forms of the receptors 
that can compete antagonistically with membrane bound receptors to reduce local TNFα 
signalling. The importance of this process in controlling inflammation is pointedly illustrated 
by the inherited disease TRAPS (TNFα-receptor-associated periodic febrile syndrome), in 
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which mutations in the ADAM17 cleavage site of TNFR-I prevent its shedding (and therefore 
its cell surface downregulation), thereby increasing cells’ susceptibility to TNFα, and resulting 
in recurring episodic high fevers due to an increased inflammatory response (McDermott et 
alet al., 1999).  
Similarly, ADAM17 is responsible for the shedding of the IL-6 receptor and IL-1 receptor II, 
and thus also represents an important level of regulation of inflammatory processes 
mediated by these two cytokines. IL-1 binds to two distinct receptors: IL-1RI and IL-1RII; of 
these, only IL-1RI is capable of transducing a signal, whilst IL-1RII acts as a decoy receptor 
(Mullberg et alet al., 2000). Of the two, only IL-1RII can be shed by ADAM17 (Orlando et alet 
al., 1997, Reddy et alet al., 2000) (whilst IL-1RI cannot be shed at all) to produce a soluble 
receptor (sIL-1RII) that acts as a competitive inhibitor of IL-1 signalling, binding soluble IL-1, 
but not the naturally occurring IL-1 antagonist IL-1RA (Symons et alet al., 1995). Thus, IL-1RII 
shedding acts as a negative regulator of IL-1-dependent inflammatory processes, in a fashion 
analogous to shedding of the TNFα receptors. Conversely however, IL-6 receptor (IL-6R) 
shedding appears to act in an agonistic way, through a process known as IL-6 trans-signalling. 
This is a mechanism by which shed, soluble IL-6R, in complex with IL-6, is capable of 
stimulating cells via interaction with the ubiquitously expressed signal transducing protein 
gp130, without the involvement of membrane bound IL-6R (Rose-John et alet al., 2006). In 
this way, shedding of the IL-6 receptor allows for the activation of numerous cell types which 
are unresponsive to IL-6 alone (due to their not expressing cell surface IL-6R). This process of 
trans-signalling has been shown to be involved in the pathogenesis of numerous chronic 
inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis and 
asthma (Rose-John et alet al., 2006), among others, and illustrates the multi-faceted and 
often paradoxical role of ADAM17 in inflammatory processes.  
 
1.2.5 ADAM17 regulation and activation 
Considering its particularly broad range of substrates and the importance of the pathways 
affected by them, tight regulation of the activity of ADAM17 by cells is to be expected. As 
previously described, the removal of ADAM17’s pro-domain is a prerequisite for ADAM17 
activity, and therefore presumably represents an important step in the regulation of its 
sheddase activity. However, ADAM17 activity can also be rapidly upregulated in response to 
a variety of stimuli (Doedens et alet al., 2003), including by bacterial lipopolysaccharide 
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(Horiuchi et alet al., 2007a), phorbol esters  (including such as phorbol myristate acetate – 
PMA; and tetradecanoyl phorbol acetate – TPA) (Horiuchi et alet al., 2007b), G-protein 
coupled receptor stimulation (to be discussed in 1.2.6), and activation of Src. The mechanism 
by which such stimuli result in the rapid upregulation of ADAM17 activity remains 
unresolved; reports have directly contradicted one another on the question of whether or 
not simulation with PMA results in increased levels of  ADAM17 pro-domain removal, and 
transport of mature ADAM17 to the plasma membrane (Horiuchi et alet al., 2007b, Nagano 
et alet al., 2004). Similarly, the requirement for phosphorylation of ADAM17’s cytoplasmic 
domain for protease activity remains unclear. The cytoplasmic domain of ADAM17 can be 
phosphorylated at threonine-735 (Diaz-Rodriguez et alet al., 2002), in a process mediated by 
extracellular signal-regulated kinase (ERK), and this phosphorylation has been described as 
being required for the trafficking of ADAM17 to the cell surface (Soond et alet al., 2005). 
However, the cytoplasmic domain of ADAM17 has also been shown to be dispensable for 
stimulated shedding of TNFα (Reddy et alet al., 2000, Doedens et alet al., 2003). The exact 
mechanisms that underlie rapid activation of ADAM17 by external stimuli are therefore still 
to be resolved. However, one recent report has suggested that phorbol ester-stimulated 
upregulation of ADAM17 shedding may not in fact require any upregulation of ADAM17 
activity at all, and that this upregulation is due to a substrate-selecting signalling pathway 
dependent on members of the protein kinase C family, which regulates the availability of 
some, but not all, ADAM17 substrates (including members of the EGFR ligand family) for 
shedding (Dang et alet al., 2013). 
 
1.2.6 G-protein coupled receptor (GPCR) and EGFR cross-talk (EGFR transactivation) and 
the importance of ADAM17 
Interestingly, ADAM17 plays an important role not only in signalling by EGFR ligands, for 
which it acts directly as a sheddase, but also in signalling by receptors whose ligands it does 
not directly cleave. Whilst shedding of EGFR ligands influences cell signalling in paracrine and 
juxtacrine manners, ADAM17 is also involved in the activation of EGFR signalling in response 
to activation of a number of G-protein coupled receptors (GPCRs) by, for example, ligands 
such as angiotensin, thrombin and 5-HT. In this process, GPCR activation activates ADAM17 
in a process dependent on either the kinases Src (Maretzky et alet al., 2011b) or ERK 
(Swendeman et alet al., 2008). ADAM17 activation in these circumstances results in the 
shedding of one or more EGFR ligands (the shed ligand is primarily HB-EGF (Prenzel et alet 
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al., 1999), though amphiregulin and TGFα are also involved), which can then activate the 
EGFR in an autocrine fashion (Edwards et alet al., 2008). Thus, EGFR signalling is activated by 
GPCR ligands, in a process known as ‘triple membrane pass signalling’, and is also referred to 
as EGFR transactivation. This function is limited not only to stimulation of GPCRs, but is also 
involved in activation of EGFR signalling by non-EGFR ligands via other tyrosine kinase 
receptors. For example, keratinocyte migration in response to keratinocyte growth factor 
(FGF7) or vascular endothelial growth factor A (VEGF-A) – which signal via the RTKs fibroblast 
growth factor receptor 2-IIIb (FGFR2b) and VEGF receptor 2 respectively – requires Src-
dependent activation of ADAM17 and HB-EGF release (Maretzky et alet al., 2011a). This 
illustrates the central role of ADAM17 in EGFR signalling, demonstrating that not only can it 
directly promote EGFR signalling via EGFR ligand release, but also control the cellular 
response to factors which are not among its substrates.  
 
1.2.7 ADAM mutations and knockouts in mice 
Striking examples of the importance of ADAM17-dependent EGFR-ligand shedding can be 
seen in Adam17-knockout (Adam17-/-) mice. These knockouts produce mice that die around 
the time of birth (perinatal lethality), aspects of whose phenotype closely resemble those 
seen in mice lacking various EGFR ligands. Examples of this include defects in epithelial 
structure maturation and morphogenesis (including un-fused eyelids and serious defects in 
skin and gastrointestinal structure and function) – resembling TGFα deficient mice (Peschon 
et alet al., 1998); defects in branching morphogenesis of the mammary gland (similar to that 
seen in Amphiregulin-deficient mice) and the lung (Zhao et alet al., 2001); and, fatally, 
defects in heart development such as cardiac muscle hyperplasia and  thickened, misshapen 
heart valves, with both heart and lung phenotypes resembling mice lacking HB-EGF (Jackson 
et alet al., 2003, Shi et alet al., 2003). Meanwhile, Adam10-/- mice die even earlier, for 
reasons also likely related to impaired angiogenesis, and display phenotypes resembling 
those of mice with knockouts of the ADAM10 substrates EGF and Notch1 (Hartmann et alet 
al., 2002). 
Whilst mouse Adam17 knockouts are not viable, hypomorphic Adam17 mice, expressing 
around 5% of a normal physiological level of the protein, have been successfully generated. 
Although viable, these mice develop eye, hair, skin and milk duct defects resembling those of 
mice lacking TGFα and amphiregulin (Chalaris et alet al., 2010), though these were less 
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severe than completely Adam17- or Egfr-null mice. Also in contrast to Egfr knockout mice, 
development of the gastrointestinal tract appeared to be superficially normal. However, 
these mice were strongly susceptible to inflammatory colitis following challenge with dextran 
sulphate, a phenotype which resulted from defective regeneration of intestinal epithelium 
due to an inability to shed EGFR ligands (Chalaris et alet al., 2010). High levels of EGFR 
ligands, in particular TGFα, were generated in the enterocytes of these mice after dextran 
sulphate challenge, but remained at the plasma membrane due to the inability to effectively 
shed them. Treatment with soluble TGFα was sufficient to restore normal intestinal epithelial 
function, demonstrating that EGFR signalling pathway dysfunction was responsible for the 
phenotype observed, and illustrating the importance of the ADAM17-EGFR axis in intestinal 
epithelial repair and remodelling.  
Tissue-restricted Adam17 mouse knockouts have also been performed, yielding useful 
information on the role of ADAM17 in specific tissues. Keratinocyte-restricted Adam17 
knockouts result in a phenotype of inflammatory dermatitis and pronounced defects in the 
integrity of the epidermal barrier, which develop soon after birth. These defects were found 
to be the consequence of a marked reduction in epidermal transglutaminase activity, 
resulting from reduced EGFR signalling due to absent EGFR ligand shedding. Indeed, the 
phenotype of keratinocyte-restricted Egfr knockout mice closely resembled this phenotype, 
and the topical application of TGFα was found both to significantly increase transglutaminase 
activity, and reduce skin inflammation in the epidermal Adam17-knockout mice (Franzke et 
alet al., 2012). 
 
1.2.8 ADAM17 and its substrates in cancer 
In its role as the sheddase enzyme for a wide variety of substrates, many of which (such as 
the EGFR ligand family described previously) are able to profoundly affect cellular growth, 
metabolism and motility, it is perhaps predictable that upregulation of various ADAMs, 
notably including ADAM17, has been observed in several cancer types. Several notable 
substrates of ADAM17 have also been shown to play key roles in cancer development, 
offering a rationale for a function for ADAM17 in oncogenesis.  
As its name suggests, TNFα was first discovered as a cytokine responsible for the 
haemorrhagic necrosis of tumours (Carswell et alet al., 1975). And whilst large doses of 
recombinant TNFα have been shown to promote tumour necrosis in rodent models (Balkwill, 
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2009), it has also been shown to have a paradoxical tumour-promoting activity in many 
circumstances (Balkwill, 2006), to be expressed constitutively in many tumour types 
(Suganuma et alet al., 1999) and may be associated with poorer prognosis in vivo. For 
example, Tnfa-knockout mice treated with skin carcinogens develop fewer tumours than 
controls (Moore et alet al., 1999), whilst serum TNFα levels in prostate cancer patients 
increase with advanced disease (Pfitzenmaier et alet al., 2003), and correlate with disease 
extent (Michalaki et alet al., 2004). Indeed, animal models have shown that constitutively 
expressed TNFα produced by many malignant cells enhances the growth and spread of skin, 
ovarian, pancreatic and bowel tumours (Balkwill, 2009). Much of the pro-tumour activity of 
TNFα is thought to derive from its potent pro-inflammatory effects, with inflammation in the 
tumour microenvironment associated with malignant cell survival, angiogenesis and 
metastasis, and in altering cellular responses to hormones and chemotherapeutics 
(Mantovani et alet al., 2008). Much of this activity derives from the interaction of TNFα with 
TNFR-I, (TNFR-I knockout mice demonstrate resistance to carcinogenesis (Arnott et alet al., 
2004)[Arnott et al., 2004]); the fact that both TNFα and its receptor are ADAM17 substrates 
therefore illustrates ADAM17’s central role in cancer pathogenesis under these 
circumstances.  
The role of ADAM17 in the shedding of the IL-6 receptor has also been implicated in the 
development and progression of cancer, most prominently in the colon. As described in 
section 1.2.4, soluble IL-6R (shed by ADAM17) is responsible for stimulation of numerous 
otherwise IL-6-insensitive cell types, via interaction with the membrane protein gp130. 
Increased expression of ADAM17 has been observed at the cell surface of epithelial cells in 
colon tumour lesions, accompanied by a loss of membrane-bound IL-6R (Rose-John et alet 
al., 2006, Becker et alet al., 2005). Furthermore, growth of colonic tumours could be 
inhibited using neutralising antibodies against soluble IL-6R, and by a soluble IL-6R antagonist 
made from a soluble gp130 Fc (immunoglobulin-like) domain (Becker et alet al., 2004), 
suggesting that IL-6R trans-signalling plays an important role in colon tumour progression.  
In addition, dysregulation or hyperactivation, at a number of different levels, of the EGFR 
pathway has been well studied in terms of cancer development and progression (Hynes and 
Lane, 2005), with cancer patients with altered EGFR activity tending to have more aggressive 
disease and poorer clinical outcomes (Zandi et alet al., 2007). Often, such dysregulation takes 
the form of ErbB receptor overexpression – such as following gene amplification in 
glioblastoma (Ohgaki et alet al., 2004), oesophageal squamous cell carcinoma (OSCC) 
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(Sunpaweravong et alet al., 2005) and many others (reviewed by Krause and van Etten 
(Krause and Van Etten, 2005)]) – or constitutive activation as a result of mutations, as in the 
well-studied example of EGFR tyrosine kinase domain mutations in non-small cell lung cancer 
(NSCLC) (Sharma et alet al., 2007). Considering its previously described importance in the 
skin, it is unsurprising that EGFR signalling is also a major component in the pathogensis of 
skin tumours (Schneider et alet al., 2008), in which it has been found to be activated by UV 
light to induce epidermal hyperplasia (El-Abaseri et alet al., 2006), and to maintain the 
proliferative potential of basal keratinocytes in epidermal tumours (Hansen et alet al., 2000).  
Moreover, overexpression and increased secretion of EGFR ligands has also been reported in 
various cancer types, with one prime example among others being TGFα upregulation in 
NSCLC, which can in turn establish a so-called ‘autocrine loop’ (in which TGFα activation of 
the EGFR stimulates the production of more TGFα) and lead to receptor hyperactivity 
(Putnam et alet al., 1992). Additionally, transgenic overexpression of TGFα in mice leads to 
the development of breast mammary carcinoma, as well as epithelial and pancreatic 
hyperplasia (Sandgren et alet al., 1990). Given the pivotal role of ADAM17 in EGFR signalling, 
its overexpression concurrent with increased ligand shedding in various cancer types may be 
relatively unsurprising; indeed, ADAM17 upregulation has been described in breast (Borrell-
Pages et alet al., 2003), colon (Blanchot-Jossic et alet al., 2005), kidney (Roemer et alet al., 
2004), liver (Ding et alet al., 2004), ovarian (Tanaka et alet al., 2005), pancreatic (Mochizuki 
and Okada, 2007) and prostate (Karan et alet al., 2003) cancers, and is often correlated with 
adverse outcomes in patients (McGowan et alet al., 2008). Despite this, to date no somatic 
mutations in ADAM17 (or any ADAM) have been linked with any type of tumour. Somatic 
mutations in numerous members of the ADAM family, including 56 coding mutations in 
ADAM17 and 57 in ADAM10, have been described to be associated with a  wide variety of 
tumour types (Forbes et alet al., 2011), underscoring the potential for the involvement of 
both ADAMs and the pathways they regulate, in oncogenesis.  
 
 
1.2.9 The desmosome 
In addition to the ectodomain shedding of membrane tethered substrates, ADAM17 plays a 
role in the regulation of intracellular junction complexes, particularly desmosomes. 
Desmosomes are intracellular junction complexes that serve to form strong adhesions 
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between two neighbouring cells, providing mechanical stability to tissues via the anchoring 
of intermediate filaments. Desmosome-type structures have been observed in numerous 
tissues that experience mechanical stress, including the intestinal mucosa, gallbladder, 
uterus and oviduct, liver, pancreas, stomach, salivary and thyroid glands and the epithelial 
cells of the nephron, but are most abundant in the skin and myocardium (Farquhar and 
Palade, 1963, Kelly, 1966, Staehelin, 1974, Holthofer et alet al., 2007), where they anchor 
cytoskeletal keratin intermediate filaments and  desmin intermediate filaments respectively 
(Green and Gaudry, 2000). In brief, desmosomes consist of desmosomal cadherins 
(desmogleins and desmocollins), which constitute the extracellular portion of the structure, 
and bind in homo-and heterodimers to the cadherins of desmosomes on neighbouring cells. 
The intracellular portions of desmosomal cadherins bind to the armadillo-family proteins 
plakoglobin and the plakophilins, which in turn link to desmoplakin, which tethers the 
desmosome to the intermediate filament network (Brooke et alet al., 2012). Patterns of 
expression of the desmosomal cadherins and plakophilins differ significantly both between 
tissues and within stratified epithelia – displaying radical changes in different layers of the 
epidermis, for example – implying a functional distinction between desmosomes in different 
tissue types and epithelial layers.  
Considering their important role in resistance to mechanical stress, it is unsurprising that 
mutations in various desmosomal components are often associated with severe inherited 
diseases, commonly affecting the skin, hair and heart. Mutations in different desmosomal 
proteins have been found to be associated with palmoplantar keratoderma, woolly hair, 
alopecia, ectodermal dysplasia, skin fragility, and arrhythmogenic right ventricular 
cardiomyopathy (ARVC; a common cause of sudden cardiac death associated with exercise), 
in various combinations (see section 1.3, and Brooke et alet al [(Brooke et alet al., 2012)] for 
an overview).  
 
1.2.10 The role of ADAM17 in desmosomal dynamics and turnover 
ADAM17 is capable of regulating the formation and turnover of desmosomes both directly 
and indirectly. Signalling through the EGFR has been shown to promote desmosome 
disassembly, a function presumably related to facilitating cell motility during wound healing 
and tissue remodelling (Lorch et alet al., 2004). Conversely, EGFR inhibition promotes 
desmosome assembly, and strengthens intercellular adhesion mediated by desmosomes. In 
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its capacity as a primary EGFR ligand sheddase, ADAM17 can therefore regulate desmosome 
assembly indirectly. However, ADAM17 is also capable of directly cleaving the desmosomal 
cadherin desmoglein 2 (DSG2) (Bech-Serra et alet al., 2006), to produce both a shed 
ectodomain and an intracellular product (Brennan et alet al., 2012). Upregulation of 
ADAM17-dependent DSG2 shedding has found to be the mechanism by which EGFR 
signalling promotes desmosome disassembly (Klessner et alet al., 2009). Any modulation of 
ADAM17 activity can therefore be expected to affect desmosome structure and stability.  
 
 
 
 
 
 
1.3 Gene discovery in inherited skin diseases 
 
1.3.1 Genetic techniques in inherited skin disease  
Numerous strategies are used in the investigation of the genetic causes of disease, several of 
which have been key to the identification of disease-associated gene variants associated to 
the diseases described in forthcoming results chapters.  
Until relatively recently, the most commonly used method of identifying regions of the 
genome associated with inherited monogenic disease relied upon linkage analysis. This 
process involves the genotyping of DNA polymorphisms, such as single nucleotide 
polymorphisms (SNPs) and repetitive elements such as microsatellites, and comparing the 
presence of these polymorphisms in the genomes of disease-affected and unaffected 
individuals in a family, to identify genomic regions that segregate with the disease (Altshuler 
et alet al., 2008).  
Modern SNP array techniques can map the presence of millions of SNPs in a single human 
genome – for example, the methodology described in section 5.2.2 involves the use of a SNP 
array mapping 2.44 million SNP loci – allowing for the very close definition of a disease linked 
region, which can then be investigated in detail to identify disease-associated variants or 
mutations. This technique was used successfully to identify the mutations described in 
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chapter 5, and in numerous other disease mapping studies. SNP array and linkage analysis 
techniques are particularly useful for identifying regions of homozygosity shared between 
individuals affected by inherited diseases in consanguineous families (or families where 
consanguinity is predicted to exist). For example, SNP arrays were used to identify the 
presence of three large stretches of homozygosity (on chromosomes 2, 5, and 21) shared by 
two individuals affected by the neonatal onset inflammatory skin and bowel disease 
described in chapter 3 (Blaydon et alet al., 2011a).  
Identifying a region of the genome linked to a particular disease then allows for the 
identification of the causative genetic mutation within the linked region. For example, in the 
investigation of a genetic cause for exfoliative ichthyosis, SNP arrays were used to identify a 
number of genomic regions linked to the disease in a large North African family. When 
analysed for potential candidate genes, the keratinocyte-expressed CSTA (cystatin A) gene 
could be identified as a likely candidate due to its presence in the linked regions, and known 
function as an inhibitor of proteases in the epidermis. This allowed for the specific 
sequencing of that gene, in which the disease associated mutation was then identified 
(Blaydon et alet al., 2011b).  
In recent years, next generation sequencing techniques have revolutionised genetic diagnosis 
of skin disease, by allowing particular, targeted portions of the genome to be specifically 
sequenced with high fidelity. This can be used, for example, to specifically capture and 
sequence exons (with or without non-coding regions of the genome) within a region 
specifically linked to disease; such as in the example of the neonatal onset inflammatory skin 
and bowel disease described above. In this case, a targeted capture array was used to 
specifically amplify all exons within the three stretches of homozygosity identified by SNP 
array as being shared between disease-affected individuals, allowing for the sequencing only 
of those regions already known to be linked to disease (Blaydon et alet al., 2011a). This 
resulted in the identification of a causative mutation that segregated with disease. A second 
practical example of a next generation sequencing technique is in the specific targeting of 
multiple genes known to be involved in disease pathogenesis, such as in the use of a targeted 
sequence capture method in the diagnosis of ichthyoses, a large and heterogeneous group of 
conditions characterised by scaling and/or hyperkeratosis over the majority of the skin. This 
technique featured the targeted capture and high-throughput sequencing of the exons of 24 
genes that had all been previously linked to varying forms of syndromic and non-syndromic 
ichthyosis, as well as striate palmoplantar keratoderma and peeling skin syndromes, by Scott 
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et alet al (Scott et al., 2013). The specific targeting of known ichthyosis genes therefore 
allowed for the genetic diagnosis of specific forms of ichthyosis in affected individuals.  
Next generation sequencing can also be used at a genome-wide level, to specifically capture 
every exon in the genome to the exclusion of all non-coding genomic regions. This technique 
is known as whole exome sequencing, and represents an efficient strategy for the detection 
of causal variants in rare inherited diseases. Only around 1% of the total human genome is 
made up of protein coding regions (split across approximately 180,000 exons), but this 1% 
harbours 85% of the mutations associated to inherited disease (Choi et alet al., 2009); as a 
result, exome sequencing allows for the efficient detection of rare variants in an individual’s 
genome, without the time, expense and resources required to sequence the entirety of that 
genome. Through bioinformatic analysis of exome data it is possible to identify rare and non-
synonymous coding variants in an individual exome, and to use these as the basis for further 
investigation into the genetic causes of Mendelian disease. In concert with SNP array 
analysis, this technique was used successfully to identify causative mutations in individuals 
affected by cryptogenic multifocal ulcerative stenosing enteritis, as described in chapter 5.  
By the nature of capturing only protein-coding portions of the genome, exome sequencing 
can however suffer from the limitation of not being able to detect disease-associated 
variants present in non-coding DNA. Examples of this include disease-associated mutations in 
gene promoter sequences, such as PTEN promoter mutations in Cowden or Bannayan-Riley-
Ruvalcaba syndromes (Zhou et alet al., 2003), TERT promoter mutations in familial 
melanoma (Horn et alet al., 2013), and APOE promoter polymorphisms associated with 
Alzheimer’s disease risk (Lambert et alet al., 1998).  In these cases, sequencing of the whole 
genome may represent a more efficient strategy.  
 
1.3.2 Genetic disease of the epidermis 
Large numbers of genes are involved in the correct differentiation and functioning of the 
epidermis, and as such numerous pathogenic mutations have been associated with diseases 
of the epidermis in humans. Although heterogeneous, many of these diseases share common 
features, such as palmoplantar keratoderma, a characteristic thickening of the skin on the 
palms and soles of the feet, which can be diffuse, focal or punctate in nature, and may or 
may not be accompanied by epidermolysis (Patel et alet al., 2007). Another major group of 
skin diseases are the ichthyoses, conditions characterised by scaling and/or hyperkeratosis 
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over the majority of the skin. The ichthyoses are separated into two major groups: the 
keratinolytic ichthyoses and the autosomal recessive congenital ichthyoses, the latter of 
which encompasses lamellar ichthyosis, congenital ichthyosiform erythroderma, and 
harlequin ichthyosis (the most severe known form) (Oji et alet al., 2010).  
The complex interactions required for the proper development and differentiation of skin 
mean that different mutations in the same gene can be associated with numerous different 
skin conditions (such as the multiple diseases arising from different KRT1 mutations), whilst 
in some cases the same disease can arise due to mutations in several distinct genes (for 
example, the multiple mutations causing lamellar ichthyosis and congenital ichthyosiform 
erthyroderma). Table 1.2 displays a selection of genes implicated in the development of 
numerous conditions which affect the epidermis. 
 
Gene Common Protein Name (if different) 
OMIM 
Number Associated Disease(s) 
AAGAB  614888 Punctate PPK 
ABCA12  607800 
Harlequin ichthyosis
Lamellar ichthyosis 
Congenital ichthyosiform erythroderma 
ABHD5  604780 Chanarin-Dorfman syndrome 
AP1S1  603531 MEDNIK syndrome 
ALOXE3 Arachidonate lipoxygenase 3 607206 Congenital ichthyosiform erythroderma 
ALOX12B Arachidonate 12-lipoxygenase, 12R 603741 Congenital ichthyosiform erythroderma 
AQP5 Aquaporin 5 600442 Non-epidermolytic PPK 
CDSN Corneodesmosin 602593 HypotrichosisPeeling skin syndrome 
CSTA Cystatin A 184600 Autosomal recessive exfoliative ichthyosis 
CYP4F22  611495 Lamellar ichthyosis 
DSG1 Desmoglein 1 125670 Striate PPK  
DSP Desmoplakin 125647 
Striate PPK 
PPK and woolly hair (with or without ARVC)  
ARVC alone 
Lethal acantholytic epidermolysis bullosa 
FLG Filaggrin 135940 Ichthyosis vulgaris Atopic eczema 
GJB2 Connexin 26 121011 
Bart-Pumphrey syndrome
Histrix-like ichthyosis with deafness 
Keratitis-ichthyosis-deafness syndrome 
PPK with deafness  
Deafness alone 
GJB3 Connexin 31 603324 Erythrokeratoderma variablis 
GJB4 Connexin 30.3 605425 Erythrokeratoderma variablis 
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JUP Plakoglobin 173325 PPK with ARVC and woolly hair (Naxos disease) 
KRT1 Keratin 1 139350 
Annular epidermolytic ichthyosis 
Epidermolytic ichthyosis 
Epidermolytic PPK 
Ichthyosis histrix 
Non-epidermolytic PPK 
Striate PPK 
KRT2 Keratin 2 600194 Superficial epidermolytic PPK 
KRT9 Keratin 9 607606 Epidermolytic PPK 
KRT10 Keratin 10 148080 
Epidermolytic hyperkeratosis 
Ichthyosis with confetti 
Cyclic Ichthyosis with epidermolytic 
hyperkeratosis 
KRT16 Keratin 16 148067 Non-epidermolytic focal PPK 
 
Table 1.2: Genes associated to selected diseases affecting the epidermis. Abbreviations: PPK – 
palmoplantar keratoderma; MEDNIK – mental retardation, enteropathy, deafness, neuropathy, 
ichthyosis and keratoderma; ARVC – arrhythmogenic right ventricular cardiomyopathy. More 
information on diseases associated to each gene can be found using the OMIM number provided.  
Gene Common Protein Name (if different) 
OMIM 
Number Associated Disease(s) 
LOR Loricrin 152445 Loricrin keratoderma 
NIPAL4  609383 Congenital ichthyosiform erythroderma 
POMP Proteasome Maturation Protein 613386 
Keratosis linearis-ichthyosis congenita-
keratoderma 
SERPINB7  603357 Nagashima-type PPK  
SLC27A4  604194 Ichthyosis prematurity syndrome 
SLURP1  606119 Meleda disease (palmoplantar hyperkeratosis) 
SNAP29  604202 CEDNIK Syndrome 
SPINK5 Lympho-epithelial Kazal-type-related inhibitor (LEKTI) 605010 
Netherton syndrome (ichthyosis with hair 
shaft defects and skin barrier dysfunction) 
STS Steroid Sulphatase 308100 Recessive X-linked Ichthyosis 
TGM1 Transglutaminase 1 190195 Lamellar ichthyosis Congenital ichthyosiform erythroderma 
TGM5 Transglutaminase 5 603805 Acral peeling skin syndrome 
 
Table 1.2 (continued): Genes associated to selected diseases affecting the epidermis. 
Abbreviations: PPK – palmoplantar keratoderma; CEDNIK – cerebral dysgenesis, neuropathy, 
ichthyosis and keratoderma; More information on diseases associated to each gene can be found 
using the OMIM number provided.  
 
 
The genes involved play a wide variety of roles in the epidermis; however, numerous genes 
identified as causing epidermal disease belong to closely related families, or contribute to 
similar processes in the epidermis, such as involvement in keratinocyte structure (keratins 1, 
2, 9, 10 and 16), stratum corneum formation (filaggrin, loricrin, TGM1 and TGM5), 
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desquamation (cystatin A, LEKTI), the packaging of lamellar granules (ABCA12), and the 
structure of intercellular junction complexes, including desmosomes (desmoplakin, 
desmoglein 1, plakoglobin, corneodesmosin) and gap junctions (connexins 26, 30.3 and 31).  
It is notable that many of these inherited skin conditions are syndromic in nature. That is, 
although skin manifestations may in many cases be a prominent feature, they are 
accompanied by disease affecting numerous other tissues. Examples of this include 
mutations in desmosomal components (such as desmoplakin or plakoglobin), which may also 
cause disorders such as (among others) woolly hair, alopecia, and arrhythmogenic right 
ventricular cardiomyopathy, in addition to skin manifestations of palmoplantar keratoderma 
or epidermolysis bullosa (Brooke et alet al., 2012). Next, mutations in the connexin 26 gene 
(GJB2) may variously cause ichthyosis, keratitis or palmoplantar keratoderma, which may or 
may not be accompanied by inherited deafness (which can also be the sole symptom of GJB2 
mutation) (Scott et alet al., 2012). Lastly, a skin phenotype may represent only one of 
numerous symptoms of wide-ranging developmental disorders, examples of which include 
MEDNIK (mental retardation, enteropathy, deafness, neuropathy, ichthyosis and 
keratoderma) (Montpetit et alet al., 2008) and CEDNIK (cerebral dysgenesis, neuropathy, 
ichthyosis and keratoderma) (Sprecher et alet al., 2005) syndromes. As such, skin diseases 
with manifestations in other tissues are not uncommon, meaning that the investigation of 
inherited skin diseases cannot always focus exclusively on the skin to the exclusion of other 
tissues.  
 
1.4 Aims and scope 
The aims of this thesis are to investigate the genetic and functional basis of three distinct 
rare inherited diseases, which variously affect the skin and gut of humans.  
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2. Materials and Methods 
 
2.1. Introduction 
This chapter will describe the materials and methods that were used to generate the data 
presented in the forthcoming results chapters 3-5. Several of the methods described here 
were used to generate results that will be shown in all three results chapters, and as such the 
methods described will not be split into chapter-specific sections, but will rather all be 
presented together.  
 
2.2. Materials and Methods 
 
2.2.1. SNP Mapping and Targeted Sequence Capture 
Genetic investigations into the pair of siblings affected by the early-onset inflammatory skin 
and bowel disease described in chapter 3, which was later discovered to be associated to 
homozygous loss-of-function mutations in ADAM17, was undertaken by Dr. Diana Blaydon 
(Centre for Cutaneous research, Blizard Institute, London), Dr. Franz Rüschendorf (Max-
Delbrück-centrer for Molecular Medicine, Berlin), Dr. Vincent Plagnol (University College 
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London Institute of Child Health, London), Prof. David van Heel (Centre for Digestive 
Diseases, Blizard Institute) and Prof. David Kelsell (Centre for Cutaneous Research, Blizard 
Institute).  
A combination of SNP homozygosity mapping, targeted sequence capture and sequencing 
were performed to identify disease-associated mutations. SNP homozygosity mapping of the 
two affected individuals, their parents and an unaffected sibling, was performed using 
Affymetrix 10K SNP arrays (Affymetrix, Santa Clara, USA); all exons in regions identified as 
having putative linkage were then included on a Nimblegen sequence capture array (Roche 
Nimblegen, Madison, USA), and were subsequently sequenced by next generation 
sequencing on an Illumina GAII sequencer (Illumina Inc. San Diego, USA).  
Full details can be found in Blaydon et alet al (Blaydon et al., 2011a). 
 
 
2.2.2. SNP Homozygosity Mapping and Linkage Analysis in a severe gut disease 
Entirely separately from the investigations in chapter 3, the severe inherited gut disease 
described in chapter 5 was investigated by a combination of SNP homozygosity mapping, 
linkage analysis and exome sequencing. SNP homozygosity mapping and linkage analysis was 
performed by Dr. Franz Rüschendorf (Max-Delbrück-centrer for Molecular Medicine, Berlin). 
Both of the affected siblings were genotyped using an Illumina Omni2.5-Quad v1.0 SNP array 
(Illumina Inc. San Diego, USA), an array that provides the position of 2.44 million SNPs 
genome-wide.  
Linkage anaylsisanalysis was performed using the program Merlin (Abecasis et alet al., 2002), 
and a reduced marker set of 64,983 SNPs, with the assumption of a degree of consanguinity 
between the parents of the two affected individuals (a second cousin marriage), a recessive 
genetic model with complete penetrance, and allele frequencies from a European 
population.  
To narrow down the border of homozygous regions identified between the two siblings, 
information on all 2.44 million SNPs mapped by the array was used. A self-written Perl script 
was used to extract regions where both affected individuals were homozygous on the same 
allele (identical by state). 
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2.2.3. Whole Exome Sequencing in a severe gut disease 
Whole exome sequencing of one of the individuals affected by the severe inherited gut 
disease was performed in tandem to the homozygosity mapping and linkage analysis 
described in the preceding section. Whole exome sequencing was carried out using a 
Sureselect Human all-exon 50Mb kit (Agilent technologies, Santa Clara, USA) and sequenced 
on an Illumina HiSeq (Illumina Inc. San Diego, USA).  
Whole exome data was were analysed by Dr. Vincent Plagnol (University College London 
Institute of Child Health, London). Sequencing reads were aligned to the hg19 build of the 
human reference genome using the software novoalign (http://www.novocraft.com). SNP 
and insertion/deletion calling were performed using samtools V.0.18 and were annotated 
using the software ANNOVAR (Wang et alet al., 2010). Candidate variants were filtered on 
the basis of function (as predicted by ANNOVAR), and 1000 Genomes 
(http://www.1000genomes.org) and NLHBI exome sequencing project 
(http://evs.gs.washington.edu/EVS/) frequencies. 
 
2.2.4. DNA and RNA Extraction 
DNA or RNA was extracted from keratinocyte cell cultures or blood specimens (collected in 
heparinised or citrate-lined collection tubes) using Qiagen DNeasy (DNA) or RNeasy (RNA) 
kits (Qiagen, Crawley, UK), according to manufacturer’s instructions.  
DNA and RNA concentrations in extracted specimens were measured using a Nanodrop ND-
1000 spectrophotometer. Concentrations of both DNA and RNA are measured by absorbance 
at 260nm, with the purity of nucleic acid present in the sample analysed by measuring the 
ratio of absorbance at 260 and 280nm, with a 260:280nm ratio above 1.8 considered to 
represent pure DNA, and a ratio above 2 representing pure RNA. 
2.2.5. Reverse Transcription 
Conversion of extracted total RNA to cDNA was performed by reverse transcription using 
Superscript II reverse transcriptase (Invitrogen, California, USA) as the active enzyme. 
Reverse transcription was performed according to manufacturer’s instructions. Briefly, for 
each sample undergoing reverse transcription a 12µl reaction volume was made up, 
containing 200ng of total RNA, 0.5μl of random hexamers (200 μM), and 1μl of dNTPs (10 
mM) in addition to distilled water (dH2O). Each reaction volume was incubated at 65°C for 5 
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minutes then chilled on ice, following which 4μl of 5x first strand buffer, 2 μl of 0.1 M DTT 
and 1 μl of RNase OUT (a recombinant ribonuclease inhibitor; all Invitrogen, California, USA) 
were added to each. Finally, 1μl  of superscript II reverse transcriptase (200U/μl) was added, 
following which the samples were incubated at 42°C for 50 minutes, then 70°C for 15 
minutes, in a PTC-225 Peltier thermal cycler (MJ Research, Quebec, Canada).  
2.2.6. Primer Design 
Primers for all standard and quantitative PCR were designed using Primer-BLAST 
(www.ncbi.nlm.nih.gov/tools/primer-blast), using gene sequences derived from Ensembl 
(www.emsembl.org; for sequencing whole exons) or Entrez gene 
(www.ncbi.nlm.nih.gov/gene; for mutation confirmation, and cDNA primers). 
For sequencing whole genes, primers were designed to lie in the introns surrounding the 
exon(s) of interest, such that the entire exon(s) and the splice site immediately flanking it 
were present in their entirety in the PCR product. For quantitative PCR of cDNA, primers 
were designed such that at least one of the primers spanned an exon-exon junction within 
the cDNA target, meaning that the only sequence amplified by the primer pair would be 
cDNA, rather than any genomic DNA contamination.  
For quantitative PCR, Taqman chemistry was used. In brief, this method detects the 
production of the targeted PCR product via the use of a fluorescently labelled probe, whose 
sequence is complimentary to a section of the PCR product amplified by the specific primers 
used. This allows for very specific detection of the specific product targeted, as unintended 
products of the primers used cannot be bound to by the probe. Furthermore, this allows for 
the simultaneous detection of two or more PCR products in a single reaction mixture (using a 
separate, differently-labelled probe for each), such as in this case the simultaneous 
measurement of a gene of interest and a control. Probes were designed using Primer-BLAST 
(as above), probes against genes of interest were labelled with the green fluorophore 6-FAM, 
whilst probes against control genes were labelled with the yellow fluorophore HEX.  
Primers and probes were purchased from, and synthesised by Sigma Aldritch (Dorset, UK). 
The sequence of each primer and probe used is shown in appendix 1.  
2.2.7. Polymerase Chain Reaction (PCR)  
Standard PCR was carried out using BioTaq DNA Polymerase (Bioline, London, UK) as the 
primary active enzyme according to well established principles. Briefly, each 20µl reaction 
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mixture was made up of 2 µl 10X PCR buffer, 1.5mM MgCl2, 200µM of each 
deoxyreibonucelotide (dNTPs), 1µM of each primer, 1U Taq polymerase, 1-5ng of sample 
DNA, and dH2O. PCR reactions consisted of 10 minutes at 95°C, followed by 35 cycles of 30 
seconds at 95°C, 30 seconds at 60°C and 1 minute at 72°C, and a final 10 minutes at 72°C. 
PCR was performed using a PTC-225 Peltier thermal cycler (MJ Research, Quebec, Canada).  
Primer products were visualised following PCR by first separating by electrophoresis in 1.6% 
agarose gels, then UV transillumination.  
2.2.8. Sanger Sequencing 
Di-deoxy Sanger sequencing of PCR products was performed privately by Source Bioscience 
(Nottingham, UK), using PCR products and primers designed as described in the preceding 
sections.  
 
 
2.2.9. Sequence Analysis 
Sequence traces were viewed and analysed using Chromas Lite 2.1 software (Technelysium, 
South Brisbane, Australia; www. technelysium.com.au). Control sequences and sequences of 
interest were aligned using the Multalin multiple alignment tool 
(multalin.toulouse.inra.fr/multalin). 
For protein sequences and analysis of conservation, details of protein sequences for non-
human species were also obtained from the NCBI Protein database 
(http://www.ncbi.nlm.nih.gov/protein); these were aligned and compared using the 
ClustalW2 multiple sequence alignment tool (www.ebi.ac.uk/tools/msa/clustalw2) and 
visualised using the Jalview multiple alignment editor (www.jalview.org).  
2.2.10. Quantitative PCR (qPCR) 
Quantitative real-time PCR was performed using a Rotorgene Q thermocycler (Qiagen, 
Crawley, UK), according to established principles. Briefly, each 20µl reaction mixture 
consisted of 2x Rotorgene multiplex PCR buffer (Qiagen, Crawley, UK), 1µM of forward and 
reverse primer for both the gene of interest and a control, 500nM of labelled probe for both 
the gene of interest and a control, 1ng cDNA, and dH2O.  
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qPCR reactions consisted of 10 minutes at 95°C, followed by 46 cycles of 95°C for 15 seconds, 
and 60°C for 50 seconds. During each 60°C step, fluorescence acquisition was performed in 
the green and yellow channels to detect fluorescence resulting from the binding of 6-FAM- 
and HEX-labelled probes respectively. Data was were collected and analysed by Rotorgene 
software.  
Expression of the gene of interest was calculated by the ΔCt method, in which expression of a 
gene of interest relative to a control is equal to 2ΔCt, where ΔCt is the difference between the 
cycle number at which the fluorescence of each probe rises above the level of background 
fluorescence (Livak and Schmittgen, 2001).  Statistical analysis was performed using 
Student’s unpaired t-test.  
2.2.11. Keratinocyte Cell Culture and Stimulation Assays 
Culture of K17, Neb1, TYLK1 and TYLK2 keratinocyte cell lines (to be described in more detail 
in chapter 4) was performed using Dulbecco’s Modified Eagle’s Medium (DMEM; Sigma 
Aldritch, Dorset, UK) supplemented with 2mM L-glutamine, 10% Foetal Bovine Serum (FBS; 
percentage by volume) 5,000U/ml Penicillin, 5,000μg/ml Streptomycin, and a keratinocyte-
specific supplement containing Transferrin (at a final concentration of 5µg/ml in medium), 
hydrocortisone (0.4µg/ml), cholera toxin (10-10M), insulin (5µg/ml), and lyothyronine (2x10-
11M). In addition, EGF was optionally added to the medium at a final concentration of 
10ng/ml; EGF-containing medium was referred to as ‘RM+’, whilst EGF-free medium was 
referred to as ‘RM-‘. Cells were cultured at 37°C and 5% CO2, and were passaged via the use 
of trypsin upon reaching 80-90% confluence.  
For keratinocyte stimulation assays, normal keratinocyte growth medium was supplemented 
variously with 100ng/ml phorbol myristate acetate (PMA; Sigma-Aldritch, Dorset, UK), 1-
1000ng/ml bacterial lipopolysaccharide (LPS; InvivoGen, San Diego, USA), 1µM GW280264X 
(an ADAM17 inhibitor; manufacturer), 2000pg/ml recombinant amphiregulin (R&D Systems, 
Minneapolis, USA), or dimethyl sulphoxide (DMSO; Sigma-Aldritch, Dorset, UK).  
For cell culture secretion assays, two slightly different protocols were used, depending on 
whether or not siRNA knockdown of particular gene expression was performed. When siRNA 
was employed, cells were seeded at an initial concentration of 1.5x105 cells per well of a 12-
well cell culture plate in standard RM+ medium; after 24 hours, siRNA was used to 
knockdown gene expression as described in section 2.13. siRNA-containing transfection 
medium was removed from the cells 24 hours after that, and (after thorough washing) 
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replaced with the medium in which protein concentrations were to be measured. In the case 
of stimulation assays, it was this medium to which the relevant stimulant was added. This 
medium was left on the cells for a further 24 hours, at which point (i.e. 72 hours after the 
cells were initially seeded) it was removed for testing by ELISA.  
When no siRNA was used, the experiment proceeded similarly, except that the initial 
concentration of cells seeded was 3x105 per well of a 12-well plate. The medium to be tested 
was then added to these cells 24 hours after seeding, and removed for testing a further 24 
hours after that (i.e. 48 hours after initial seeding). When the small molecule GW280264X 
was used to inhibit ADAM17-dependent shedding, GW280264X-containing medium was 
added to the cells 2 hours before the start of the 24-hour measurement period. After 2 hours 
this medium was replaced with fresh GW280264X-containing medium, which was then 
tested by ELISA after 24 hours incubation. 
In all cases, each cell line was cultured in triplicate under every condition tested. In chapter 4, 
data is are often presented as pooled results from ‘control’ (K17 and Neb1) and ‘tylosis’ 
(TYLK1 and TYLK2) keratinocytes. Each of these therefore represents 6 biological replicates.  
2.2.12. Three dimensional organotypic keratinocyte cell culture 
Three-dimensional organotypic keratinocyte cell culture models were made by Prof. Spiro 
Getsios, and Dr. Nihal Kaplan (Northwestern University Feinberg School of Medicine, 
Chicago, USA), using control and TOC keratinocytes according to methods previously 
described (Getsios et alet al., 2009, Simpson et alet al., 2010).  
Briefly, J2-3T3 fibroblasts maintained in DMEM containing 10% FBS were trypsinized and 
resuspended (2.5x105/ml) in an ice-cold, pH neutralized DMEM-rat tail collagen (4 mg/ml; BD 
Biosciences, San Jose, CA) solution. The collagen-fibroblast slurry was polymerized in a 12 
well plate (2 ml/well) at 37 oC for 30 minutes and maintained in J2-3T3 culture medium for 
24 hours in a humidified tissue culture incubator at 37 oC and 5% CO2.  Control or TOC 
keratinocyte lines were trypsinised and resuspended in RM+ DMEM. 5x105/ml keratinocytes 
were seeded onto a collagen-fibroblast plug established in duplicate for each experiment. 
Keratinocyte-collagen plugs were maintained as submerged cultures for 48 hours to ensure 
an intact, confluent epidermal sheet of keratinocytes covered the entire surface of the 
dermal equivalent prior to air exposure. A sterilized metal spatula was used to transfer the 
keratinocyte-collagen plug to the top of a stainless steel meshed wire grid raised above the 
surface of a 60 mm petri dish. RM- FAD medium was added to the bottom chamber of the 
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wire mesh in contact with the base of the collagen plug, thereby exposing the keratinocytes 
to an air-liquid interface. The culture medium was replaced every two days, and the  
organotypic cultures were maintained in a humidified tissue culture incubator at 37°C and 
5% CO2 for 12 days. Duplicate cultures were established from each control and TOC 
keratinocyte cell line, and the raft culture experiment was repeated on three separate 
occasions.  
Following the establishment of three-dimensional cultures, cell culture supernatants were 
removed for analysis by ELISA, and the cultures themselves were either sectioned (for 
histological examination, immunohistochemistry, or transglutaminase activity assays) or 
homogenised and lysed (for western blotting examination). Subsequent assays were then 
performed as described in the relevant sections of this chapter.  
 
2.2.13. siRNA Knockdown 
siRNA knockdown of ADAM17 or iRHOM2 was performed on keratinocytes in culture using 
OnTarget SMARTPool siRNA specific to ADAM17, iRHOM2, or non-targeting pool (NTP) siRNA 
(Thermo Fisher Dharmacon, Lafayette, Colorado, USA). In brief, growing cells are were 
incubated for 24 hours at 37°C and 5% CO2 with penicillin- and streptomycin-free medium, 
containing 100nM ADAM17, iRHOM2 or NTP siRNA, alongside the transfection reagent 
DharmaFECT 1 (Thermo Fisher Dharmacon, as above). Following this, expression of ADAM17 
and iRHOM2 was analysed by western blot and qPCR, as described in the relevant sections of 
this chapter. 
2.2.14. Enzyme-linked Immunosorbent Assays (ELISA) 
ELISA techniques were used to measure the secretion of TNFα, IL-6, IL-8, amphiregulin, TGFα, 
HB-EGF, IL-17A, IL-17F, IL-22 and IL-23 in the culture medium in which keratinocytes and 
PBMCs had been cultured. DuoSet ELISA kits for each of the above were purchased from R&D 
systems (Minneapolis, USA) and used according to manufacturer’s instructions. 
In brief, ELISA-specific MaxiSorp 96-well plates (Thermo Fisher Nunc) were first incubated 
overnight with an assay-specific primary ‘capture’ antibody diluted to an assay-specific 
concentration in 1% bovine serum albumin in PBS solution (1% BSA/PBS). Unless otherwise 
noted, 100µl of all solutions were added to each well of the 96-well plate. The following day, 
this antibody was washed off by filling each well of the 96-well plate three times with a wash 
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buffer made up of 0.05% Tween 20 in PBS, and drying (this standard wash was repeated 
between every step of the ELISA process). Next, non-specific binding was blocked by a 1-hour 
incubation with 1% BSA/PBS. After washing, the supernatants of interest were added to the 
plate and incubated for 2 hours. Depending on the assay and the concentration of the 
substrate expected to be present, supernatants may have been diluted in 1% BSA/PBS before 
being added to the ELISA plate; for example, supernantants were typically diluted 1 in 10 for 
amphiregulin ELISAs and 1 in 20 for IL-8 ELISAs, but were undiluted for TGFα and HB-EGF 
ELISAs. After washing, an assay-specific biotinylated ‘detection’ antibody diluted in 1% 
BSA/PBS is was next added to the plate, and incubated for a further 2 hours. The plate was 
then washed again, after which a solution of horseradish peroxidase (HRP)-streptavidin, 
diluted 1/200 in 1% BSA/PBS, was added, and incubated in darkness for 20 minutes. The 
plate was then washed for the final time, and a solution of HRP substrate (R&D Systems, 
Minneapolis, USA) was added, which produces a colour change proportionate to the HRP 
activity of each well, and therefore proportionate to the concentration of the ELISA target in 
the supernatant sample tested in each well. After 20 minutes incubation in darkness, the 
colour change reaction was stopped by the addition of 50µl 2N H2SO4 to each well, following 
which the absorbance readings of every well were read at 450nm.  
Aside from the use of different capture and detection antibodies (and the concentrations 
thereof), ELISAs for all of the tested substrates described above followed the same protocol, 
with the sole exception of IL-8 ELISAs, in which 1% BSA/PBS was replaced throughout with 
0.1% BSA/PBS containing 0.05% Tween 20, and in which the blocking step was performed 
using 1% BSA/PBS supplemented with 0.05% sodium azide (NaN3), per manufacturer’s 
instructions.  
To calculate the concentration of the ELISA target protein in each well, each ELISA plate 
included a 1-in-2 dilution series of the relevant protein being tested, at an assay dependent 
series of concentrations. Each of these dilution series contained 8 dilutions of the relevant 
protein (including a zero). The absorbance readings of these standards were used to make a 
standard curve for that ELISA plate, from which the concentrations of the protein in each of 
the other sample wells can be calculated. Each supernatant sample being tested was assayed 
in duplicate on each ELISA plate, with the mean of these duplicate results then used to 
calculate the protein concentration of each sample.  
Statistical analysis of ELISA results was performed using 2-way ANOVA and Bonferroni’s post-
hoc test, to analyse whether or not levels of secreted protein were significantly different 
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between control and tylosis keratinocytes, and between treated (with, for example, PMA, 
ADAM17 siRNA or GW280264X) and untreated keratinocytes.  
2.2.15. Wound healing (scratch) assays 
To assess the wound healing activity of keratinocytes, scratch assays were performed on 
monolayer keratinocytes under standard cell culture conditions (37°C and 5% CO2). 
Keratinocytes were seeded in triplicate at a concentration of 4x105 cells per well of a 12-well 
cell culture plate, in RM+ medium, and allowed to proliferate for 48 hours before the scratch 
assay took place.  This medium was removed, and replaced (after thorough washing) with 
RM- medium two hours prior to scratch wounding taking place. If GW280264X was being 
used to block ADAM17 activity, this inhibitor was included in the RM- medium added at this 
point.  
Each keratinocyte monolayer was then scratched using a 1000µl pipette tip, once 
horizontally and once vertically, to form a cross pattern. After washing, scratches were 
visualised using a Nikon Eclipse TE-2000S microscope (Nikon Instruments, Kingston-Upon-
Thames, UK) and a picture was immediately taken of the section of the vertical scratch 
immediately above the centre of the cross (the 0 hour time point) using a Nikon Digital Sight 
DS-Fi2 Camera (Nikon Instruments, UK). The medium in which the keratinocytes were 
cultured was changed after 24 and 48 hours, at which points a second and third picture of 
the same section of each well was taken. The area of the scratch wound shown in each 
picture was quantified using ImageJ software (US National Institutes of Health, Bethesda, 
USA; www.imagej.nih.gov/ij). The differences in the size of the scratch wound after 24 and 
48 hours were then used to calculate the area over which the keratinocytes had migrated in 
that time period. An example of this calculation can be seen in figure 2.1. Every condition 
tested was examined in triplicate for each cell line.  
For scratch assays examining the effect of keratinocyte conditioned media, the TYLK- or 
Control-conditioned mediums were made by pooling equal proportions of RM- medium in 
which either K17 and Neb1 (Control-conditioned medium) or TYLK1 and TYLK2 (TYLK-
conditioned medium) had been growing for 24 hours.  
To measure growth factor secretion into the medium following scratch wounding, the 
medium removed from the keratinocytes after 48 hours (i.e. that representing the second 24 
hour period after the scratch wound took place) was collected and analysed by ELISA. To 
measure amphiregulin secretion over time, each keratinocyte cell line was seeded in 
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triplicate into wells representing 1, 3, 6, 12, 24 and 48 hours, which were all scratched at the 
same time, with medium being removed from each at the appropriate time point and 
analysed by ELISA.  
 
 
 
 
 
Figure 2.1: Quantification of scratch wounding assays. To quantify keratinocyte migration in 
scratch wounding assays, a picture was taken of the same part of the scratch wound immediately 
after wounding (0h) and at 24 hour intervals after wounding (24h and 48h). The area of the 
scratch wound in each image was then quantified as shown, using ImageJ software (US National 
Institutes of Health, Bethesda, USA; www.imagej.nih.gov/ij), with migration then calculated as 
the difference between the scratch wound areas at 0h and 24 or 48h. The pictures in this 
example show TYLK2 keratinocytes in control medium in the absence of exogenous EGFR ligands, 
and also appear in figure 4.24. Note that the pictures taken appear to be different colours due to 
the 0h and 24h picturtespictures being taken with the cells in cell culture medium, whilst the 48h 
picture is in PBS (the medium having been removed for ELISA analysis).  
 
Statistical analysis of keratinocyte migration was performed using 2-way ANOVA and 
Bonferroni’s post-hoc test, to analyse whether or not migration differed significantly 
different between control and tylosis keratinocytes, and between treated (with, for example, 
GW280264X or TYLK-conditioned medium) and untreated keratinocytes.  
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2.2.16. Peripheral Blood Mononuclear Cell (PBMC) Extraction and Culture 
Isolation of PBMCs from whole venous blood samples of subjects for analysis was performed, 
following manufacturer’s instructions, using  Ficoll Paque Premium isolation medium (GE 
Healthcare Life sciences, Buckinghamshire, UK), a density gradient medium that allows for 
the separation of whole blood into plasma, erythrocytes, granulocytes and PBMCs. In brief, 
2ml of isolated, anticoagulant-treated whole blood was mixed 1:1 with PBS; the 4ml of 
diluted blood was then carefully layered on top of 3ml of Ficoll Paque premium in a 
centrifuge tube (for larger blood samples, these volumes could also be proportionally scaled 
up using larger centrifuge tubes), after which the tube was centrifuged for 40 minutes at 
400x g, with the centrifuge brake disabled. This process effectively splits each blood sample 
into the layers described above, meaning that PBMCs (the second-to-top layer) can be 
extracted and re-suspended in PBS once the uppermost serum layer is removed.  
Rather than DMEM (as used for keratinocytes), isolated PBMCs were cultured at 37°C and 5% 
CO2 in RPMI medium supplemented with 10% FBS. PBMCs were counted and 2x105 PBMCs 
from each specimen of interest were seeded in triplicate into 96-well cell culture plates. The 
PBMCs were then cultured for 24 hours in either non-supplemented medium, or medium 
supplemented with 100ng/ml PMA (Sigma-Aldritch, Dorset, UK) or 1-1000ng/ml LPS 
(InvivoGen, San Diego, USA). Alternatively, the PBMCs could be seeded into 96-well cell 
culture plates which were coated with an anti-CD3 antibody (BD Biosciences, Oxford, UK), 
and treated with an anti-CD28 antibody (eBioscience, San Diego, USA) at a concentration of 
1µg/ml. After 24 hours, the cell culture supernatants were removed and analysed by ELISA. 
2.2.17. Immunocytochemistry 
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Immunofluorescence staining of keratinocyte monolayers was performed on cells which had 
been seeded and cultured directly on 16mm-diameter circular glass cover slips. Cells were 
fixed in a solution of 4% paraformaldehyde (PFA) for 30 minutes, following which cell 
membranes were made permeable by incubation with a solution of 0.5% Triton-X100 in PBS 
for 10 minutes at room temperature. After thorough washing (at least five times for five 
minutes) in PBS, the cells were next incubated for 30 minutes in a solution of 10% goat 
serum in PBS in order to block non-specific antibody binding. 
For antibody incubation steps, keratinocytes were incubated with antibody solution via the 
inversion of the keratinocyte-coated coverslip onto a 50µl droplet of antibody solution. Cells 
were incubated with a solution of one or two (for co-localisation staining) primary 
antibodies, diluted to an assay dependent dilution in either 3% BSA or 5% goat serum in PBS, 
for one hour at room temperature. A list of antibodies used in immunocytochemistry, 
immunohistochemistry and western blotting, and the concentrations at which each was 
used, is shown in table 2.1. After primary antibody incubation, cells were thoroughly washed 
in PBS, then incubated simultaneously with one or more fluorophore-conjugated secondary 
antibodies, diluted in PBS only, under the same conditions as for primary antibodies. Cells 
were then once more thoroughly washed, before being mounted in Immuno-Mount 
mounting medium (Thermo Scientific, Pittsburgh, USA) containing 10µg/ml 4’6-diaminido-2-
phenylindole (DAPI), a nuclear stain. Cells were viewed and imaged using a Leica DM5000 
automated epifluorescence microscope (Leica, Milton Keynes, UK).  
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Primary Antibodies
Antibody 
(species and type) 
Manufacturer 
& Product Code 
Immunocyto-
chemistry 
dilution 
Immunohisto-
chemistry 
dilution 
Western blot 
dilution 
ADAM10 
(Rabbit polyclonal) 
Millipore 
AB19026 - - 1/1000 
ADAM17 Total  
(Rabbit polyclonal) 
Abcam 
Ab2051 1/100 1/150 1/2000 
ADAM17 Pro-domain 
(Rabbit polyclonal) 
Abcam  
Ab39161 - - 1/2000 
Calnexin 
(Mouse monoclonal) 
BD Biosciences 
610523 1/100 - - 
Cytosolic 
Phospholipase A2-α 
(Rabbit polyclonal) 
Abcam  
Ab58375 - 1/100 1/2000 
Desmoglein 2 
(Rabbit polyclonal) 
Gift from Dr. 
My Mahoney 
(Jefferson Inst. 
Philadelphia, 
USA) Ab10 
1/200 - 1/1000 
Filaggrin 
(Rabbit polyclonal) 
Covance 
PRB-417P - 1/400 - 
GAPDH 
(Rabbit polyclonal) 
Abcam
Ab9485 - - 1/2000 
GM130 
(Mouse monoclonal) 
BD Biosciences 
610882 1/100 - - 
IL-17A 
(Rabbit polyclonal) 
Abcam 
Ab79056 - 1/100 - 
Involucrin 
(Mouse polyclonal) 
Abcam
SY5 - 1/100 - 
iRHOM2 
(Rabbit polyclonal) 
Sigma-Aldritch 
HPA018080 - 1/100 1/500-1500 
Keratin 2E 
(Mouse polyclonal) 
Abcam 
Ab19122 - 1/100  
Loricrin Covance - 1/400 - 
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(Rabbit polyclonal) PRB-145P 
Transglutaminase 1 
(Mouse polyclonal) 
Biogenesis 
Ab5500-6006 - 1/100 - 
Immunofluorescence Secondary Antibodies
AlexaFluor-488 
Goat anti-rabbit 
Invitrogen 
A11008 1/1000-2000 1/1000 - 
AlexaFluor-488 
Goat anti-mouse 
Invitrogen 
A11029 1/1000-2000 1/1000 - 
Alexa-Fluor-594 
Donkey anti-mouse 
Invitrogen 
A21203 1/1000-2000 - - 
Western Blot Secondary Antibodies
HRP-conjugated 
Swine anti-rabbit 
Dako
P0399 - - 1/2000-5000 
HRP-conjugated 
Rabbit anti-mouse 
Dako  
P0260 - - 1/500-3000 
Table 2.1: Antibodies used in immunofluorescence staining and western blot studies 
 
2.2.18. Immunohistochemistry 
Both frozen and paraffin embedded tissues sections were used for immunohistochemistry, 
which necessitated slightly different staining protocols for each. In every case, the control 
tissue used for each staining experiment was from the same tissue as the diseased or patient 
specimens, and had been either frozen or embedded in the same way.  
For paraffin embedded tissue samples, sections were de-paraffinised by serial immersion in 
xylene (twice, for 5 minutes each), 100% ethanol (twice, 3 minutes each), 90% ethanol (3 
minutes), 70% ethanol (3 minutes) and finally running water (5 minutes). Antigen retrieval 
was then performed on each section, which consisted of heating each section three times for 
5 minutes in boiling citrate buffer (18ml 0.1M citric acid, 82ml 0.1M trisodium citrate, per 1L, 
in water). Frozen tissue sections were allowed to defrost and air-dry at room temperature. 
Following this, a protocol analogous to that used for immunocytochemistry was performed 
(using antibodies as shown in table 2.1), with the single exception being that antibody 
solutions were placed directly atop each tissues section, rather than the section being 
inverted onto them. 
2.2.19. Western Blotting 
For western blotting, whole cell lysates of keratinocytes were made by direct lysis of cells in 
the tissue culture plates in which they were cultured. Keratinocytes were lysed directly in a 
reducing and denaturing sample buffer containing 0.1M tris-HCl, 4% SDS, 20% Glycerol, 
1.44M β-mercaptoethanol and 0.001% bromophenol blue. For PBMC lysates, cells were 
collected as described in section 2.16, suspended in PBS, and spun into a cell pellet, which 
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was lysed directly by the addition of the lysis buffer described above. The resulting whole cell 
lysates from keratinocytes or PBMCs were subsequently heated at 95°C for at least 5 
minutes; if the lysates were excessively viscous, they were sonicated for 10-30 seconds.  
Western blotting of the collected lysates was performed according to standard principles. 
Briefly, the lysates were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 
8-12% polyacrylamide gels, alongside a 225-10kDa protein size marker (Rainbow Ladder, GE 
Healthcare, Buckinghamshire, UK). Proteins were then transferred onto Hybond C 
nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK) by electrophoretic transfer 
at either 300mA for 2 hours, or 100mA overnight. SDS-PAGE and electrophoretic transfer 
were performed using hardware from Bio-Rad (Hercules, California, USA).  
Non-specific binding was blocked by incubation of the membrane in either 10% milk or 10% 
BSA diluted in tris-buffered saline (TBS), supplemented with 1% Tween-20 (TBS-T), for one 
hour. Membranes were then cut to size, and incubated with primary antibody (at dilutions 
specified in table 2.1) diluted in 5% milk or 3% BSA in TBS-T, at 4°C overnight. After thorough 
washing in TBS-T (at least 4 washes for 5 minutes), membranes were then incubated with 
secondary antibody (as described in table 2.1) diluted in TBS-T for 2 hours at room 
temperature. After further thorough washing in TBS-T, membranes were treated with 
Immobilon Western chemiluminescent HRP substrate (Millipore, Bilerica, USA) to visualise 
proteins, which were shown using Amersham Hyperfilm ECL (GE healthcare, 
Buckinghamshire, UK) chemiluminescence film, developed with an automated developing 
machine.  
2.2.20. Transglutaminase Activity (Biotinylated-monodansylcadaverine) Assay  
For in situin situ detection of epidermal transglutaminase activity, the biotinylated 
monodansylcadaverine (biot-MDC) assay was used, as previously described (Raghunath et 
alet al., 1998). This assay works on the principle of the covalent incorporation of a 
biotinylated amine donor (monodansylcadaverine) into the active site of a transglutaminase, 
which can then be detected by the addition of a fluorphore conjugated to streptavidin. 
Because Biot-MDC can only be incorporated into transglutaminase 1 when it is in an active 
conformation, this assay will effectively measure the activity of TGM1, rather than simply 
measuring its presence. This assay has in the past therefore proven useful for the assessment 
of patients affected by lamellar ichthyosis (caused by mutations in the TGM1 gene), who may 
show normal levels of TGM expression in the skin, even though the associated mutations 
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have significantly reduced or entirely abrogated its enzymatic function (Raghunath et alet al., 
1998). Furthermore, by controlling the pH at which the assay is performed, it is possible to 
specifically differentiate TGM1 activity (TGM1 is active at pHs from 7 to 9) from that of the 
other major epidermal transglutaminase TGM3 (which is active only in a narrow pH window 
of around 8-8.4).  
In brief, frozen epidermal sections from normal controls and disease-affected individuals 
were preincubated with 1% BSA in 0.1 M Tris-HCl, at pH 7.4 (at which pH TGM1 is selectively 
active) for 30 min. The sections were then incubated for 2 hours with 100µM biot-MDC (or 
10mM EDTA as a negative control) and 5mM CaCl2 in 0.1 M Tris-HCl at pH 7.4. The reaction 
was halted by the addition of 10mM EDTA solution and washing with PBS, following which 
the sections were stained using a solution of Streptavidin conjugated to the fluorophore 
AlexaFluor-488 (Invitrogen, Massachusetts, USA), and mounted in medium containing DAPI. 
To quantify TGM1 activity in the granular layer, the average fluorescence intensity of the 
epidermis of negative control skin was calculated using ImageJ image analysis software (as 
previous), then subtracted from Biot-MDC positive specimen images. The fluorescence 
intensity in the granular layer of these normalised images was then isolated and measured 
specifically, using ImageJ.  
Statistical analysis was performed using Student’s unpaired t-test, to separately measure the 
significance of differences in the fluorescence intensity of TGM1 activity in the granular layer 
of control, ADAM17-null and TOC epidermis. 
The biotinylated-MDC used in the transglutaminase activity assays described here was a gift 
from Dr. Claus-Werner Franzke (University of Freiburg, Germany). 
2.2.21. Electron microscopy 
For electron microscopy studies of desmosomes, TOC and control epidermis specimens were 
fixed in phosphate buffered 4% glutaraldehyde, post-fixed in 1% osmium tetroxide and 
dehydrated through a graded ethanol series. They were then cleared in propylene oxide and 
infiltrated with Araldite. The cells were embedded by inverting ‘BEEM’ capsules filled with 
partly cured Araldite over the monolayer and incubating them at 60°C for 48 hours. After 
cutting away the silicone membrane, semi-thin sections (0.5 mm) for light microscopy were 
cut and stained with Toluidine Blue. Ultrathin sections (60–80 nm) were cut, mounted on 
copper grids and stained with uranyl acetate and lead citrate. They were examined in a 
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J.E.O.L. JEM 1230 electron microscope and images collected with an Olympus ‘Morada’ 2K × 
2K digital camera. 
Embedding of skin specimens was performed by Graham McPhail (Department of Cellular 
Pathology, Barts and The London NHS Trust, London, UK), whilst electron microscopy was 
performed by Professor Akemi Ishida-Yamamoto (Department of Dermatology, Asahikawa 
Medical University, Japan). 
 
 
 
 
2.2.22. Cytosolic Phospholipase A2-α activity Assays 
The majority of the cPLA2α activity studies described were carried out in collaboration with 
the research group of Prof. Tim Warner (William Harvey Research Institute, Barts and the 
London School of Medicine and Dentistry). 
Briefly, whole venous blood specimens were collected by venepuncture into tri-sodium 
citrate-lined vacutainers (BD Diagnostics, UK). Platelet-rich plasma (PRP) was obtained from 
whole blood by centrifugation at 175x g for 15 minutes at 25°C, followed by decanting of the 
topmost plasma layer. Platelet-poor plasma (PPP) was obtained by centrifugation of PRP at 
15000x g for 2 min. All experiments were completed within 2 hours of blood collection.  
For light transmission aggregometry, responses to arachidonic acid (1mM; Sigma, UK), 
‘Horm’ collagen (a suspension of native collagen fibrils; 0.3-3μg/ml; Nycomed, Austria) or 
ADP (5μM; Chronolog, UK) were measured in a Bio/Data PAP-8E turbidometric aggregometer 
(37°C, 1200rpm stir speed, 4min) with platelet aggregation determined as % change in 
absorbance PRP vs. PPP. At the end of the PRP aggregation monitoring, cyclo-oxygenase 
activity was halted by the addition of 1mmol/L diclofenac (Sigma, UK), the samples 
centrifuged at 1300g for 10min at 4°C, and the supernatants removed and frozen. Plasma 
thromboxane B2 (TXB2) levels, as a surrogate for thromboxane A2 production, were 
subsequently determined using a selective, competitive enzyme immunoassay (Cayman 
Chemical, USA) according to manufacturer’s instructions.  
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Platelet aggregation was also determined by a standardised optical multichannel 
absorbance-based method (‘Optimul’), as previously described (Chan et alet al., 2011, Chan 
and Warner, 2011). In brief, PRP was added to clear half-area 96-well microplates containing 
lyophilized platelet agonists: arachidonic acid (at a final concentration of 0.03-1mM), ADP 
(0.005-40μM), Horm collagen (0.01-40μg/ml), epinephrine (0.0004-10μM; Chronolog, UK), 
U46619 (a thromboxane A2 receptor agonist; 0.005-40μM; Cayman Chemical, USA) or 
ristocetin (0.14-4mg/ml; Helena Bioscience, UK) or vehicle.  PPP was added to some wells as 
reference to 100% aggregation. Plates were then vigorously mixed (1200rpm, 37°C; BioShake 
IQ, Q Instruments, Germany) for 5min and absorbance at 595nm measured using a standard 
absorbance microplate reader (Sunrise, Tecan, Switzerland). Platelet aggregation was 
calculated as % change in absorbance PRP vs. PPP. 
In all platelet studies, responses of sibling platelets were compared to those prepared from 
healthy volunteers, with and without in vitro treatment with aspirin (30 μM; Sigma, UK). ATP 
and TXB2 release data were normalised to the platelet count in PRP. 
2.2.23. Figures and Graphs 
All graphs presented in this thesis were produced using GraphPad Prism (GraphPad Software, 
San Diego, USA), and all figures were drawn using Adobe Illustrator CS6. All statistical 
analyses were likewise performed using GraphPad Prism. The cPLA2α structure shown in 
chapter 5 was retrieved from the NCBI Conserved Domains database (accession number: 
cd07200) and visualised using Cn3D software (Wang et alet al., 2000).  
2.2.24. Statistical Analysis 
All statistical analyses were likewise performed using GraphPad Prism (San Diego, USA). For 
simple pairwise comparisons, student’s unpaired t-test was used, whilst for analyses 
comparing the effect of more than one independent variable (such as the effect of an 
inhibitor drug on keratinocytes derived from control or TOC-affected individuals) two-way 
ANOVA followed by Bonferroni’s post-hoc test was used. The statistical analysis used to 
analyse significance is detailed in the legend of each figure, where appropriate. . 
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3. ADAM17 Loss-of-function mutations in humans 
 
3.1. Introduction 
This chapter describes investigations into the genetic cause and pathophysiology of a rare, 
neo-natal onset, recessively-inherited syndrome of skin and bowel inflammation. Through a 
combination of SNP homozygosity mapping and targeted next-generation sequencing, this 
syndrome was associated in a single, consanguineous affected family with a homozygous 
deletion mutation in ADAM17, a gene encoding the multi-substrate ectodomain sheddase 
enzyme ADAM17 (also known as tumour necrosis factor-alpha [TNFα] converting enzyme; 
TACE), which is described in detail in chapter 1.  
Investigations into the pathophysiology of this syndrome were carried out using blood and 
skin samples derived directly from one affected individual, his unaffected mother, and a 
number of otherwise healthy normal controls.  
 
3.2. Results – ADAM17 mutations in a UK-based family 
 
3.2.1. A neonatal-onset inflammatory skin and bowel syndrome – phenotype 
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A neonatal-onset syndrome of inflammatory skin and bowel disease was identified in two of 
three children (one male, one female) born to consanguineous (first cousin) parents of 
Lebanese origin. The clinical features involved were the same for both children, and 
developed very soon after birth, with skin lesions being observed on the second day of life, 
and diarrhoea within a week. Both siblings developed perioral and perianal erythema with 
fissuring, and a generalised pustular rash that developed into psoriasiform erythroderma, 
with flares of erythema and scaling. The skin phenotype can be observed in figure 3.1 (A-B). 
The skin of both affected siblings was prone to Staphylococcus aureus infection, which 
resulted in repeated instances of blepharitis (inflammation of the eyelids), and otitis externa 
(external ear infection) as well as skin infection. Similarly, the nails were thickened, and 
susceptible to frequent instances of paronychia caused by bacterial and fungal (Candida) 
infections (figure 3.1, C).  
The hair of the affected individuals was short and broken, whilst the eyebrows and eyelashes 
were wiry and disorganised (figure 3.1, A). Microscopic examination of the hair revealed the 
presence of an unusual hair shaft abnormalilty, severe weathering, and a markedly damaged 
cuticle. In addition to the inflammatory skin phenotype, both siblings were affected by 
recurrent diarrhoea, which worsened in parallel with increases in the severity of the skin 
disease, and was predominantly bloody with malabsorbtive characteristics.  
The affected girl died aged 12 from fulminant myocarditis associated to parvovirus B19 
infection. On subsequent investigation, the affected boy’s heart was found to have moderate 
left ventricular dilatation and borderline-dysfunctional systolic function (an ejection fraction 
of 55%, where 45% is regarded as dysfunctional) (Blaydon et alet al., 2011a).  
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Figure 3.1: The phenotype of a neonatal-onset inflammatory skin and bowel disease. 
Representative images of the skin, hair and nail phenotype of the affected siblings. Adapted from 
Blaydon et alet al (Blaydon et al., 2011a). 
 
3.2.2. Genetic investigations 
To attempt to identify a genetic cause of this inherited condition, a combination of SNP 
homozygosity mapping (employed due to the known consanguinity between the parents of 
the affected individuals), targeted sequence capture and next generation sequencing was 
employed. These genetic investigations were undertaken by Dr. Diana Blaydon (Centre for 
Cutaneous research, Blizard Institute, London), Dr. Franz Rüschendorf (Max-Delbrück-centrer 
for Molecular Medicine, Berlin), Dr. Vincent Plagnol (University College London Institute of 
Child Health, London), Prof. David van Heel (Centre for Digestive Diseases, Blizard Institute) 
and Prof. David Kelsell (Centre for Cutaneous Research, Blizard Institute). 
SNP homozygosity mapping was performed on five members of the affected family: the two 
affected individuals; their unaffected brother and both parents, using Affymetrix 10K SNP 
arrays. Analysis of SNP array data revealed linkage to three large stretches of SNP 
homozygosity in the two affected siblings (on chromosomes 2, 5, and 21). After ruling out 
plausible candidate genes by Sanger sequencing, probes for all exons found in these three 
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regions of the genome were included on a custom capture array, a total of 1468 exons 
corresponding to 439kb of DNA. All of these exons were captured and sequenced in the 
affected boy, with the sequence data then analysed for single nucleotide variants and 
insertion/deletion variation. This analysis revealed the presence of a novel 4-base pair 
deletion in exon 5 of the ADAM17 gene (c.603-606delCAGA) on chromosome 2 (Blaydon et 
alet al., 2011a). 
 
3.2.3. Confirmation of a mutation in ADAM17 
To confirm the presence of the c.603-606del mutation in the two affected siblings, and its 
segregation with disease, Sanger sequencing was performed using primers designed 
specifically to amplify exon 5 of ADAM17 (primer sequences are shown in appendix 1). 
Sequencing was carried out by Dr. Diana Blaydon, on genomic DNA specimens taken from 
the two affected individuals, their unaffected parents, and their unaffected brother.  
Sequence analysis confirmed the presence of the c.603-606delCAGA mutation in the two 
affected individuals, where it was found in homozygosity (figure 3.2, A). Confirming the 
segregation of the c.603-606delCAGA mutation with disease, both parents of the affected 
individuals were found to be heterozygous for the mutation, which was entirely absent in 
their unaffected brother. This thus resulted in the family pedigree shown in figure 3.2, B. 
No rare variants that were predicted to result in loss of function could be found for ADAM17 
in any of the dbSNP, 1000 genomes, or exome variant server databases. This meant that this 
discovery represented the first association of any mutation in ADAM17 with disease in 
humans, though mouse models of Adam17 mutation have been generated (as described in 
section 1.2.7). 
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Figure 3.2 Confirmation of ADAM17 mutations and their segregation with disease. A: Sanger 
sequence traces of a portion of the ADAM17 exon 5 containing a deletion mutation, in five 
members of the family affected by the disease described. The orange box illustrates the deleted 
bases, and orange arrows show the position from which the residues are missing in the affected 
individuals. B: A family pedigree demonstrating the segregation of the c.603-606delCAGA 
mutation with disease. White shapes illustrate unaffected individuals, grey shapes illustrate 
affected individuals. Adapted from Blaydon et alet al (Blaydon et al., 2011a). Formatted: Font: Not Italic
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3.2.4. Characterisation of the identified ADAM17 mutation 
The c.603-606delCAGA ADAM17 mutation found homozygously in the two affected siblings 
results in the deletion of 4 base pairs from exon 5 of the gene. Bioinformatic analysis predicts 
that this 4 base pair deletion will cause a frameshift in the transcript of ADAM17, which 
would result in a transcript encoding 10 further codons after the deletion, followed by a 
premature stop codon. The mutation can therefore be annotated as p.D201fsX10. As the 
deletion mutation results in the introduction of a premature stop codon at a relatively early 
point in the ADAM17 transcript (in exon 5 of 19), it would be expected to produce a severely 
truncated protein. This truncated transcript is predicted to encode a protein containing only 
the ADAM17 pro-domain (the most N-terminal domain in the complete protein), and 
therefore lacking the active ADAM17 metalloprotease domain, as well as the disintegrin, 
cysteine-rich, transmembrane and cytoplasmic domains. As such, this truncated protein 
would be expected to have no active protease function. The predicted structure of the 
truncated protein, alongside a full-length, functional ADAM17 protein, is illustrated in figure 
3.3. 
 
 
Figure 3.3 Predicted structure of the ADAM17 protein encoded by a normal ADAM17 transcript 
(A), and the transcript affected by the c.603-606delCAGA mutation  (B).  
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3.2.5. Expression of ADAM17 in the skin and blood cells of affected individuals  
To assess the effect of the c.603-606delCAGA mutation on expression of ADAM17, western 
blotting was performed on lysates taken from the cells of the disease-affected male (the 
female having died aged 12), his unaffected mother (a heterozygous carrier of the c.603-
606delCAGA mutation), and a number of normal controls.  
ADAM17 expression was first examined in protein lysates derived from peripheral blood 
mononuclear cells (PMBCs) from the affected individual, his mother, and three otherwise 
healthy normal control individuals. Western blotting of ADAM17 was performed using an 
antibody that binds to an epitope in the enzyme’s metalloprotease (active site) domain, and 
which therefore detects ADAM17 in both its pro-protein form, and the mature, active form 
that results from the removal of its inhibitory pro-domain during maturation. As a result, 
western blotting with this antibody produces a characteristic double band, representing 
these two forms of the protein. However, as the c.603-606delCAGA mutation would be 
predicted to produce a protein lacking its metalloprotease domain, this antibody would not 
be expected to detect this severely truncated form of the protein, if it were produced. 
Western blotting of these PBMCs revealed a complete lack of expression of either pro- or 
mature ADAM17 in the affected male’s cells, whilst expression was robust in the PBMCs of 
each of the other four individuals tested (figure 3.4). 
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Figure 3.4 Western blotting of ADAM17 in PBMC lysates from the c.603-606delCAGA-affected 
individual, his unaffected mother and three normal controls. GAPDH was used as a loading 
control.  
 
Next, expression of ADAM17 was examined by western blotting in primary keratinocytes 
derived from the affected male, and from a normal control. Once more, no ADAM17 
expression could be observed in the affected male, whilst it was clearly visible in normal 
keratinocytes (figure 3.5, A). 
Meanwhile, to examine whether loss of ADAM17 resulted in compensation from other 
metalloproteases, expression of the closely related ectodomain sheddase ADAM10, which 
cleaves similar (and in some cases the same – as shown in table 1.1) substrates as ADAM17, 
was also examined in keratinocytes. In this case, no difference in the expression of ADAM10 
was observed between the keratinocytes of the affected male and a healthy control (figure 
3.5, B), suggesting that reduced ADAM17 expression does not lead to compensatory 
upregulation of ADAM10. 
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Figure 3.5 Western blotting of ADAMs in primary keratinocytes. A: Western blotting of ADAM17 
in lysates of primary keratinocytes from the affected male and a normal control. B: Western 
blotting of ADAM10 in lysates of primary keratinocytes from the affected male and a normal 
control. GAPDH (for ADAM17 western blots) and β-Actin (ADAM10) were used as loading 
controls.  
 
3.2.6. Expression of ADAM17 in the epidermis of affected individuals and controls 
Immunohistochemical staining of ADAM17 was next performed in skin biopsies taken from 
the affected male and a healthy control. This immunohistochemical staining was performed 
by Dr. Wei-Li Di (Department of Paediatric Dermatology, University College London Institute 
of Child Health, London), and revealed ADAM17 staining throughout the epidermis of normal 
skin, whilst staining was substantially reduced in the skin of the affected male (figure 3.6, top 
panel).  
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Figure 3.6 Immunohistochemical staining of ADAM17 in paraffin-embedded skin sections of the 
affected male and a normal control. Staining is shown when performed using an anti-ADAM17 
antibody (top row), and without any primary antibody (bottom row). Staining was performed by 
Dr. Wei-Li Di (University College London Institute of Child Health, London). Figure Aadapted from 
Blaydon et alet al (Blaydon et al., 2011a). 
 
In addition to staining in the epidermis, immunohistochemical staining was also performed in 
paraffin-embedded sections of the small intestine (the other main tissue affected by this 
disease) taken from both affected children. Concurring with the pattern seen in the 
epidermis, substantially reduced ADAM17 staining was also observed in the small intestine. 
Taken together, the data from western blotting and immunohistochemical studies suggested 
that the c.603-606delCAGA mutation in ADAM17 resulted in the expression of no functional 
ADAM17 in the affected individuals. 
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3.2.7. ADAM17 mRNA expression 
To confirm that differences in ADAM17 expression were a result of the mutation, rather than 
a reduction in the transcription of ADAM17 in the affected individual, mRNA expression of 
the ADAM17 transcript was measured by quantitiative PCR (qPCR). This was carried out using 
primers targeting a region across exons 1 and 2 of the mRNA, whose amplification of the 
mRNA would therefore be unaffected by the c.603-606delCAGA mutation in exon 5. qPCR 
was carried out on cDNA ultimately derived from the keratinocytes of the affected individual 
and a healthy control. This revealed that, although ADAM17 mRNA expression was 
somewhat reduced, there was no significant difference between the level of expression in 
the affected male and a healthy control (figure 3.7).  
 
Figure 3.7 mRNA expression of ADAM17 in primary keratinocytes derived from the affected male 
and a healthy control. Expression was measured by qPCR and is shown relative to the expression 
of GAPDH. Significance was calculated using Student’s unpaired t-test; Nns: not significant.  
 
 
 
 
 
 
 82 
 
3.2.8. ADAM17 sheddase activity in controls and affected individuals 
To examine the functional effects of the reduction in ADAM17 expression in the affected 
individual, shedding of the ADAM17 substrate tumour necrosis factor-alpha (TNFα) from 
PBMCs was measured under various conditions. Shedding from PBMCs derived from the 
affected male, his unaffected mother and three healthy controls was measured following 
stimulation with either increasing concentrations of bacterial lipopolysaccharide (figure 3.8, 
A), activating antibodies against the T-lymphocyte co-receptors CD3 and CD28 (figure 3.8, B), 
or phorbol myristate acetate (PMA) and the calcium ionophore ionomycin (figure 3.8, C). 
Following stimulation, shedding of TNFα and other pro-inflammatory cytokines over 24 hours 
was measured by ELISA.  
In each of these three cases, shedding of TNFα by the PBMCs of the affected male was very 
substantially reduced compared to his mother, and all three healthy controls. Meanwhile, 
the secretion of non-ADAM17-dependent cytokines (interleukin-1β and interferon-γ) by the 
affected male’s PBMCs was unaffected, and was observed at a level comparable to that seen 
in his mother and healthy controls (figure 3.8).  
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Figure 3.8 Secretion of cytokines (measured by ELISA) from stimulated PBMCs isolated from the 
affected male, his mother and three healthy control individuals. A: Measurement of TNFα and 
Interleukin-1β secretion from PBMCs following stimulation with increasing levels of bacterial 
lipopolysaccharide (LPS). B: Measurement of TNFα and Interferon-γ secretion from PBMCs 
following stimulation with anti-CD3 and anti-CD28 antibodies. C: Measurement of TNFα and 
Interferon-γ secretion from PBMCs following stimulation with phorbol myristate acetate (PMA; 
100ng/ml) and ionomycin (500ng/ml). ELISA experiments were performed alongside Dr. Diana 
Blaydin and Dr. Paolo Biancheri (Blizard Institute, London). Figure Aadapted from Blaydon et alet 
al (Blaydon et al., 2011a). 
 
Therefore, not only was ADAM17 protein expression observed to be markedly reduced or 
absent in the affected male compared to controls, shedding of ADAM17 substrates was also 
substantially reduced, supporting the hypothesis that the c.603-606delCAGA mutation 
abolishes or severely abrogates ADAM17 function in the affected individual.  
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3.2.9. Characterisation of epidermal barrier protein expression 
Because the clearest manifestation of the disease associated with the c.603-606delCAGA 
mutation was seen in the skin, investigations next focussed on the expression of proteins 
involved in the generation of the skin barrier, several of which can themselves be mutated in 
epidermal disease (as shown in table 1.2). 
To examine this, immunohistochemical staining of filaggrin, involucrin, loricrin and keratin 2E 
was carried out in the skin of the affected male and a healthy control. As shown in figure 3.9, 
staining of each of these four barrier proteins was very similar between the affected male 
and a normal control, demonstrating no obvious up- or downregulation, or any aberrant 
staining pattern. The epidermis of the affected male was noticeably hyperproliferative and 
thicker than the normal control, and therefore displayed a larger amount of each of the 
proteins examined, but the distribution and staining intensity of the tested proteins 
throughout the epidermal layers was unaltered.  
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Figure 3.9 Immunohistochemical staining of proteins involved in the epidermal barrier, in frozen 
skin sections derived from the affected male and a healthy control. Scale bars represent 100µm 
in all cases. 
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However, in contrast to the four epidermal barrier-associated proteins shown in figure 3.9, a 
noticeable difference between healthy control skin and the skin of the affected male was 
observed when staining for transglutaminase 1 (TGM1). As shown in figure 3.10, the intensity 
of TGM1 staining in the granular layer of the epidermis was markedly reduced in the skin of 
the affected male, compared to a normal control.  
 
Figure 3.10 Immunohistochemical staining of transglutaminase 1 in frozen skin sections derived 
from the affected male and a healthy control. Scale bars represent 100µm in all cases. 
 
3.2.10. Transglutaminase 1 activity in control and affected individuals’ individual’s skin 
To investigate the observation of reduced TGM1 staining in the affected individual’s upper 
epidermis, an assay directly measuring in situin situ TGM1 activity (rather than expression) 
was performed. This assay uses an amine donor – monodansylcadaverine (MDC) – which is 
covalently incorporated into the active site of transglutaminase 1 when it is in an active 
conformation. When MDC is biotinylated (Biot-MDC) this allows for fluorescent detection of 
MDC bound to active TGM1 via the use of a streptavidin-conjugated fluorophore, and 
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therefore the quantitative measurement of TGM1 activity in situin situ. As such, this assay 
has proven useful in the past in the diagnosis of lamellar ichthyosis (caused by mutations in 
the TGM1 gene), sufferers of which may show normal levels of TGM1 expression in the skin, 
even though the associated mutations have significantly abrogated or entirely abolished its 
enzymatic function (Raghunath et alet al., 1998).  
In normal control skin, robust TGM1 activity can be observed in the granular layer of the 
epidermis (figure 3.11), corresponding to the region where TGM1 protein is most highly 
expressed (as shown in figure 3.10). However, in the skin of the affected male, no visible 
TGM1 activity could be detected by Biot-MDC incorporation in this upper epidermal layer 
(figure 3.11).  
 
Figure 3.11 Transglutaminase 1 activity in frozen skin sections derived from the affected male 
and a healthy control, measured using the Biotinylated-MDC assay. Scale bars represent 100µm 
in all cases. Camera exposure times are given to illustrate that some signal could be seen in the 
affected male’s skin when exposed for a lengthy period.  
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Taken together, the finding of substantially reduced TGM1 expression and the lack of any 
detectable in situin situ TGM1 activity, suggested that the function of TGM1 was severely 
impaired in the individual affected by the c.603-606delCAGA ADAM17 mutation.  
Subsequent to the finding of reduced TGM1 expression being published, it was shown that a 
keratinocyte-restricted knockout of Adam17 in mouse skin led to a significantly reduced level 
of TGM1 activity in that skin, as a consequence of reduced ADAM17-dependent EGFR ligand 
shedding (which could be rescued by the topical application of the ADAM17 substrate TGFα). 
This reduction in TGM1 activity in mouse skin, and the reduction in epidermal barrier activity 
that results from it, was shown to be primarily responsible for the inflammatory skin 
phenotype that develops in these mice (Franzke et alet al., 2012), which bears a close 
resemblance to the human disease seen in the affected male described here. Furthermore, 
mutations affecting TGM1 function underlie some types of autosomal recessive congenital 
ichthyosis, illustrating the importance of TGM1 activity in proper epidermal function in 
humans. Therefore, the reduced expression and activity of TGM1 observed in the affected 
male’s skin offers a plausible mechanism for at least part of the inflammatory skin phenotype 
observed. 
  
3.2.11. Expression of desmosome proteins in control and affected individuals 
As well as its primary function in ectodomain shedding, ADAM17 is also intimately involved 
in the regulation of desmosomes, intercellular junction complexes which play a key role in 
the mechanical stability of particular tissues by providing strong adhesions between 
individual cells. Desmosomes are found particularly in tissues undergoing high degrees of 
mechanical stress, such as the skin and the heart, meaning that mutations in various 
desmosome components are often associated with inherited syndrome diseases affecting 
the skin and heart (as described in section 1.3.2). A detailed description of desmosome 
structure and function, and their regulation by ADAM17 and EGFR signalling, can be found in 
section 1.2.9-10.  
The primary desmosome component regulated by ADAM17 is the cadherin desmoglein 2 
(DSG2) (Bech-Serra et alet al., 2006, Brennan et alet al., 2012). Western blotting was used to 
assess the expression of desmogleins in the keratinocytes of the affected male and a normal 
control, by Dr. Rita Cabral (Blizard Institute). The antibody used for this western blotting was 
co-specific for DSG1 and DSG2; however, the keratinocytes were cultured in medium 
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containing FBS, which is known to greatly decrease the expression of DSG1 in cultured 
keratinocytes (Denning et alet al., 1998), meaning that the vast majority of the expression 
seen represents DSG2. Western blotting revealed the presence of an increased level of DSG 
expression in keratinocytes from the affected male, compared to a normal control (figure 
3.12).  
 
 
Figure 3.12 Western blotting of desmogleins 1 and 2 in primary keratinocyte lysates derived from 
the affected male and a healthy control. βΒ-actin was used as a loading control. Western blot was 
carried out by Dr. Rita Cabral (Blizard Institute, London). Figure Aadapted from Blaydon et alet al 
(Blaydon et al., 2011a). 
 
In addition, staining of DSG2 was shown to be upregulated in the affected male’s skin, 
compared to a healthy control (Blaydon et alet al., 2011a). Together, these data are 
indicative of reduced cleavage of DSG2 by ADAM17 in keratinocytes, leading to accumulation 
of the cadherin at the plasma membrane. Not only does this support the contention that 
ADAM17 activity is severely downregulated or absent in the individual affected by the c.603-
606delCAGA mutation, but it also provides interesting clues to the phenotype observed.  
Dysregulation of DSG2 processing in the affected male individual is particularly interesting in 
the light of the heart phenotype observed in the two affected individuals: a moderate 
ventricular dilatation in the affected male, as well as the fact that the affected female died 
from a heart-related condition (infectious myocarditis). Mutations in DSG2 can be 
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responsible for the inherited heart disease arrhythmogenic right ventricular cardiomyopathy 
(ARVC), a cause of sudden cardiac death (Brooke et alet al., 2012). Meanwhile, ADAM17 can 
also regulate the heart during development, via its shedding of members of the EGFR ligand 
family, which offers a second potential route to heart dysfunction in cases of ADAM17 loss-
of-function. The implications of a loss of ADAM17 activity on heart development and 
function will be discussed in more detail in chapter 6.  
 
3.2.12. Investigation of the Th17 pathway in affected individuals 
The skin phenotype associated with homozygous c.603-606delCAGA ADAM17 mutation in 
these two affected individuals resembled in some ways that of psoriasis, with the skin 
condition having being described previously as ‘psoriasiform ethyroderma’ (Blaydon et alet 
al., 2011a). As such, the resemblance to psoriasis was investigated at the level of the affected 
male’s PBMCs and skin. Accumulating evidence has suggested that signalling by the Th17 T-
lymphocyte lineage is key to the induction, development and propagation of psoriasis 
(Coimbra et alet al., 2012, Elloso et alet al., 2012).  
Th17 cells are CD4-positive (CD4+) lymphocytes that are distinct from the classically 
described Th1 and Th2 lymphocyte subsets, and are characterised by their ability to produce 
the cytokines IL-17A, IL-17F and IL-22 (Coimbra et alet al., 2012). They differentiate from 
naïve CD4+ lymphocytes under stimulation from IL-1, IL-6 and TGF-β, whilst another cytokine 
– IL-23 – drives their proliferation (Vanden Eijnden et alet al., 2005).  These cells are 
recognised as playing a central role in the pathogenesis of a number of autoimmune and 
inflammatory conditions, including psoriasis. In particular, IL-17A is a critical component in 
the establishment and perpetuation of inflammation, due to its induction of pro-
inflammtoryinflammatory cytokine production (Coimbra et alet al., 2012). IL-17A mRNA is 
detectable in psoriatic lesions (Teunissen et alet al., 1998), while increased blood 
concentrations of it correlate with psoriasis severity (Arican et alet al., 2005, Caproni et alet 
al., 2009).  
To investigate the activity of the Th17 pathway in the affected male, PBMCs from him, his 
mother and two otherwise healthy normal controls were isolated, and stimulated with either 
PMA and ionomycin, or activating anti-CD3 and anti-CD28 antibodies for 24 hours (in the 
same fashion as was described in section 3.2.8), following which levels of the cytokines IL-
17A, IL-17F, IL-22 and IL-23 were measured by ELISA. In order to establish whether any 
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potential differences observed were dependent on ADAM17 activity, PBMCs were also 
treated with either the small-molecule ADAM17 inhibitor GW280264X (Dreymueller et alet 
al., 2012, Ludwig et alet al., 2005, Rabinowitz et alet al., 2001), an anti-ADAM17 blocking 
antibody, or relevant vehicle controls for the two (DMSO and IgG, respectively), in addition 
to stimulation by PMA and Ionomycin, or activating anti-CD3 and anti-CD28 antibodies. 
When measured by ELISA, secretion of IL-17A and IL-23 by the PBMCs of the affected 
individual was not substantially different to the levels of secretion seen from either his 
mother or a pair of healthy controls (figure 3.13). Some variation in IL-17A secretion was 
observed following stimulation with PMA and ionomycin, but levels did not vary notably 
between the affected individual and controls. IL-17A secretion following stimulation with 
activating anti-CD3 and anti-CD28 antibodies, and IL-23 secretion under all the tested 
conditions, was virtually identical (figure 3.13). Levels of secreted IL-17F and IL-22 were 
below the limit of detection for the ELISA kits used and are not shown.  
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Figure 3.13 Secretion of Th17 family cytokines, measured by ELISA by stimulated PBMCs.              
A: IL-17A secretion by PBMCs derived from the affected individual, his unaffected mother and 
two healthy controls, following stimulation with either PMA (100ng/ml) and ionomycin 
(500ng/ml) or activating anti-CD3 and anti-CD28 antibodies (α-CD3/28). In addition, PBMCs were 
treated with either DMSO, the ADAM17 inhibitor GW280264X (GW), IgG or an ADAM17-blocking 
antibody. B: IL-23 secretion measured under the same conditions as described for A. 
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From these results, it can be surmised that there was no particular enrichment of Th17 
lymphocytes in the PBMC fraction of the affected individuals blood, compared to controls, as 
any significantly greater level of Th17 cells would produce notably higher levels of IL-17A 
upon stimulation (particularly with direct stimulation of the T cell co-receptors CD3 and 
CD28). This corresponds with the IL-23 secretion data, for which significantly increased IL-23 
would be expected to be seen if the Th17 compartment was especially enriched, due to the 
requirement for IL-23 for Th17 cell proliferation.  
As well as studies in PBMCs, expression of IL-17A was also examined in paraffin-embedded 
sections of the epidermis of the affected male, as well as a normal control and a specimen of 
psoriasis skin, by immunohistochemistry. Staining of IL-17A was relatively weak and diffuse 
throughout the epidermis of all three types of section tested, and no obvious differences 
could be observed between the affected male’s epidermis and either of the other two tested 
(figure 3.14).  
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Figure 3.14 Immunohistochemical staining of IL-17A in paraffin-embedded skin sections derived 
from the affected male, a healthy control, and a psoriasis patient. Scale bars represent 100µm in 
all cases. Note the reduced magnification of the psoriasis skin picture.  
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In addition, simple, superficial comparison of skin sections from the affected individual with 
those taken from psoriatic skin reveal obvious differences in the epidermal structure. 
Although the epidermis of the affected male is hyperproliferative and somewhat thicker than 
that of a normal control individual, it lacks the extreme hyperplasia, folding, and elongated, 
bulbous rete ridges (extensions of the epidermis into the underlying dermis) that 
characterise and are clearly visible in psoriatic skin.  
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3.3. Results – genetic investigations in other disease candidates  
In addition to the UK-based family of Lebanese origin in which the c.603-606delCAGA 
ADAM17 mutation was identified, individuals who displayed skin phenotypes superficially 
similar to those described in section 3.2.1, belonging to three other, unrelated families, were 
also investigated for mutations in ADAM17. For this ADAM17 genotyping, PCR primers were 
designed to separately amplify each of the 19 exons of the gene. Every exon of ADAM17, as 
well as the splice sites immediately before and after each, was then amplified by PCR and 
sequenced, in the affected individual in each family, as well as in at least one parent of that 
individual.  
In two of these families, no novel or potentially disease-causing mutations were identified in 
any of the exons of ADAM17 after thorough sequencing of the whole gene, making it unlikely 
that their conditions share a similar pathophysiology to the one described throughout this 
chapter. However, investigations into a family from the Netherlands have suggested that 
there may be at least one other family in which this disease is present.  
 
3.3.1. Neonatal-onset inflammatory skin and bowel disease in a Netherlands family – 
phenotype  
ADAM17 genotyping was performed in a single female child from the Netherlands, who 
suffered from an inflammatory skin and bowel disease similar to that seen in the UK-based 
family described in section 3.2. The affected girl had a low birth weight, and suffered from 
intractable diarrhea from shortly after birth, requiring full parenteral nutrition. She displayed 
a skin phenotype that consisted of erythema and very dry skin, which was described as 
almost resembling ichthyosis, and recurrent infections. She was thought to suffer from 
alopecia, displayed very little hair growth, developed a cardiomyopathy, and died at an early 
age.  
The obvious similarities of this phenotype with that described in section 3.2.1 made a 
mutation in ADAM17 an attractive candidate for a cause of this condition. However, unlike 
the individuals described in section 3.2, no consanguinity was known to exist between the 
parents of the affected child.  
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3.3.2. ADAM17 sequencing in a Netherlands individual 
To establish whether or not ADAM17 mutations may contribute to the phenotype of this 
child, each exon of ADAM17 was sequenced in a genomic DNA sample derived from the 
affected girl. A single heterozygous nonsense point mutation was identified in exon 16 of 
ADAM17, annotated as c.2113C>T (figure 3.15). Bioinformatic analysis predicts that this 
mutation would result in the substitution of an arginine codon for a premature stop codon 
(p.644R>X), and thus to result in the production of a transcript encoding a truncated 
ADAM17 protein.  
This identified mutation was completely novel, and has neither been previously been 
described, nor is present in any databases of genomic variation examined (including the 1000 
genomes, dbSNP and exome variant server databases). Furthermore, this represents the first 
identification of any nonsense point mutation in ADAM17, strongly implying that this 
mutation may be disease associated. As no consanguinity is known or suspected to exist 
between the parents of the affected girl, a mechanism of compound heterozygous mutations 
in ADAM17 would appear to be the most likely cause of a disease resulting from ADAM17 
loss-of-function under these circumstances.  
At present, a second ADAM17 mutation (that would be required to confirm a compound 
heterozygous loss-of-function of ADAM17) has yet to be identified in the affected individual. 
To confirm the segregation of any mutations with disease, it would be desirable to sequence 
both the parents of the affected individual as well. To date, only DNA from the mother has 
been available; sequencing of exon 16 in the mother revealed the presence of the 
heterozygous mutation in exon 16 (figure 3.15), indicating that any second ADAM17 
mutation would be inherited from the father.  
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Figure 3.15 Sanger sequencing of a portion of exon 16 of ADAM17 in a disease-affected Dutch 
child, her unaffected mother, and a healthy control. Orange arrows illustrate the position of the 
detected heterozygous mutation.  
 
As only a single ADAM17 mutation has been identified in this affected individual, genetic 
investigations into the cause of the disease in the patient described here are ongoing at the 
time of publication.  
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3.4. Discussion Summary of chapter 
The data presented in this chapter describe investigations into the genetic causes and 
pathophysiology of an autosomal recessive, neonatal-onset inflammatory skin and bowel 
disease, which was associated in two affected individuals in the same family with a 
homozygous deletion mutation in ADAM17, a gene encoding the multi-substrate ectodomain 
sheddase enzyme of the same name.  
The presence of this deletion was associated with an absence of ADAM17 expression in 
keratinocytes and peripheral blood mononuclear cells (PBMCs) of an affected individual, 
despite a non-significantly changed level of mRNA expression, and resulted in an inability for 
affected PBMCs to shed the ADAM17 substrate TNFα, and an accumulation of the substrate 
desmoglein 2 at the plasma membrane of keratinocytes. In investigating the inflammatory 
skin phenotype, it was observed that expression of the skin barrier proteins filaggrin, 
involucrin, loricrin and keratin 2E was normal, whilst both the expression level and in situin 
situ activity of transglutaminase 1 was severely reduced. Furthermore, despite the superficial 
resemblance of the skin phenotype to psoriasis, no evidence could be found of activation of 
the Th17 signalling pathway in either the blood or the epidermis.  
The wide range of substrates shed by cells as a result of ADAM17 activity mean that a 
deletion of its enzymatic activity could be expected to result in severe consequences in 
humans. A number of the pathogenic defects observed in individuals affected by this 
ADAM17 deletion can readily be associated to the loss of shedding of one or more of its 
substrates, offering some rationale for the particular set of symptoms observed. The 
implications of this loss-of-function mutation on the disease seen will be discussed in greater 
detail in chapter 6.  
Lastly, ongoing investigations into other individuals affected by diseases with phenotypes 
similar to that seen in the individuals described here, suggest the possibility that disease 
resulting from ADAM17 mutation may be present in more than the single family described in 
section 3.2, and may reflect the existence of a novel disease entity.  
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4. The iRHOM2-ADAM17 Axis in Tylosis with Oesophageal Cancer 
 
4.1. Introduction 
This chapter describes investigations into the pathophysiology of the rare inherited skin 
disease Tylosis with Oesophageal Cancer (TOC). These investigations were undertaken using 
material derived directly from TOC-affected individuals, including skin sections and 
peripheral blood cells, as well as a pair of immortalised keratinocyte cell lines derived from 
TOC patients in the UK.  
 
4.1.1. Tylosis with Oesophageal Cancer 
Tylosis with oesophageal cancer (TOC; OMIM: 148500) is a rare, dominantly-inherited 
genetic disorder comprising an early onset focal, non-epidermolytic palmoplantar 
keratoderma (PPK; hyperkeratosis of the skin on the palms and soles, particularly prevalent 
in areas which undergo significant mechanical stress), accompanied by oral leukokeratosis, 
follicular hyperkeratosis, and a vastly increased risk of developing oesophageal squamous cell 
carcinoma (OSCC) (Blaydon et alet al., 2012, Field et alet al., 1997). This phenotype is 
illustrated in figure 4.1. An affected individual belonging to a large, TOC-affected family in the 
UK has been calculated as having a 92% probability of dying from oesophageal cancer by the 
age of 70 (Ellis et alet al., 1994).  PPK in these individuals is inherited with complete 
penetrance, with onset at around 7-8 years of age (Kelsell et alet al., 1996). Whilst a 
comparatively rare condition, TOC has been reported to date in at least five extensive family 
pedigrees worldwide, three reported in the mid-nineties, located in the UK (Ellis et alet al., 
1994), USA (Stevens et alet al., 1996) and Germany (Hennies et alet al., 1995), and twice 
more very recently in Spain (Varela et alet al., 2011) and Finland (Saarinen et alet al., 2012).  
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Figure 4.1: Clinical pictures illustrating the phenotype of TOC. A: palmoplantar keratoderma. B: 
Oral leukokeratosis. Adapted from Blaydon et alet al (Blaydon et al., 2012).  
 
4.1.2. TOC-associated mutations 
The TOC locus was mapped to a region of chromosome 17q25 as long ago as 1996 (Risk et 
alet al., 1994, Kelsell et alet al., 1996, Risk et alet al., 2002), though efforts to identify a 
causative gene by sequencing were unsuccessful (Langan et alet al., 2004). However, upon 
re-assessing the TOC minimal region and revising the status of affected family members, the 
author’s research group was recently able identify TOC as being associated with 
heterozygous mis-sense mutations (consistent with a dominant pattern of inheritance) in 
exon six of the RHBDF2 gene, responsible for encoding the catalytically inactive Rhomboid 
protease iRHOM2, in the UK, USA and German families (Blaydon et alet al., 2012). The UK 
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and US families share the same mutation – c.557T>C, leading to the novel isoleucine to 
threonine substitution p.Ile186Thr – whilst the mutation affecting the German family is 
distinct, but located  very close by, just three residues away in the full length protein – 
c.566C>T, which causes the proline to leucine substitution p.Pro189Leu. Subsequent to this 
study, a Finnish family affected by TOC was examined, and found to  harbour a third, distinct 
TOC-associated mutation in RHBDF2 (Saarinen et alet al., 2012). Intriguingly, this mutation 
was found in the exact same region as those affecting the UK and USA families, lying 
between the two previously described mutations at residue 188 (p.Asp188AnsAsp188Asn). 
Each of the three affected residues is highly conserved both between species and between 
iRHOM2 and its close family member iRHOM1. The obvious clustering of mutations, as well 
as this high level of conservation, (Figure 4.2) strongly suggests the mutations alter a site-
specific function of iRhom2 iRHOM2 to give rise to TOC. Aside from offering strong clues as 
to the pathogenesis of TOC, this discovery also represented the first linkage of any gene to 
inherited oesophageal cancer. 
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Figure 4.2: TOC-associated iRHOM2 mutations. The residues mutated in TOC, and their high 
degree of conservation, are illustrated in iRHOM2 protein sequences from a wide variety of 
animals, and in the closely related human iRHOM1. The location of the TOC-associated mutations 
in a long N-terminal domain of iRHOM2 is also illustrated. Adapted from Blaydon et alet al 
(Blaydon et al., 2012).  
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4.1.3. The rhomboid protease family – structures 
iRHOM2 is a member of the relatively recently discovered family of rhomboid proteases, 
named after the effect of mutations in Drosophila, which affect the first family member to be 
discovered (now known as Rhomboid-1) and produced an abnormal, rhomboid-shaped head 
skeleton (Ha et al., 2013) (Mayer and Nusslein-Volhard, 1988). Rhomboids are a family of 
highly conserved transmembrane serine proteases, found in all eukaryotes and many 
prokaryotes, which are distinct from most other protease types in that their site of 
proteolytic activity resides within the membrane; as such, they are referred to as 
‘intramembrane’ proteases. Mammalian rhomboids have been divided into four subgroups, 
secretase A, secretase B, PARL, and the iRHOMs (Lemberg and Freeman, 2007, Etheridge et 
alet al., 2013). The simplest of these in structure are those belonging to the secretase B 
subgroup (known as ‘basic’ rhomboids, and represented in humans by the active protease 
RHBDL4), which contain 6 transmembrane domains. In common with the secretase A and 
PARL Rhomboids, these contain the highly conserved serine (in transmembrane domain 4) 
and histidine (in transmembrane domain 6) residues that are required for Rhomboid catalytic 
activity. These two residues were first identified in Escherichia coli and Haemophilus 
influenzae rhomboids (named GlpG in both) as Ser201 and His254, which interact via a strong 
hydrogen bond (Wang et alet al., 2006, Lemieux et alet al., 2007, Ben-Shem et alet al., 2007). 
In addition to the six found in secretase B rhomboids, both secretase A and PARL-type 
rhomboids contain an additional transmembrane domain, with the additional domain in 
secretase A rhomboids found at the C-terminal end of the protein, and the additional domain 
in PARL being found at the N-terminal end, relative to the structure of secretase B (figure 
4.3). All three of these rhomboid subgroups are catalytically active, with their substrate 
specificity dependent on the recognition of a ‘partially disordered conformation’ in their 
substrates’ transmembrane domains, a result of the presence of helix-destabilising residues 
such as glycine and alanine (Urban and Freeman, 2003). 
In contrast to the three other subgroups of rhomboids, the iRHOMs lack the catalytic serine 
residue in their fourth transmembrane domain, (instead, a proline residue is invariantly 
found in the position immediately proximal to where the serine would be positioned) 
(Lemberg and Freeman, 2007) and consequently lack any active protease function. The 
iRHOMs do however display a clear topological homology with the other rhomboids, 
containing seven transmembrane domains arranged as in the secretase A subgroup. In 
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addition, iRHOMs contain a unique long N-terminal cytoplasmic domain and an ‘iRHOM 
homology’ loop domain found between the first two transmembrane regions, both of which 
are very highly conserved and unique to the family. It is in the unique long N-terminal 
domain that the iRHOM2 mutations associated with TOC are found.  
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Figure 4.3: Structure of the Rhomboid family proteases. A: Topology models illustrating the 
protein structures and phylogenetic relationships between the major groups of the Rhomboid 
family. The catalytic dyad of serine and histidine in proteolytically active Rhomboids is illustrated 
in red, with the invariant proline residue of iRHOMs shown in yellow. Major differences from the 
most basic Rhomboid structure (as found in the secretase B family) are illustrated in orange. 
Examples of Rhomboids belonging to each group found in Homo sapiens and selected other 
organisms are listed below, demonstrating the highly conserved nature of the Rhomboid family. 
Rhomboid structures are Aadapted from Lemberg & Freeman (Lemberg and Freeman, 2007).  B: 
Detailed structure model of iRHOM2, illustrating each individual domain, and the location of TOC-
associated mutations.  
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4.1.4. The rhomboid protease family – functions 
As mentioned, the catalytically active rhomboids function as intramembrane serine 
proteases, and function to regulate diverse processes in the wide variety of organisms in 
which they are expressed. The first rhomboid to be discovered, now known as the Drosophila 
Rhomboid-1 was first studied due to its involvement in developmental control mediated 
through the EGFR (Urban et alet al., 2001), which it was found to accomplish via cleavage of 
the EGFR ligand Spitz (a homologue of TGFα) (Lee et alet al., 2001). As well as influencing the 
morphology of the head skeleton in development, Rhomboid-1-dependent regulation of 
EGFR signalling also regulates sleep patterns in Drosophila (Foltenyi et alet al., 2007), a 
function which has established rhomboid activity as the key regulator of EGFR signalling in 
these insects. Similarly, rhomboid activity has been implicated in EGFR signalling in 
Caenorhabditis elegans, in which the EGF-like ligand Lin-3 is proteolytically released by the 
rhomboid ROM-1 (Dutt et alet al., 2004).  
Intercellular signalling is also the function of a rhomboid in an entirely different organism, 
the opportunistic bacterial pathogen Providencia stuartii. In these bacteria, the rhomboid 
AarA functions to cleave and thereby activate TatA, a cell wall protein translocase that 
functions in the transmission of bacterial cell-cell communication proteins, as part of the 
bacterial communication process known as quorum sensing. Despite the vast evolutionary 
distance between the two organisms, the rhomboids from Drosophila and P. stuartii have 
been shown to share substrate specificity, and are even capable of functionally replacing 
each other in vivo (Gallio et alet al., 2002, Urban et alet al., 2002), impressively illustrating 
the highly conserved nature of rhomboids. 
In humans, the active rhomboid RHBDL2 has perhaps been the most closely studied in terms 
of its functional activity. Illustrating a conservation of function with Drosophila and C. elegans 
rhomboids, RHBDL2 has been found to cleave EGF (along with very low levels of betacellulin 
and neuregulin-1, but no other EGFR ligands) in a manner independent of ADAM10 (Adrain 
et alet al., 2011), and therefore appears to play a role in signalling through the EGFR. The 
expression profile of RHBDL2 is limited to certain tissues, suggesting that RHBDL2 may play 
tissue-specific roles in EGFR signalling, as opposed to the widely expressed ADAM10 (Adrain 
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et alet al., 2011). As well as EGF, RHBDL2 has a number of other substrates in humans. These 
include thrombomodulin (Lohi et alet al., 2004), a glycoprotein expressed on the surface of 
keratinocytes and endothelial cells, the soluble form of which is involved keratinocyte 
proliferation and migration during in wound healing in the skin. Also substrates of RHBDL2 
are members of the Ephrin B family, particularly Ephrin B3 (Pascall and Brown, 2004). Ephrins 
are ligands of the Eph tyrosine kinase receptors, signalling through which is bi-directional 
(affecting both the sending and receiving cell). Eph-Ephrin signalling is involved in a range of 
processes, including intercellular communication, adhesion and migration (Pasquale, 2005, ; 
Pasquale, 2008).  
In contrast to the other members of the rhomboid family, the single human PARL rhomboid 
is restricted in its distribution to the mitochondria. Indeed, all eukaryotes express a 
mitochondrial rhomboid (Freeman, 2008), which form a distinct rhomboid subgroup, as 
shown in figure 4.3. Rather than a secretory function, PARL is involved in the regulation of 
the shape of mitochondrial christae, through its cleavage of the dynamin-like mitochondrial 
protein OPA1. Mouse knockouts of PARL resulted in cells that demonstrate excessive release 
of cytochrome c from mitochrondria and a heightened sensitivity to apoptotic stimuli 
(Cipolat et alet al., 2006). The balance of cleaved and membrane bound OPA1 regulates the 
sealing of junctions between the christae of mitochondria, and therefore cytochrome c 
release and apoptosis, making PARL and important regulator of both mitochondrial function 
and the apoptotic response.  
 
4.1.5. The functions of iRHOM2 
The absence of the highly conserved catalytic serine and histidine residues found in other 
rhomboids suggest that the iRHOM proteins are not proteolytically active, which for many 
years made the extremely high level of conservation of these proteins in mammals 
somewhat puzzling. However, several roles for iRHOM2 have recently become apparent, 
which may offer interesting insights into the pathology of TOC. Although incapable of 
proteolysis, iRHOM2 has emerged as a novel regulator of EGFR signalling, which it can 
accomplish through two distinct processes. In the first of these, iRHOM2 is capable of directly 
binding to EGFR ligands, and regulating the level their shedding by driving pro-ligands into 
the ER-associated degradation (ERAD) machinery, a system which functions to degrade 
proteins using the proteasome. By initiating the degradation of EGFR ligands at the level of 
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the ER, there are therefore prevented from reaching later stages in the secretory pathway, 
where they can be proteolytically shed by either ADAMs or RHBDL2 (Zettl et alet al., 2011). 
 
4.2. Results – the iRHOM2-ADAM17 axis in tylosis with oesophageal cancer 
 
4.2.1. Immortalised TOC keratinocyte cell lines 
To investigate the effect of TOC-associated iRHOM2 mutations in skin, studies were carried 
out in immortalised keratinocyte cell lines derived from two TOC patients (TYLK1 and TYLK2; 
a male and a female) carrying the iRHOM2 mutation associated to TOC in the UK family 
(p.Ile186Thr, the same as is found in the American TOC family) (Blaydon et alet al., 2012). 
These keratinocytes were immortalised by transfection with human papilloma virus (HPV)-16 
open reading frames E6 and E7, which when co-expressed are necessary and sufficient to 
immortalise human keratinocytes (Munger et alet al., 1989, Hawley-Nelson et alet al., 1989). 
Though a number of cellular targets have been described for both E6 and E7, the interactions 
of the two with the tumour suppressors p53 (which is degraded by E6) and pRb (which is 
bound and degraded by E7) are the key functional activities in keratinocyte immortalisation 
by these proteins (Buitrago-Perez et alet al., 2009).  
In each study, TYLK keratinocytes were compared with a pair of normal control keratinocyte 
cell lines which had been immortalised in the same manner, both of which have previously 
been described (K17 ([Morley et alet al., 1995)] and Neb1 ([Morley et alet al., 2003)]).  
 
4.2.2. Dysregulation of EGFR signalling in TOC keratinocytes 
Prior to the studies described here, dysregulation of EGFR signalling in TOC keratinocyte cell 
lines was described by the author’s group. Proliferation of TOC keratinocytes was found to be 
significantly higher than controls, but was insensitive to supplementation with exogenous 
EGF, whilst control keratinocytes’ proliferation increased significantly upon EGF 
supplementation. Similarly, TOC keratinocytes migrated at a significantly higher rate when 
cultured in the absence of exogenous EGFR ligands in a simulated wounding (‘scratch’) assay 
(Blaydon et alet al., 2012). As such, TOC keratinocytes were considered to act in an EGFR 
ligand-independent fashion.  
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4.2.3. iRHOM2 in ADAM17 loss-of-function skin 
The observed dysregulation of EGFR signalling in TOC keratinocytes meant that the possibility 
of an interaction between iRHOM2 and ADAM17 – in its role as the principal sheddase of 
EGFR ligands – warranted investigation. To first examine this potential relationship, the 
expression of iRHOM2 was investigated by immunohistochemistry in the skin of the ADAM17 
loss-of-function individual described in chapter 3, by Sarah Etheridge (Centre for Cutaneous 
Research, Blizard Institute). 
As shown in figure 4.4, iRHOM2 in the epidermis is found largely at the plasma membrane. In 
ADAM17 loss-of-function skin, iRHOM2 displays a notably reduced level of staining and 
punctate localisation. These data were indicative of the possibility of an interaction between 
iRHOM2 and ADAM17 in the epidermis. Strikingly, siRNA knockdown of ADAM17 in 
keratinocytes also results in a reduction in the expression of iRHOM2 (to be discussed in 
section 4.2.4).  
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Figure 4.4: iRHOM2 staining (green) in control and ADAM17 loss-of-function epidermis. Scale 
bars (top left) in all cases represent 100µm. Staining was carried out by Sarah Etheridge (Blizard 
Institute, London). 
 
 
 
 
4.2.4. ADAM17 expression in TOC and control keratinocytes 
To investigate the expression of ADAM17 and its possible relationship with iRHOM2 in 
keratinocytes, western blotting of both ADAM17 and iRHOM2 was performed in each of the 
four keratinocyte cell lines investigated, with and without siRNA knockdown of ADAM17 or 
iRHOM2. Western blotting of ADAM17 was performed using an antibody whose epitope lies 
in the enzyme's active site domain – which is therefore unaffected by ADAM17 maturation – 
which as a result detects ADAM17 in both its pro-protein form, and the mature, active form 
that results from cleavage by pro-protein convertases in the Golgi apparatus. Western 
blotting of ADAM17 using this antibody therefore results in the presence of characteristic 
double band (as shown in figure 4.5), representing pro- and mature ADAM17.  
Western blotting of ADAM17 in all four keratinocyte cell lines revealed an intriguing 
expression profile. Most notably, relative expression levels of the mature, active form of 
ADAM17 were significantly increased in non-targeting pool (NTP)-treated TOC keratinocytes, 
compared to controls (p<0.01; figure 4.5, *symbols).  
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As would be expected, siRNA knockdown of ADAM17 led to a significant reduction in both 
pro- and mature ADAM17 in all four cell lines (p<0.05 in all cases; figure 4.5, # symbol), but 
also interestingly caused a corresponding reduction in expression of iRHOM2 in all four cell 
lines. This observation not only further illustrates the close relationship between the two 
proteins in keratinocytes, but also tallies with previous observations, such as the reduced 
level of iRHOM2 staining in the epidermis of the ADAM17 loss-of-function patient (shown in 
figure 4.4) and a subsequently published study showing a reduction in the overall level of 
ADAM17 expression in murine iRHOM1 and 2 knockouts (Christova et alet al., 2013).  
Interestingly, siRNA knockdown of iRHOM2 was found to abolish the increased level of 
mature ADAM17 in TOC keratinocytes, with mature ADAM17 expression significantly 
reduced in anti-iRHOM2 siRNA-treated TYLK1 and TYLK2 cell lines (p<0.01; figure 4.5, § 
symbols) but not the two control cell lines, suggesting that the increased level of mature 
ADAM17 in the TYLK cell lines is iRHOM2-dependent.  
The western blot shown in figure 4.5 was performed by Sarah Etheridge (Centre for 
Cutaneous Research, Blizard Institute), whilst the results in the graph below the western blot 
represent data from three individual experiments, performed by the author and Sarah 
Etheridge.  
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Figure 4.5: ADAM17 and iRHOM2 expression in control and TOC keratinocyte cell lines. 
Expression of iRHOM2 and ADAM17 is shown in two control (Neb1 and K17) and two TOC (TYLK1 
and 2) keratinocyte cell lines in whole cell lysates collected 24 hours after transfection with non-
targeting pool (NTP) siRNA, or siRNA against either ADAM17 (si-A17) or iRHOM2 (si-iR2). The 
western blot shown was performed by Sarah Etheridge (BLIzard Institute, London), whilst Tthe 
graph shown represents results from three separate experiments carried out by both Sarah 
Etheridge and the author. Statistical analysis was performed using two-way ANOVA with 
Bonferroni’s post-hoc test; * signifies that expression of mature ADAM17 is individually 
significantly higher in both TOC cell lines than both control cell lines (p<0.01 in all cases); # 
signifies that expression of both pro- and mature ADAM17 is significantly reduced in all 
keratinocytes treated with si-A17, compared to those treated with NTP (p<0.01 in all cases); § 
symbols signify that expression of mature ADAM17 is significantly reduced in both TOC cell lines 
treated with si-iR2 compared to NTP, but not in either of the control cell lines (p<0.05 in each 
case). 
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Next, an antibody was used that binds to the ADAM17 pro-domain, and therefore detects 
the presence of the free pro-domain released upon ADAM17 maturation. Blotting with this 
antibody demonstrated an increase in this free pro-domain in TOC keratinocytes relative to 
controls, as shown in figure 4.6.  
 
Figure 4.6: Expression of the free ADAM17 pro-domain in control and TOC keratinocyte cell lines, 
in whole cell lysates.  
 
4.2.5 iRHOM2 and ADAM17 interaction 
These data are particularly interesting in light of the findings of a pair of subsequent studies, 
which illustrated that, in addition to its role in regulating the intracellular degradation of 
EGFR ligands, iRHOM2 can act as a novel regulator of ADAM17. As previously discussed, in 
order for Pro-ADAM17 to become activated, removal of its inhibitory pro-domain must 
occur, a process catalysed by the pro-protein convertase furin. iRHOM2 is capable of 
regulating this maturation process, as it is required for the transit of Pro-ADAM17 from the 
ER into the Golgi apparatus (Adrain et alet al., 2012, McIlwain et alet al., 2012). Activity of 
iRHOM2 is therefore absolutely required for ADAM17 activity in some cell types. iRHOM2 can 
therefore be considered to play a dual role in the ER, both in regulating the availability of 
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EGFR ligands for shedding (as discussed in section 1.2.5), and in the regulation of ADAM17. 
This dual role is illustrated in figure 4.7.  
 
 
Figure 4.7: The Dual role of iRHOM2. An illustration of iRHOM2’s two distinct roles in the ER: 
targeting membrane bound pro-EGFR ligands (multi-coloured) for ER-associated degradation in 
the proteasome (red); and facilitating the transit of pro-ADAM17 (purple) from the ER into the 
Golgi, where its pro-domain is removed by the actions of the pro-protein convertase furin 
(brown).  
 
Interestingly, the function of iRHOM2 in supporting ADAM17 maturation has recently been 
shown to be shared with its close relative iRHOM1, with a high degree of redundancy having 
been observed between the two iRHOMs in tissues where both are highly expressed 
(including the skin) (Christova et alet al., 2013). The fact that only the iRHOMs, and not any 
other rhomboid, are capable of supporting ADAM17 maturation in this way, implies that this 
function may be related to one of the unique domains specific to the iRHOMs. Indeed, it has 
recently been shown that the abrogation of KitL2 (a model ADAM17 substrate) shedding  in 
iRhom2-/- mouse embryonic fibroblasts could be rescued by overexpression of wild-type 
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iRhom2, but not by an iRHOM2 mutant lacking its iRHOM-specific N-terminal cytoplasmic 
domain, in which TOC-associated mutations are located (Maretzky et alet al., 2013).  
The key function of iRHOM2 in supporting the maturation of ADAM17 was discovered as a 
result of iRhom2 knockout mice, which are viable and show no obvious defects, but fail to 
control the replication of the pathogenic bacteria Listeria monocytogenes, as a result of 
impaired shedding of the ADAM17 substrate TNFα (McIlwain et alet al., 2012). Similarly, 
iRhom2-/- mice were recently shown to be protected from inflammatory arthritis to the same 
extent as mice lacking either ADAM17 or TNFα (Issuree et alet al., 2013). Although they do 
display an obvious phenotype, iRhom2 knockout mice did not display a phenotype of 
anything like the same severity as that seen in Adam17 knockout mice, which die perinatally 
of severe morphological defects resulting from the inability to shed EGFR ligands (Peschon et 
alet al., 1998). The apparent paradox of iRHOM2 being required for ADAM17 maturation, the 
lethality of Adam17 knockouts in mice and the seeming lack of effect of iRhom2 knockouts 
may be explained by recent reports showing that the closely related iRHOM1 is also capable 
of supporting ADAM17 maturation in the same way as iRHOM2, in a number of different cell 
types (Issuree et alet al., 2013, Christova et alet al., 2013). 
Murine knockouts of iRhom1 result in lethality between 9 days and 6 weeks (dependent on 
mouse genetic background), and a much more severe phenotype than knockout of iRhom2 
(Christova et alet al., 2013). This phenotype included pronounced intracerebral 
haemorrhages, a lack of any detectable white fat deposits, morphological defects of the bone 
marrow, spleen and pancreas, and evidence of neurological defects. Interestingly, mouse 
iRhom1 knockouts do not exactly phenocopy Adam17 knockouts, which characteristically 
display open eyes at birth and hair follicle defects, neither of which were present in iRhom1 
knockout mice. Double knockouts of both iRHOMs resulted in embryonic lethality in mice, at 
a much earlier stage than even Adam17 knockouts. From these data it can therefore be 
inferred that iRHOMs may have a larger role than the regulation of ADAM17 alone, due to 
the increased severity of double iRhom knockouts compared to Adam17, and the presence of 
not-obviously-ADAM17-related phenotypes in iRhom knockout mice, such as brain 
haemorrhages and organ dysfunction. These functions do not however include supporting 
the maturation of other ADAMs: while double iRhom knockout mice display no detectable 
mature ADAM17, maturation of all other widely expressed ADAMs is not affected, nor is the 
trafficking of other transmembrane proteins – including various EGFR ligands and ErbB2 – 
adversely affected (Christova et alet al., 2013). Furthermore, the fact that a double iRhom 
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knockout results in a more severe phenotype than would be expected from a simple 
combination of two single knockouts implies that there is a large degree of functional 
redundancy between the two.  
As could therefore be expected, the two iRHOMs are often co-expressed in a number of 
tissues; interestingly, the tissue with the highest level of expression of both iRHOM1 and 
iRHOM2 is the skin, offering some rationale for why a syndrome related to iRHOM2 
mutations would manifest itself in the first instance as a cutaneous disease.  
In the light of these studies, these data illustrate that although both iRHOMs are expressed in 
keratinocytes, iRHOM2 in is particularly important in the process of ADAM17 maturation in 
this cell type. Furthermore, the increased expression of mature ADAM17 in TOC 
keratinocytes suggests that TOC-associated iRHOM2 mutations may directly affect its role in 
the ADAM17 maturation, and lead to an upregulation of this process. iRHOM2 knockdown 
would not be expected to completely block ADAM17 maturation, due to the co-expression of 
iRHOM1 in keratinocytes.  
 
4.2.6 Three-dimensional organotypic culture of TOC and control keratinocytes   
In order to investigate the phenotype of TOC in circumstances more similar to those found in 
vivo, experiments involving TOC keratinocytes were performed in organotypic, three-
dimensional cultures, as well as in keratinocyte monolayers under standard cell culture 
conditions (as shown in the preceding section). Three-dimensional cultures of both TOC cell 
lines and one control (K17) were performed by Prof. Spiro Getsios and Dr. Nihal Kaplan at 
Northwestern University, Chicago, USA. All staining of three-dimensional culture sections 
was performed at Northwestern University, whilst western blotting of lysates derived from 
the cultures were performed primarily at Northwestern, and in part by the author. All ELISAs 
of supernatants derived from the cultures were performed by the author.  
These three-dimensional cultures yielded fully differentiated skin equivalent models for each 
cell line (figure 4.8, A), which expressed a range of differentiation markers, including loricrin, 
involucrin and transglutaminase 1 (TGM1; figure 4.8, B), and displayed robust TGM1 activity 
in their upper layers (to be discussed in section 4.2.18). The two TOC cell lines yielded 
stratified epithelial tissues with distinct morphologies; however, all lines generate epidermal 
equivalents that express differentiation products similar to controls. Also importantly, the 
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effects on ADAM17 and the EGFR observed (to be discussed in detail below) were consistent 
between TYLK1 and TYLK2.  
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Figure 4.8: Three-dimensional organotypic cultures of TOC and control keratinocytes. A: 
Haematoxylin and Eosin (H&E) stain of three-dimensional culture models of one control (K17 and 
two TOC (TYLK1 and TYLK2) cell lines, illustrating their stratified, three-dimensional structure. 3D 
cultures were performed by Prof. Sipro Getsios and Dr. Nihal Kaplan (Northwestern University, 
Chicago, USA). Scale bars (black) in each case represent 100µm. B: Western blotting of the 
differentiation markers loricrin, involucrin and transglutaminase 1 (TGM1) in each three-
dimensional culture, illustrating that full terminal differentiation is taking place in each culture 
model. Robust TGM1 activity is also seen in each model (see section 54.2.18). 
 
4.2.7 Expression of ADAM17 in three-dimensional organotypic keratinocyte culture 
To investigate ADAM17 expression, the same western blotting strategy as was used in 
monolayer keratinocytes was adopted in protein lysates taken from the three-dimensional 
keratinocyte cultures described in section 4.2.6. Expression of ADAM17 in these cultures 
displayed a very similar pattern to that seen in keratinocyte monolayers, in that TOC 
keratinocytes were characterised by relatively increased levels of mature ADAM17 compared 
to pro-ADAM17, and increased levels of the free ADAM17 pro-domain (figure 4.9).  
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Figure 4.9: ADAM17 expression in three-dimensional organotypic cultures. Expression of pro- and 
mature ADAM17 and the free ADAM17 pro-domain is shown in whole cell lysates taken from 
three-dimensional organotypic cultures of a control (K17) and two TOC (TYLK1 and TYLK2) cell 
lines.  
 
Taken together, these results imply that ADAM17 maturation is increased in TOC 
keratinocytes relative to controls, and that this increase is dependent on TOPC-associated 
mutations in iRHOM2 – a protein intimately involved in the generation of mature ADAM17, 
and whose knockdown significantly reduces ADAM17 maturation, with a particularly potent 
effect in TOC keratinocytes.  
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4.2.8 Localisation of ADAM17 in TOC and control keratinocytes in monolayer and in 3D 
three-dimensional culture 
To further investigate the observation of increased ADAM17 maturation in TOC 
keratinocytes, immunocytochemical co-staining of ADAM17 – alongside markers of the 
endoplasmic reticulum (ER), Golgi apparatus and plasma membrane – was performed in the 
four cell lines previously described. ADAM17 displayed clear staining at the plasma 
membrane (its primary site of ectodomain sheddase activity) and also within the Golgi 
apparatus (figure 4.10, A). The clear staining of ADAM17 in the Golgi in both TOC and control 
cell lines demonstrated that TOC-associated iRHOM2 mutations were not negatively 
affecting the ability of iRHOM2 to traffic pro-ADAM17 into the Golgi. When comparing all 
four cell lines it was noticeable that the two TOC cell lines displayed greater levels of 
ADAM17 at the plasma membrane (as shown in detail in figure 4.10, B).  
 
Figure 4.10: Immunocytochemical staining of control and TOC keratinocyte cell lines. A: Staining 
of ADAM17 (green) and the Golgi apparatus marker GM130 (red) is shown in control and TOC 
keratinocytes in monolayer culture. B: Detail of ADAM17 staining. Scale bars in all cases 
represent 100µm.  
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Immunohistochemical staining of ADAM17 was next performed in three-dimensional 
organotypic keratinocyte cultures, where findings once again corresponded with those seen 
in keratinocyte monolayers. ADAM17 staining at the plasma membrane of TOC keratinocyte 
three-dimensional cultures was significantly higher than controls, as shown in figure 4.11.   
These findings of increased ADAM17 localisation to its primary site of activity, in addition to 
the increased expression of mature ADAM17 in TOC keratinocytes shown by western blot, 
further suggested an upregulation of ADAM17 maturation in TOC, which was present in both 
keratinocyte monolayers and three-dimensional cultures.  
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Figure 4.11: Immunohistochemical staining of ADAM17 (red) in three-dimensional organotypic 
culture models of control (K17) and TOC (TYLK1 and TYLK2) keratinocytes. Data quantified in the 
graph represent results from three separate experiments. 3D cultures were performed by Prof. 
Sipro Getsios and Dr. Nihal Kaplan (Northwestern University, Chicago, USA). Scale bars in all cases 
represent 100µm; Statistical analysis was performed using student’s unpaired t-test to 
individually compare the TYLK1 and TYLK2 cell line results against K17; *p<0.05; **p<0.01; 
***p<0.001. 
 
4.2.9 Shedding of pro-inflammatory cytokines and EGFR ligands by TOC and control 
keratinocytes 
To examine the effect of the apparent upregulation of mature ADAM17 in TOC keratinocytes, 
shedding of ADAM17 substrates was examined in the four cell lines studied, and in 
peripheral blood mononuclear cells (PBMCs) derived from TOC patients and controls.  
Tumour necrosis factor-α (TNFα) – arguably ADAM17’s best known substrate – was shed at a 
significantly higher level by TOC keratinocytes than controls (in which levels of TNFα shed 
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were below the limit of detection; figure 4.12, A) when these cells were stimulated with 
phorbol myristate acetate (PMA; 100ng/ml). Importantly, this excess TNFα shedding was 
found to be dependent on ADAM17, as siRNA mediated knockdown of ADAM17 (illustrated 
in figure 4.5) was sufficient to significantly reduce the excess shedding observed. Similarly, 
secretion of TNFα from PBMCs isolated from three TOC patients was also significantly higher 
than matched controls following PMA stimulation (figure 4.12, B). No significant difference in 
TNFα secretion was observed constitutively, or when these cells were stimulated with 
varying concentrations of lipopolysaccharide (LPS; not shown). These findings show that TOC 
keratinocytes harbouring mutant iRHOM2 protein are not only capable of shedding TNFα (in 
contrast to macrophages of iRHOM2-knockout mice, which cannot ([Adrain et alet al., 
2012)]) but do so in a more efficient manner than wild-type cells.  
 
 
 
Figure 4.12: TNFα shedding. A: Shedding of TNFα from control and TOC keratinocytes following 
stimulation with 100ng/ml phorbol myristate acetate (PMA). Results represent shedding over a 
24 hour period, beginning 24 hours after transfection of keratinocytes with non-targeting pool 
(NTP) or anti-ADAM17 siRNA. B: Shedding of TNFα from peripheral blood mononuclear cells 
(PBMCs) derived from TOC patients or controls (n=3 each) with or without 100ng/ml PMA 
stimulation. Data in all cases represent results from three separate experiments. “Control” 
results represent pooled data from K17 and Neb1 cell lines, “Tylosis” results represent pooled 
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data from TYLK1 and TYLK2 cell lines. Statistical analysis was performed using 2-way ANOVA with 
Bonferroni’s post-hoc test (A) or student’s unpaired t-test (B); nd: not detected; *p<0.05; 
**p<0.01; ***p<0.001. 
 
As described in section 4.2.2, TOC keratinocytes have previously been shown to proliferate 
and migrate at a significantly higher rate than controls in a scratch assay, and do so 
independently of exogenous EGFR ligands (Blaydon et alet al., 2012). Consequently, the 
shedding of ADAM17’s substrates in the EGF growth factor family, specifically amphiregulin, 
TGFα and HB-EGF, was examined when cells were cultured in the absence of exogenous 
EGFR ligands. Constitutive shedding of all three growth factors (i.e. in the absence of any 
stimulation, by PMA or otherwise) was shown to be significantly higher in TOC keratinocytes 
than controls, with amphiregulin shedding around two orders of magnitude higher than that 
of TGFα and HB-EGF (figure 4.13). In each of these cases, the elevated shedding observed 
could be significantly reduced by siRNA mediated knockdown of ADAM17 in TOC 
keratinocytes, illustrating the ADAM17-dependent nature of the observed increase.  
 
 
Figure 4.13: Shedding of ADAM17 substrate EGFR ligands from control and TOC keratinocytes. 
Shedding of amphiregulin (A), TGFα (B), and HB-EGF (C) from control and TOC keratinocytes 
measured by ELISA, representing shedding over a 24 hour period, beginning 24 hours after 
transfection of keratinocytes with non-targeting pool (NTP) or anti-ADAM17 siRNA. Data in all 
cases represent results from three separate experiments. “Control” results represent pooled data 
from K17 and Neb1 cell lines, “Tylosis” results represent pooled data from TYLK1 and TYLK2 cell 
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lines. Statistical analysis was performed using 2-way ANOVA with Bonferroni’s post-hoc test; nd: 
not detected; ns: not-significant; *p<0.05; **p<0.01; ***p<0.001. 
 
 
Secretion of EGFR ligands from organotypic culture models of TOC was also examined. 
Amphiregulin secretion was again observed to be significantly higher in TOC cells than 
controls (figure 4.14), whilst TGFα and HB-EGF shedding levels were below the limit of 
detection (not shown).  
 
Figure 4.14: Amphiregulin shedding, measured by ELISA, from three dimensional (3D) 
organotypic cultures of control and TOC keratinocytes. Data represent results from three 
separate experiments. Statistical analysis was performed using student’s unpaired t-test; 
*p<0.05; **p<0.01; ***p<0.001. 
 
The secretion of a number of pro-inflammatory cytokines – specifically IL-6 and IL-8 – was 
also examined in TOC and control keratinocytes. Although not directly shed by ADAM17, 
secretion of both of these cytokines can be regulated downstream of ADAM17 substrate 
activity, and both are important mediators of inflammation, epidermal wound healing and 
keratinocyte migration. For example, IL-8 synthesis and release in the skin depend on the 
activation of the EGFR (Frankart et alet al., 2012), and the release of both IL-6 and IL-8 
require EGFR transactivation by ADAM17 in skin injury models (Buchau, 2010) (the same is 
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also true of other cytokines and anti-microbial peptides). Furthermore, IL-6 signalling is 
regulated in large part by shedding of the soluble IL-6 receptor (as discussed in section 1.1.4), 
a direct ADAM17 substrate.  
 
Constitutive secretion of both IL-6 and IL-8 was found to be significantly upregulated in TOC 
keratinocytes compared to controls, with IL-8 secretion in particular hugely upregulated. 
Secretion of both was sensitive to siRNA knockdown of ADAM17  in TOC cells, but not 
controls, illustrating that the excessive secretory phenotype of TOC keratinocytes is 
dependent at least in part on ADAM17 (figure 4.15). 
 
 
Figure 4.15: Interleukin (IL)-6 and IL-8 secretion, measured by ELISA, from control and TOC 
keratinocytes. These data represent secretion over a 24 hour period, beginning 24 hours after 
transfection of keratinocytes with non-targeting pool (NTP) or anti-ADAM17 siRNA. Data in all 
cases represent results from three separate experiments. “Control” results represent pooled data 
from K17 and Neb1 cell lines, “Tylosis” results represent pooled data from TYLK1 and TYLK2 cell 
lines. Statistical analysis was performed using 2-way ANOVA with Bonferroni’s post-hoc test;  ns: 
not-significant; *p<0.05; **p<0.01; ***p<0.001. 
 
4.2.10 mRNA expression of ADAM17 substrates in keratinocytes 
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To illustrate the ADAM17-dependent nature of the increased shedding observed, and that 
shedding reductions in cells treated with anti-ADAM17 siRNA were ADAM17-dependent, 
mRNA expression of each of the shed factors described above, and of ADAM17 itself, was 
also performed.  
Other than ADAM17, no significant change at the mRNA transcript level of any protein was 
observed when ADAM17 siRNA was applied (figure 4.16), illustrating that differences in 
shedding observed were dependent on the activity of ADAM17. In general, mRNA transcript 
levels of EGFR ligands were marginally higher in TOC keratinocytes, which would be 
expected, as signalling through the EGFR promotes the production of more EGFR ligands. 
Additionally, these differences would not appear to explain the large degree to which 
shedding levels were elevated in TOC cells.  
siRNA knockdown of ADAM17 robustly reduces ADAM17 mRNA levels, as would be expected. 
Additionally, expression of ADAM17 mRNA in TOC and control keratinocytes is comparable, 
meaning that increased levels of mature ADAM17 and the increased presence of ADAM17 at 
the plasma membrane cannot be explained simply by upregulation of ADAM17 expression at 
the transcription level, further implicating iRHOM2-dependent ADAM17 maturation as a key 
event in ADAM17 activity in TOC keratinocytes.  
It is also interesting to observe that shedding levels of various substrates of ADAM17 often 
do not correlate with expression at the mRNA level. For example, expression of 
amphiregulin, TGFα and HB-EGF mRNA is broadly comparable, yet amphiregulin shedding is 
around two orders of magnitude higher than either of the other two growth factors, 
illustrating the importance of regulation at levels beyond mRNA expression.  
In common with the very high levels of secretion observed, IL-8 mRNA expression was 
notably higher in TOC keratinocytes than controls, and was by far the highest expressed of 
the mRNA transcripts examined.  
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Figure 4.16: mRNA levels of various proteins in control and TOC keratinocytes. mRNA levels were 
measured in RNA extracted from whole cell lysates 48 hours after transfection with non-targeting 
pool (NTP) or anti-ADAM17 siRNA (the same cells responsible for the ligand shedding displayed in 
figures 4.8, 4.9 and 4.11). Data in all cases represent results from three separate experiments. 
“Control” results represent pooled data from K17 and Neb1 cell lines, “Tylosis” results represent 
pooled data from TYLK1 and TYLK2 cell lines. Statistical analysis was performed using 2-way 
ANOVA with Bonferroni’s post-hoc test;  ns: not significant; *p<0.05; **p<0.01; ***p<0.001 
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4.2.11 EGFR phosphorylation in TOC and control keratinocytes in three dimensional 
organotypic culture 
Next, the consequences of increase EGFR ligand shedding by TOC keratinocytes were 
investigated. Western blotting of the EGFR in three-dimensional culture models revealed 
variable expression of total EGFR, but notably increased EGFR phosphorylation at three 
separate tyrosine residues (Y845, Y1045 and Y1068) in TOC cultures (figure 4.17), suggesting 
that increased EGFR ligand shedding is accompanied by increased EGFR signalling in these 
models.   
 
Figure 4.17: Phosphorylation of the EGFR at three separate tyrosine residues in three-
dimensional organotypic culture models of a control (K17) and two TOC (TYLK1 and TYLK2) 
keratinocyte cell lines. Western blotting was performed by Prof. Sipro Getsios and Dr. Nihal 
Kaplan (Northwestern University, Chicago, USA). 
 
4.2.12 Scratch assays as a measure of keratinocyte migration and wound healing 
As previously mentioned, TOC keratinocytes have been shown to proliferate and migrate at 
significantly higher rates than controls keratinocytes in scratch wounding assays. These 
assays measure the migration of keratinocytes across a scratch made in a keratinocyte 
monolayer, and as such simulate the wound healing response in keratinocytes.  
 135 
 
The increased migration of TOC keratinocytes has been described as being EGFR ligand 
independent. That is, when keratinocytes are cultured in medium lacking any exogenous 
EGFR ligands, TOC keratinocyte migration is significantly higher than that seen in controls. To 
confirm this finding, scratch assays were performed in the absence of exogenous EGFR 
ligands on all four keratinocyte cell lines described previously, with keratinocyte migration 
measured 24 and 48 hours after scratching. As shown in figure 4.18, migration of both TYLK1 
and TYLK2 cell lines was significantly higher than both K17 and Neb1 cell lines after 24 and 48 
hours (p <0.001 in all cases).  
 
 
Figure 4.18: Migration of control and TOC keratinocytes 24 and 48 hours following simulated 
wounding, in medium lacking any exogenous EGFR ligands. Data represent three separate 
experiments for each cell line. Statistical analysis was performed using Student’s unpaired t-test; 
*p<0.05; **p<0.01; ***p<0.001. Significance lines represent that both (non-pooled) TYLK1 and 
TYLK2 migration was significantly higher than both K17 and Neb1, at both 24 and 48 hours 
(p<0.001 in all cases).   
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4.2.13 The effect of secreted factors on keratinocyte migration 
As the increased TOC keratinocyte migration observed is independent of exogenous EGFR 
ligands, it was reasonable to hypothesise that the significantly increased level of EGFR ligand 
shedding observed in TOC keratinocytes would contribute to the excessive migratory 
phenotype.  
To investigate this, shedding of amphiregulin (the growth factor present at by far the highest 
levels in cell culture supernatants derived from TOC keratinocytes) was first examined over 
time, in supernatants derived from all four cell lines following scratch wounding. 
Amphiregulin production was upregulated very quickly after scratch wounding in TOC cells 
relative to controls, was significantly higher after only one hour (figure 4.19), and remained 
at a significantly higher level than controls over 48 hours after scratch wounding.  
 
 
Figure 4.19: Amphiregulin shedding following scratch wounding. Amphiregulin shedding, 
measured by ELISA, is shown at 1, 3, 6, 12, 24 and 48 hours following scratch wounding, in 
control and TOC keratinocytes. Data in all cases represent results from three separate 
experiments on each cell line. “Control” results represent pooled data from K17 and Neb1 cell 
lines, “Tylosis” results represent pooled data from TYLK1 and TYLK2 cell lines. Statistical analysis 
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was performed using student’s unpaired t-test for pairwise comparisons at each time point; ns: 
not-significant; *p<0.05. 
 
 
 
To investigate the effect of shed growth factors on keratinocyte migration, cell culture 
medium in which TOC keratinocytes had previously been grown (TYLK-conditioned medium, 
composed of a 1:1 blend of medium – otherwise containing no exogenous EGFR ligands – 
derived from TYLK1 and TYLK2 cells) and which therefore contained the high levels of shed 
growth factors that characterise TOC keratinocytes, was used in place of otherwise normal 
medium containing no exogenous EGFR ligands, in a scratch assay of all four cell lines.  
As shown in figure 4.16, the use of TYLK-conditioned medium significantly increased the 
migration of control keratinocytes after both 24 and 48 hours (figure 4.20, B), though the 
level of migration seen was still lower than that of TOC keratinocytes in otherwise normal 
medium. TYLK-conditioned medium also increased the migration of TOC keratinocytes, 
though this increase was not significant.  
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Figure 4.20: The effect of TYLK-conditioned medium on migration of control and TOC 
keratinocytes. A: representative pictures of scratch wounding of Neb1 (control) and TYLK2 (TOC) 
keratinocytes, at 0 and 48 hours after scratch wounding, when cultured in otherwise normal or 
TYLK-conditioned medium (both lacking exogenous EGFR ligands). B: Quantification of 
keratinocyte migration 24 and 48 hours after scratch wounding. Data in all cases represent 
results from three separate experiments on each cell line. “Control” results represent pooled 
data from K17 and Neb1 cell lines, “Tylosis” results represent pooled data from TYLK1 and TYLK2 
cell lines. Statistical analysis was performed using 2-way ANOVA with Bonferroni’s post-hoc test; 
ns: not-significant; *p<0.05; **p<0.01; ***p<0.001.  
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Next, the effect of medium conditioned by control keratinocytes in the same fashion 
(control-conditioned medium) was examined, to investigate whether or not the increase in 
migration observed could be explained by those factors shed excessively by TOC 
keratinocytes in particular.  
As shown in figure 4.21, control-conditioned medium had no significant effect on migration 
of either control or TOC keratinocytes; though a small but insignificant reduction in the 
migration of control keratinocytes was observed.  
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Figure 4.21: The effect of Control-conditioned medium on migration of control and TOC 
keratinocytes. A: representative pictures of scratch wounding of Neb1 (control) and TYLK2 (TOC) 
keratinocytes, at 0 and 48 hours after scratch wounding, when cultured in otherwise normal or 
Control-conditioned medium (both lacking exogenous EGFR ligands). B: Quantification of 
keratinocyte migration 24 and 48 hours after scratch wounding. Data in all cases represent 
results from three separate experiments on each cell line. “Control” results represent pooled 
data from K17 and Neb1 cell lines, “Tylosis” results represent pooled data from TYLK1 and TYLK2 
cell lines. ns: not-significant; Statistical analysis was performed using 2-way ANOVA with 
Bonferroni’s post-hoc test; *p<0.05; **p<0.01; ***p<0.001.  
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Therefore, medium conditioned by TOC keratinocytes is sufficient to significantly increase 
the migration of control keratinocytes, whilst medium conditioned by control cells has no 
effect on migration by any cell type, implying that factors shed by TOC cells only are 
important in the excessive cell migration phenotype observed in these keratinocytes.  
Next, the effect of TYLK-conditioned medium on EGFR ligand production was observed. 
Culturing control keratinocytes in TYLK-conditioned medium resulted in the presence of 
significantly increased levels of amphiregulin in supernatants from these cells after 24 hours 
(figure 4.22), an increase which correlates with the observed increase in migration. However, 
whether this represents increased amphiregulin shedding in response to increased EGFR 
signalling, or residual amphiregulin ultimately derived from the TOC keratinocytes used to 
produce the TYLK-conditioned medium, remains unclear, though some combination of the 
two would be expected.  
 
 
Figure 4.22: The effect of TYLK-conditioned medium on amphiregulin shedding in control and 
TOC keratinocytes. Amphiregulin concentrations were measured 24 hours after scratch 
wounding, in otherwise normal or TYLK-conditioned medium in which control or TOC 
keratinocytes had been cultured. Data in all cases represent results from three separate 
experiments on each cell line. “Control” results represent pooled data from K17 and Neb1 cell 
lines, “Tylosis” results represent pooled data from TYLK1 and TYLK2 cell lines. Statistical analysis 
was performed using 2-way ANOVA with Bonferroni’s post-hoc test;  ns: not-significant; *p<0.05; 
**p<0.01; ***p<0.001.  
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4.2.14 Inhibition of ADAM17 with the small molecule GW280264X 
Next, the degree to which ADAM17 contributes to the phenotype of excessive migration was 
investigated via chemical inhibition of ADAM17. This was performed with the use of 
GW280264X, a small molecule ADAM17 inhibitor used to potently inhibit ADAM17 activity 
(Dreymueller et alet al., 2012, Ludwig et alet al., 2005, Rabinowitz et alet al., 2001). 
Treatment with GW280264X at 1µM potently and significantly reduces the shedding of the 
ADAM17 substrates amphiregulin and TGFα (figure 4.23) from both control and TOC 
keratinocytes, with a particularly pronounced effect on TOC cells.  
 
Figure 4.23: The effect of GW280264X on ADAM17 substrate shedding. Shedding of amphiregulin 
and TGFα from control and TOC keratinocytes measured by ELISA, representing shedding over a 
24 hour period, when keratinocytes were cultured in the presence of 1µM GW280264X (GW) or a 
vehicle control (DMSO). Data in all cases represent results from three separate experiments. 
“Control” results represent pooled data from K17 and Neb1 cell lines, “Tylosis” results represent 
pooled data from TYLK1 and TYLK2 cell lines. Statistical analysis was performed using 2-way 
ANOVA with Bonferroni’s post-hoc test;  *p<0.05; **p<0.01; ***p<0.001. 
 
4.2.15 The effect of ADAM17 inhibition on EGFR ligand shedding and keratinocyte 
migration 
In addition to potently blocking EGFR ligand shedding by keratinocytes, treatment with 
GW280264X was also effective in significantly reducing the migration of both control and 
TOC keratinocytes following scratch wounding. As with its effects on ADAM17 shedding, 
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GW280264X had a particularly potent effect on TOC keratinocyte migration, where it 
significantly reduced migration at both 24 and 48 hours (control keratinocyte migration was 
significantly reduced only after 48 hours) and reduced migration down to a level below that 
seen in control keratinocytes either with or without GW280264X treatment (figure 4.24). 
 
Figure 4.24: The effect of the ADAM17 inhibitor GW280264X on migration of control and TOC 
keratinocytes. A: representative pictures of scratch wounding of Neb1 (control) and TYLK2 (TOC) 
keratinocytes, at 0 and 48 hours after scratch wounding, when cultured in medium (lacking 
exogenous EGFR ligands) supplemented with either a vehicle control (DMSO) or 1µM 
GW280264X (GW). B: Quantification of keratinocyte migration 24 and 48 hours after scratch 
wounding. Data in all cases represent results from three separate experiments on each cell line. 
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“Control” results represent pooled data from K17 and Neb1 cell lines, “Tylosis” results represent 
pooled data from TYLK1 and TYLK2 cell lines. Statistical analysis was performed using 2-way 
ANOVA with Bonferroni’s post-hoc test; ns: not-significant; *p<0.05; **p<0.01; ***p<0.001.  
These data indicate that the excessive migration observed in TOC keratinocytes cultured in 
the absence of EGFR ligands is dependent on the sheddase actions of ADAM17, which 
corresponds with the earlier observation that factors shed by TOC keratinocytes are able to 
stimulate the migration of control keratinocytes.  
 
4.2.16 The effect of EGFR ligand supplementation on keratinocyte migration 
Having established that inhibition of ADAM17 is sufficient to block the excessive migration of 
TOC keratinocytes in EGFR ligand-free medium, the possibility of overcoming the effects of 
ADAM17 inhibition by exogenous supplementation with EGFR ligands was next investigated. 
As amphiregulin is the growth factor present at by far the highest level, and as increased 
amphiregulin levels correlate with increased migration (figure 4.22), it appeared to be the 
best candidate for supplementation studies.  
As shown in figure 4.25, the addition of amphiregulin at 2000pg/ml (a concentration 
resembling that found in supernatants conditioned by TOC keratinocytes) does significantly 
increase migration by control keratinocytes, but not TOC keratinocytes (figure 4.25, A), in a 
fashion similar to that seen when supplementing with TYLK-conditioned medium (figure 
4.20). However, amphiregulin supplementation had no effect on the migration inhibition 
mediated by GW280264X in either control or TOC keratinocytes.  
Similarly, amphiregulin supplementation did not induce any significant upregulation of its 
own shedding in either control or TOC cells (though a small but insignificant increase was 
observed in controls cells). 
 
 
 146 
 
 
Figure 4.25: The effect of amphiregulin supplementation on migration of control and TOC 
keratinocytes, GW280264X-induced migration inhibition, and amphiregulin shedding. A: 
Quantification of keratinocyte migration 48 hours after scratch wounding, when cultured in 
medium (lacking exogenous EGFR ligands) supplemented with either a vehicle control (DMSO), 
2000 pg/ml amphiregulin, 1µM GW280264X (GW), or both amphiregulin and GW280264X (both 
at the same concentrations) B: Shedding of amphiregulin from control and TOC keratinocytes 
measured by ELISA, representing shedding over a 24 hour period, when keratinocytes were 
cultured in the same conditions as described for A. Data in all cases represent results from three 
separate experiments on each cell line. “Control” results represent pooled data from K17 and 
Neb1 cell lines, “Tylosis” results represent pooled data from TYLK1 and TYLK2 cell lines. Statistical 
analysis was performed using 2-way ANOVA with Bonferroni’s post-hoc test; ns: not significant; 
*p<0.05; **p<0.01; ***p<0.001. 
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Therefore, although it is capable of stimulating increased migration in the presence of 
functional ADAM17, amphiregulin alone is not capable of compensating for the loss of 
ADAM17 function mediated by GW280264X. These data therefore imply that either other 
factors than amphiregulin, or a combination of amphiregulin and other factors shed by 
ADAM17, are responsible for the migratory activity seen in TOC keratinocytes. Considering 
the wide range of substrates shed by ADAM17, and the influence these substrates can have 
on other signalling pathways (such as on IL-6 and IL-8 secretion), it would be expected that 
the interplay of several shed factors would influence the migratory phenotype observed.  
 
4.2.17 Electron microscopy of desmosomes in TOC and control epidermis  
As well as its sheddase activities, ADAM17 plays a key role in the regulation of desmosomes, 
intercellular junction complexes which function to provide strong adhesions between cells in 
tissues subject to high levels of mechanical stress, particularly the skin and heart. The 
structure and function of desmosomes, and their regulation be ADAM17 and EGFR signalling, 
are described in sections 1.1.14-15.  
To investigate the status of desmosomes in TOC, keratinocytes from the spinous layer of 
TOC-affected individuals’ skin were examined by electron microscopy, and their desmosomes 
studied. When analysed, it was observed that the desmosomes in TOC skin lacked the 
electron-dense midline found in mature desmosomes of control skin (figure 4.26, white 
arrows). This absence of a midline is indicative of the desmosomes being in a calcium-
dependent, immature state associated with wound healing, keratinocyte motility and mitosis 
(Brooke et alet al., 2012), that contrasts with the hyperadhesive, calcium-independent state 
of midline-containing desmosomes that are found in normal epidermis under standard 
conditions. 
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Figure 4.26: Control and TOC desmosome electron microscopy. Analysis of desmosomes in TOC 
skin from three TOC-affected individuals, compared to controls showed the presence in TOC skin 
of desmosomes lacking the electron-dense midline (white arrows) found in mature, calcium-
independent desmosomes of control skin. 
 
4.2.18 Desmoglein expression in TOC and control keratinocytes 
Next, the expression of the desmosomal cadherin desmoglein 2 (DSG2), whose cleavage is 
dependent on ADAM17 and EGFR signalling, was examined by western blotting. The 
importance of ADAM17 in DSG2 cleavage is illustrated by the ADAM17-null individual 
described in chapter 3. This individual displayed increased expression of DSG2 by western 
blotting in his keratinocytes, and an increased presence of DSG2 at the plasma membrane of 
keratinocytes in epidermal sections (see section 3.2.11). 
When keratinocytes expressing ADAM17 are grown in the presence of EGF, DSG2 shedding 
can be expected to occur constitutively, due to the presence of active EGFR signalling, and 
result in the presence of a relatively low level of DSG2 (figure 4.27, A, left panel). However, 
removal of EGF can be expected to lead to a reduction in EGFR signalling, and therefore DSG2 
cleavage, in control cell lines and thereby increase levels of DSG2 in cell lysates. Meanwhile, 
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TOC keratinocytes will retain a similar level of DSG2 shedding, and hence show no increase in 
the presence of DSG2 by western blot, as a result of the increased level of constitutive EGFR 
ligand shedding displayed by them. As expected, this pattern of DSG2 expression was 
observed (figure 4.27, A, right panel). When grown in the presence of EGF, levels of DSG2 
expression did not differ significantly between any of the four cell lines tested; whereas in 
the absence of EGF, DSG2 expression in both TYLK1 and 2 cells was significantly lower than 
either control cell line (p<0.05 in all cases).  
To further investigate ADAM17-mediated DSG2 cleavage, expression of its specific 
intracellular cleavage product (Nava et alet al., 2007) was measured in all cell lines, in the 
presence and absence of EGF. Corresponding with expression of full-length DSG2, expression 
of this cleavage product did not differ between all cell lines in the presence of EGF, but was 
noticeably reduced in control cells in the absence of EGF, whilst remaining present in TYLK1 
and 2 cells (figure 4.27, B). 
 
 150 
 
 
Figure 4.27: Desmoglein 2 expression in control and TOC keratinocytes. A: Western blotting of 
full-length desmoglein 2 (DSG2) in control and TOC keratinocytes, in whole cell lysates of 
keratinocytes cultured for 24 hours in the presence (left) or absence (right) of exogenous EGF. 
Data shown in the graph is are representative of three separate experiments. B: Western blotting 
of a specific intracellular DSG2 cleavage product in the same whole cell lysates described for A. 
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4.2.19 Transglutaminase activity in TOC and control epidermis, and in 3D culture of TOC 
and control keratinocytes 
ADAM17-dependent signalling through the EGFR has recently been shown to regulate the 
function of Transglutaminase 1 (TGM1) in the epidermal barrier (Franzke et al., 
2012)(Franzke et al., 2012)(Franzke et al., 2012)(Franzke et al., 2012)(Franzke et al., 2012). In 
keratinocyte-restricted ADAM17-knockout mice, loss of ADAM17 sheddase activity 
significantly reduced TGM1 activity in the upper layers of the epidermis (Franzke et alet al., 
2012), a phenotype which could be reversed by the application of topical TGFα. Similarly, in a 
human ADAM17 loss-of-function individual (whose inflammatory skin disease superficially 
resembles that seen in mice lacking epidermal ADAM17 or EGFR expression) TGM1 activity 
was significantly reduced in the epidermis (as shown in section 3.2.10).  
TGM1 activity in the epidermis of TOC patients and controls was quantified using an assay 
based on the incorporation of the biotinylated amine donor mono-dansylcadaverine (Biot-
MDC), as described in section 3.2.10 Significantly increased TGM1 activity staining was 
observed in the granular layer of TOC skin compared to controls (figure 4.28, A), indicative of 
increased activity. Furthermore, a significant increase in TGM1 activity was also observed in 
three-dimensional, organotypic culture models of TOC keratinocytes, where the enzyme 
activity was more broadly distributed throughout the suprabasal epidermal layers (figure 
4.28, B). These data suggest an increased level of EGFR-dependent TGM1 function in TOC 
skin, and imply that TOC epidermis may demonstrate improved barrier function.  
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Figure 4.28: Transglutaminase 1 (TGM1) activity in control and tylosis epidermis and epidermal 
equivalents. A: TGM1 activity in the granular layer (white arrows) of control and TOC-affected 
epidermis, assayed by the Biot-MDC amine donor assay.. B: TGM1 activity (measured by the Biot-
MDC assay) in three-dimensional organotypic culture models of a control (K17) and two TOC 
(TYLK1 and TYLK2) keratinocyte cell lines. Data in the graphs shown represent results from three 
separate experiments each. Statistical analysis was performed using student’s unpaired t-test to 
compare between control and tylosis skin (A) or to individually compare the results of both TYLK 
cell lines with K17; *p<0.05; **p<0.01; ***p<0.001. 
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4.3 Discussion Summary of chapter 
In this chapter, the relationship between iRHOM2 and ADAM17, and its downstream effects, 
is examined in the inherited skin disease Tylosis with Oesophageal Cancer (TOC). Western 
blotting and immunofluorescence staining of ADAM17 in keratinocytes derived from TOC-
affected individuals revealed the presence of an increased level of mature, active ADAM17, 
and increased localisation of ADAM17 to the plasma membrane (its primary site of sheddase 
activity) in TOC keratinocytes compared to controls. This increased expression of mature 
ADAM17 was dependent on iRHOM2, and implies that TOC-associated iRHOM2 mutations – 
which affect an iRHOM2 domain required for interaction with ADAM17 during its maturation 
process – contribute to an upregulation of ADAM17 maturation and activity in TOC 
keratinocytes. This increase in maturation is accompanied by increased, ADAM17-dependent 
shedding of ADAM17 substrates, notably including numerous members of the EGFR ligand 
family, and other cytokines from these keratinocytes. Importantly, the effects of TOC on 
ADAM17 are consistently observed in two different TOC cell lines, and are apparent when 
these cells are cultured under standard monolayer conditions, and in three-dimensional, 
organotypic, epidermal-equivalent cultures. Upregulation of ADAM17 substrate shedding is 
also observed in peripheral blood mononuclear cells from TOC patients, illustrating the 
physiological relevance of these findings.  
Prior to the investigations described here, TOC keratinocytes had notably been described as 
displaying increased proliferation and migration, and to act in an EGFR ligand-independent 
manner in both these aspects. In the studies described here, growth factors shed by TOC 
keratinocytes, but not control keratinocytes, were shown to be able to significantly increase 
keratinocyte migration. Inhibition of ADAM17 sheddase activity with the small molecule 
inhibitor GW280264X led to an almost total abrogation of ADAM17-dependent EGFR ligand 
shedding, and a concurrent, highly significant reduction in keratinocyte migration, an effect 
which was particularly potent in TOC keratinocytes compared to controls. Application of the 
ADAM17 substrate amphiregulin (the EGFR ligand shed at the highest level by TOC 
keratinocytes) also led to increased control keratinocyte migration, in a fashion resembling 
that seen with the application of medium conditioned by TOC keratinocytes, but could not 
however compensate for the migration reduction resulting from ADAM17 inhibition.  
As well as substrate shedding, other processes regulated by ADAM17 in keratinocytes also 
showed signs of perturbation in TOC. Desmosomes in TOC epidermis were noticeably lacking 
in the electron dense midlines found in the mature desmosomes of otherwise normal control 
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skin – an arrangement indicative of desmosomes being present in a calcium-dependent, 
immature state associated with keratinocyte migration and wound-healing activity. 
Corresponding with this finding, turnover of the ADAM17 substrate (and desmosome 
component) desmoglein 2 appeared to be upregulated in TOC keratinocytes compared to 
controls. Finally, activity of the differentiation-dependent enzyme transglutaminase 1, which 
is regulated by ADAM17-dependent EGFR signalling, was found to be significantly 
upregulated in TOC, in both skin sections from TOC patients, and organotypic keratinocyte 
cell line cultures. This is indicative of increased EGFR signalling in the TOC epidermis (a 
suggestion borne out by increased EGFR phosphorylation in organotypic TOC keratinocyte 
cultures), and implies that increased barrier function may be present in TOC skin.  
The findings of increased ADAM17 activity, and particularly of upregulated EGFR ligand 
shedding, offer several potential clues to the pathogenesis of TOC in the skin, and to the 
striking susceptibility to oesophageal squamous cell carcinoma that is observed in TOC 
patients. The implications of these finding will be discussed in greater detail in chapter 6.  
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5  Cytosolic Phospholipase A2-α mutation in Cryptogenic Multifocal 
Ulcerative Stenosing Enteritis 
5.1.    Introduction 
This chapter describes investigations into the cause and pathogenesis of a severe, autosomal 
recessive gastrointestinal disease, in a single family of Serbian origin. This condition has been 
lifelong, and features multiple severe extra-intestinal complications. Genetic analyses (to be 
described below) associated this condition to a homozygous deletion mutation in the 
PLA2G4A gene, which segregates with disease in the siblings’ family. 
This chapter will describe in detail the role of PLA2G4A’s gene product cytosolic 
phospholipase A2-α (henceforth cPLA2α; also known as phospholipase A2 group IVA) in the 
small intestine, the disease observed, the genetic investigations that led to the identification 
of PLA2G4A mutations as being associated with it, and the predicted functional 
consequences of the mutation. Expression of cPLA2α will be examined in the intestine and 
peripheral blood cells of the affected individuals,individuals and the function of cPLA2α will 
be analysed, using the platelet-aggregating activity of the cPLA2α product thromboxane A2 as 
a measure of enzyme function.  
 
5.1.1 The small intestine 
The small intestine (small bowel) is the section of the gastrointestinal tract that immediately 
follows the stomach. Made up of three distinct sections (the duodenum, jejunum and ileum), 
it is the primary site where the digestion and absorption of food takes place. Unlike other 
parts of the gastrointestinal tract, cancer of the small intestine remains relatively rare 
(Matsumoto et alet al., 2004), though inflammatory small bowel conditions represent a 
significant health burden. The intestinal lumen is lined with a specialised columnar 
epithelium which is described in detail in section 1.1.2.  
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5.1.2 Cryptogenic Multifocal Ulcerative Stenosing Enteritis 
The syndrome known as cryptogenic multifocal ulcerative stenosing enteritis (CMUSE) is an 
extremely rare condition characterised by recurrent upper small intestinal ulceration and 
stenosis (the abnormal narrowing of the small bowel resulting from the development of 
numerous fibrous strictures) of unknown aetiology. The condition was probably first 
described in the late fifties and early sixties (Kohoutova et alet al., 2013), and remains very 
rarely diagnosed, with only around sixty cases published so far. However, there is a high 
likelihood that the condition may frequently be misdiagnosed and mistaken for more 
common causes of small bowel ulceration, such as Crohn’s disease and non-steroidal anti-
inflammatory drug (NSAID)-induced enteropathy (to be discussed in 5.1.3).  
The pathophysiology of CMUSE has not presently been clarified. The suggestion that the 
pathology of CMUSE may be immunological in nature is supported by a favourable response 
to treatment with systemic glucocorticosteroids in numerous CMUSE-affected individuals 
(Kohoutova et alet al., 2010). Intestinal ulceration can also be caused by a number of 
medications, including thiazides and potassium tablets (Campbell and Knapp, 1966). Most 
strikingly however, the numerous small bowel lesions that are observed in these patients 
resemble those associated with the use of non-steroidal anti-inflammatory drugs (NSAIDs), 
an extremely common class of analgesic and anti-inflammatory drugs that includes 
medications such as aspirin and ibuprofen.  
 
5.1.3 Non-steroidal anti-inflammatory drugs (NSAIDs) in bowel inflammation 
NSAID use is extremely well described as a cause of gastro-duodenal (Soll et alet al., 1991, 
Griffin et alet al., 1991) and small intestinal (Higuchi et alet al., 2009, Allison et alet al., 1992) 
ulceration, as well as strictures of the small intestine (so-called ‘diaphragm disease’) that 
result in multiple concentric stenoses of the intestinal lumen (Bjarnason et alet al., 1988, 
Matsuhashi et alet al., 1992, De Petris and Lopez, 2008, Fellows et alet al., 1992), which are 
observed following long-term use of NSAIDs at high doses.  NSAIDs mechanism of action is as 
inhibitors of the cyclooxygenase (COX-1 and -2) enzymes, which function as the rate limiting 
synthases in the production of prostaglandins, prostacyclins and thromboxanes (a sub-group 
of eicosanoids together known as prostanoids). Reduction in the synthesis of prostanoids is 
considered to be primarily responsible for NSAID-induced small bowel disease (Yamada et 
alet al., 1993, Higuchi et alet al., 2009). 
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5.1.4 Prostanoids 
Prostanoids are a group of lipid intercellular mediators derived from fatty acids. They are 
part of a larger grouping known as eicosanoids – all of which are synthesised ultimately from 
the polyunsaturated omega-6 fatty acid arachidonic acid (Vane et alet al., 1998) – within  
which they are defined by the requirement for COX enzymes in their synthesis. An illustration 
of the prostanoid synthesis pathway is shown in figure 5.1, which also shows the structures 
of the common prostanoids prostaglandin E2 (PGE2), D2 (PGD2), and I2 (PGI2, also known as 
prostacyclin), and thromboxane A2 (TxA2). Prostanoids signal through specific G-protein 
coupled receptors; a single receptor each exists for TxA2, PGI2 and PGF2 (a derivative of 
PGD2), whilst two exist for PGD2, and four for PGE2 (Smyth et alet al., 2009).  
As described, prostanoid synthesis is dependent on the actions of COX enzymes, which 
convert arachidonic acid into prostaglandin H2, which can then be converted into the various 
prostanoids through the actions of specific synthase enzymes. Two closely related COX 
enzymes (COX-1 and -2) exist; COX-1 is expressed constitutively in most mammalian cells, 
and is the dominant source of prostanoids involved in normal housekeeping functions, 
including gastrointestinal cytoprotection. Meanwhile COX-2 is inducible by stimuli such as 
pro-inflammatory cytokines and mechanical stress (FitzGerald and Loll, 2001).  
Prostanoids have wide ranging effects on numerous tissues in mammals. For example, 
prostanoid synthesis is significantly increased in inflammation (largely as a result of COX-2 
induction), during which PGE2 and PGI2 promote blood flow to inflamed areas, enhancing 
oedema and leukocyte infiltration (Hata and Breyer, 2004). The same two prostaglandins 
reduce the activation threshold of peripheral nociceptor (pain-sensing) neurons to 
stimulation, potentiating the effects of locally acting autocoids such as bradykinin in 
producing pain (Smyth et alet al., 2009). The importance of prostanoids in pain generation is 
underlined both by the use of COX-1 and -2 inhibitors as analgesics, and by prostaglandin 
receptor-knockout mice, who display increased tolerance to pain (Minami et alet al., 2001). 
Among other tissues, prostanoids also play important roles in the kidney, modulating renal 
blood flow and glomerular filtration (Breyer and Breyer, 2000), and the lungs, where they are 
involved in airway inflammation.  
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Figure 5.1: The eicosanoid synthesis pathway. An illustration of the eicosanoid synthesis pathway 
downstream of cytosolic phospholipase A2-α (cPLA2α). Particular focus is given to those members 
of the prostaglandin family which lie downstream of the cyclooxygenase enzymes COX-1 and 
COX-2, as these are the eicosanoids whose absence is considered the principal cause of NSAID-
induced enteropathy.  
 
5.1.5 Prostanoids in gastrointestinal defence 
The most easily disrupted role of prostanoids in mammals is their function in gastrointestinal 
defence. To protect against the numerous potentially damaging factors present in the 
gastrointestinal environment (such as very strong acid, tissue digesting enzymes and 
microorganisms), a variety of strategies are employed to protect the gastrointestinal mucosa. 
These include a high level of epithelial cell production (as discussed in section 1.1.10), and 
the production of a mucus barrier lining the epithelium, which both physically protects 
epithelial cells, and also traps secreted bicarbonate ions to protect against acid (principally 
important in the stomach, where large amounts of hydrochloric acid are generated) (Laine et 
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alet al., 2008). Gastrointestinal mucus is made up of 95% water, and around 5% mucin 
glycoproteins, which form into large multimeric structures (Laine et alet al., 2008). Mucus 
has different properties in different sections of the GI tract, being more penetrable to 
nutrients in the small intestine, whilst adopting a complex dual-layer structure in the 
stomach and colon to provide better protection against acid and bacteria respectively 
(Ermund et alet al., 2013).  
Continuous generation of prostanoids is of key importance to the maintenance of GI mucosal 
integrity, a fact which has been clear since prostanoid inhibition was identified as the major 
method by which NSAIDs produce GI damage in 1971 (Vane, 1971). PGE2 and PGI2 play 
particularly important roles, stimulating the secretion of mucus (and bicarbonate in the 
stomach), increasing blood flow to the epithelium and accelerating restitution of the 
epithelium in case of damage. In the latter case, PGE2 in particular has been shown to 
stimulate cell proliferation, via transactivation of the EGFR in a process dependent on Src, 
metalloproteases and TGFα (Pai et alet al., 2002), and which therefore can be presumed to 
involve ADAM17. The importance of prostanoids in GI epithelial healing is illustrated by the 
fact that depletion of prostaglandins during the healing of gastric ulcers both reduces the 
rate of healing, and predisposes the future ulcer relapse (Kobayashi and Arakawa, 1995). 
Furthermore, treatment with neutralising antibodies against PGE2 and PGI2 results in the 
formation of gastric and duodenal ulcers in rabbits and dogs (Redfern and Feldman, 1989, 
Redfern et alet al., 1988).  
 
5.1.6 The phospholipase family 
Production of prostanoids is dependent on the activity of the COX enzymes, using free 
arachidonic acid as a substrate. In mammals, the release of arachidonic acid is one of a 
number of processes that come under the control of the phospholipase family, a large group 
of diversely expressed and often structurally unrelated enzymes responsible for the 
hydrolysis of phospholipids. In mammals, the phospholipases are grouped into four broad 
categories, phospholipases A (further subdivided into A1 and A2), C and D, according to the 
type of reaction they catalyse (De Maria et alet al., 2007). All phospholipases hydrolyse 
reactions in the region of the glycerol ‘backbone’ of a phospholipid, but in differing positions 
and with different products. The structure of a typical phospholipid, and the different 
cleavage sites of the phospholipase enzymes, is illustrated in figure 5.2.  
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Figure 5.2: An illustration of the structure of a typical phospholipid (a phosphatidylcholine), 
showing the different positions that are hydrolysed by the four major families of phospholipase 
(PLA1, A2, C and D). Note that the fatty acid chains shown are for representative purposes and 
may not represent a conformation found in nature, and that the choline group can be replaced 
with a number of other groups, such as serine or ethanolamine.  
 
In brief, enzymes of the phospholipase A class are known as deacylating phospholipases, as 
they are responsible for the release of acyl chains associated with phospholipids. PLA1 
phospholipases cleave the sn-1 position of phospholipids, which is enriched in saturated fatty 
acids, to release the fatty acid chain associated to that position (Ghosh et alet al., 2006); 
whilst the PLA2 class cleave at the sn-2 position – enriched for unsaturated fatty acids – to 
release the fatty acid chain found associated there (Leslie, 1997, Ghosh et alet al., 2006). The 
numerous members of the PLC class hydrolyse phospholipids between the glycerol head and 
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phosphate group, and are responsible for the hydrolysis of the inner membrane phospholipid 
phosphatidylinositol-4,5-bisphosphate (PIP2), generating the release of the second 
messengers inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Lyon and Tesmer, 
2013). This is an important cellular signalling process, involved in the regulation of multiple 
physiological processes, including muscle contraction, chemotaxis, cell proliferation and 
survival (Lyon and Tesmer, 2013), making PLCs among the best studied of the 
phospholipases. Meanwhile, the phospholipase D enzymes catalyse hydrolysis of 
phospholipids after the phosphate group, and are classically involved in the hydrolysis of 
phosphatidylcholine, to yield phosphatidic acid and a free choline (Jenkins and Frohman, 
2005).  
Of particular interest are those enzymes belonging to the PLA2 family, as it is to this subgroup 
that the enzyme responsible for intracellular arachidonic acid generation – cytosolic 
phospholipase A2-α – belongs.  There are approximately 20 human genes that encode 
members of the PLA2 family (Six and Dennis, 2000). Ten of these are members of the 
subgroup of secreted PLA2s (sPLA2s), while the remainder are intracellular, belonging to 
either the group VI, calcium-independednt PLA2s (iPLA2s), or the group IV, cytosolic PLA2s 
(cPLA2s) (Ghosh et alet al., 2006). The sPLA2s have diverse functions, including hydrolysis of 
cell surface phospholipids (Bezzine et alet al., 2000), potent anti-microbial activity via the 
degradation of bacterial phospholipids (Koduri et alet al., 2002), and regulation of serum 
lipoproteins (Webb, 2005). The intracellular PLA2s have no structural homology to the sPLA2s 
(Ghosh et alet al., 2006), and play a wide variety of roles within the cell, which depend 
largely on their specificity for particular phospholipids or acyl chains.  
 
5.1.7 Cytosolic Phospholipase A2-α and eicosanoid synthesis 
Cytosolic phospholipase A2-α (cPLA2α) is a very highly conserved member of the PLA2 family: 
human and mouse cPLA2α  homologues share over 95% amino acid identity, and over 80% 
identity is shared between the human enzyme and its homologues in the chicken, zebrafish, 
and Xenopus (Clark et alet al., 1991). cPLA2α is joined in the cytosolic PLA2 family by five 
other members, commonly referred to as cPLA2β, γ, δ, ε, and ζ, which share 30-37% amino 
acid identity with cPLA2α (Ghosh et alet al., 2006). All members of the subgroup contain an 
aspartic acid residue in the active site (Asp549 in cPLA2α) which forms an active dyad with a 
serine residue (Ser228), with the presence of an arginine (Arg200) residue also required for 
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catalytic activity. All but one of the cytosolic PLA2 family contain a C2 domain, a calcium-
binding domain found in many mammalian proteins which promotes interaction with 
phospholipid membranes (Nalefski and Falke, 1996). Calcium binding to specific loops in the 
C2 domain is critical for its penetration into the membrane (Murray and Honig, 2002), 
making the cPLA2 enzymes highly calcium-dependent. Differences in the C2 domains of each 
enzyme are thought to contribute to the specificity of the enzyme, by regulating the 
membrane-binding properties of each, and therefore the types of phospholipid each enzyme 
will interact with. cPLA2α differs from the other members of the cPLA2 family in being almost 
ubiquitously expressed, where most other members of the family, excluding the also widely 
expressed cPLA2β, are limited to specific tissues or disease states. These include cPLA2γ, 
found only in the heart, skeletal muscle and brain; and cPLA2δ, found only in the cervix, 
foetal skin, and psoriatic lesions (Ghosh et alet al., 2006). Crystal structure models of cPLA2α 
are shown in figure 5.3, illustrating the major domains.  
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Figure 5.3: Crystal structure models of cPLA2α. A: A tubular model of cPLA2α, showing secondary 
and tertiary structures of the enzyme, and the two major domains: the C2 domain (pink), and 
catalytic domain (blue). The binding sites of Ca2+ atoms in the C2 domain are shown in yellow. B: 
Space filling model of cPLA2α (from the reverse angle) illustrating the location of the active site 
residues (yellow), which are found at the end of a ‘funnel-shaped’ cavity. The cPLA2α structure 
was retrieved from the NCBI Conserved Domains database (accession number: cd07200) and 
visualised using Cn3D software.  
 
Of the PLA2 enzymes, cPLA2α has attracted most interest due to its ability to selectively 
cleave arachidonic acid – from phospholipids such as phosphatidylcholines, 
phosphatidylethanolamine, and phosphatidylinositides – a function not shared by any other 
member of the cPLA2 family. The specificity of cPLA2α for arachidonic acid is dependent on 
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the architecture of its ‘funnel-shaped’ active site (Dessen et alet al., 1999). The composition 
of the active site cleft of the closely related cPLA2γ differs from that of cPLA2α by only 2 
amino acid residues; however, this is sufficient to render cPLA2γ unable to cleave arachidonic 
acid (Dessen et alet al., 1999). cPLA2α activity, and therefore intracellular arachidonic acid 
production, is tightly regulated by intracellular calcium concentration and phosphorylation of 
the enzyme at two separate sites (Ser505 and Ser727) by mitogen-activated protein (MAP) 
kinases and MNK1-related kinases (Hefner et alet al., 2000, Tian et alet al., 2008). cPLA2α 
activity is also upregulated by numerous stimuli, including TNFα (Lee et alet al., 2013), 
ceramide-1-phosphate (Pettus et alet al., 2004) and binding to PIP2 (Mosior et alet al., 1998).  
As previously described, arachidonic acid serves as the substrate for a broad spectrum of 
enzymes involved in the synthesis of eicosanoids, including COX-1 and -2, lipooxygenases, 
and cytochrome P450 expoxygenase. cPLA2α-mediated arachidonic acid release is thus a rate 
limiting step in eicosanoid production, and  cPLA2α activity therefore plays an important role 
in the wide variety of physiological and pathological processes affected by eicosanoids. An 
illustration of the eicosanoid synthesis pathway dependent on cPLA2α activity is shown in 
figure 5.1. 
Mice deficient in cPLA2α show normal development and life-span, but demonstrate defects 
in reproduction (Bonventre et alet al., 1997), parturition (Uozumi et alet al., 1997), renal 
function (Uozumi and Shimizu, 2002) and the allergic response (Uozumi et alet al., 1997), 
alongside exaggerated heart and striated muscle growth (Haq et alet al., 2003), and the 
presence of numerous ulcerative lesions of the small intestine (Takaku et alet al., 2000). 
These effects can be associated with particular eicosanoid pathways.  For instance, mice 
deficient in COX-2 demonstrate impaired inflammatory responses, impaired resolution of 
inflammation,  impaired renal development, and impaired female reproduction (Yu and Funk, 
2007),(Rouzer and Marnett, 2009). However, these mice also demonstrate a degree of 
resistance to inflammatory diseases; for example, they are highly resistant to experimental 
autoimmune encephalomyelitis, a mouse model of multiple sclerosis (Marusic et alet al., 
2005).  
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5.1.8 The importance of cPLA2α in humans 
Considering its central role in the synthesis of prostanoids and other members of the 
eicosanoid family, it would be expected that any disruption in cPLA2α function would have 
significant effects on health, in particular on the gastrointestinal tract.  
A single case of ileo-jejunal ulceration, accompanied by gastrointestinal blood loss, anaemia, 
and impaired eicosanoid biosynthesis (symptoms of which developed in the 4th decade of 
life), has previously been reported to be associated with compound heterozygous single 
base-pair missense mutations in PLA2G4A. These rare (not previously described) missense 
mutations were expected to alter the conformation of cPLA2α in the individual studied, who 
was found to have reduced (but not absent) cPLA2α protein expression, and reduced 
eicosanoid secretion (TxA2, PGI2 and PGE2 were found at 16, 30 and 43% of normal 
expression levels respectively) (Adler et alet al., 2008).  
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5.2   Results – cytosolic phospholipase A2-α mutation in cryptogenic multifocal 
ulcerative stenosing enteritis 
5.2.1 Case reports 
This report describes a disease present in a pair of siblings (one male, born 1963; and one 
female, born 1966), of Serbian origin. The parents of the affected siblings were not known to 
be consanguineous, though both did hail from the same small, isolated community in Serbia. 
The case reports below are adapted from those written by Dr. Hilary Longhurst (Consultant 
Immunologist, Barts Health NHS Trust, London).  
Both siblings have suffered from severe gastrointestinal (GI) disease from an early age, first 
presenting at age 4 in the male, and age 2 in the female. Both have suffered from repeated 
episodes of severe gastric (stomach) and duodenal ulceration, and multiple instances of 
stenosis (abnormal narrowing of the GI tract resulting from the development of fibrous 
strictures), particularly affecting the duodenum, ileum and pylorus (the most distal part of 
the stomach, immediately preceding the duodenum). The severe ulceration has resulted in 
the formation of perforated ulcers of the stomach and ileum, in the male and female 
respectively. Multiple adhesions of the small intestine (scar tissue forming across the 
intestinal lumen in response to damage; particularly in the male sibling), and volvulus 
(twisting of the intestine) have also been seen, often resulting in bowel obstruction, and 
gangrene in one case. Both siblings have been affected by gastrointestinal fistulae. In most 
cases, this disease has been limited to the upper GI tract, with a normal terminal ileum and 
large intestine having been observed in the male sibling.  
Treatments for this in both patients have included vagotomy (resection of the vagus nerve), 
gastrojejunostomy (the creation of a connection between the stomach and jejunum), and 
pyloroplasy (widening of the pylorus), as well as emergency surgeries to treat perforated 
ulcers (in both individuals) and a gangrenous ileum. Secondary to the severe gastrointestinal 
disease, complications have included dysphagia (difficulty swallowing), oesophagitis, vitamin 
B12 deficiency, and bile duct ulceration and fibrosis. Both individuals have developed severe 
malnutrition and hypoalbuminaemia, requiring total parenteral nutrition.  
As well as gastrointestinal disease, both individuals have been affected by a differing 
spectrum of other disease, including anaemia, renal failure and osteoporosis in both; liver 
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abcesses, type 2 diabetes and peripheral neuropathy in the male; and gall stones, left 
ventricular cardiac hypertrophy, bladder fibrosis, endometrosisendometriosis and infertility 
in the female. Furthermore, the female sibling in particular has suffered from repeated 
infectious disease, with multiple episodes of severe Campylobacter enteritis, Salmonella 
enteriditis and Candida albicans infections, and infectious xanthogranulomatous 
pyelonephritis. Full details of the clinical history of the two sibling can be found in Brooke et 
alet al (Brooke et al., 2014b).  
Based on the clinical history and histology, the siblings are considered to have severe 
cryptogenic multifocal ulcerating stenosing enteritis (CMUSE), accompanied by wide ranging 
complications which may or may not be secondary to the severe gut disease. Symptoms in 
both siblings have progressed despite maximal medical therapy – most recently with high 
dose proton pump inhibitors – including eradication of Helicobacter pylori. Short courses of 
moderate-dose corticosteroids were unhelpful in the male sibling, and have not been 
evaluated in the female. The siblings’ mother, father and brother are healthy and have no 
family history of similar symptoms, with the single exception of a peptic ulcer in the father’s 
middle age, which resolved with a typical clinical course.  
 
5.2.2 SNP homozygosity mapping and exome sequencing 
To attempt to identify a genetic cause for the condition observed in the two siblings, a 
combination of whole genome single nucleotide polymorphism (SNP) array analysis – to 
search for regions of homozygosity shared between the two siblings – and exome sequencing 
was performed.  
Whole-genome SNP array analysis of the two affected siblings was performed by Dr. Franz 
Rüschendorf (Max Delbrück Center for molecular medicine, Berlin, Germany), to identify 
shared regions of homozygosity. Linkage analysis was performed using two different marker 
sets, containing 64,983 and 2.44 million SNPs across the entire genome, based on a 
hypothetical pedigree which assumed a degree of consanguinity between the parents of the 
affected siblings (a 2nd degree cousin marriage), allele frequencies from a European 
population, and a model of disease assuming recessive inheritance and complete 
penetrance. Using this pedigree, the maximum LOD score possible was around 2.38. This 
linkage analysis revealed two long stretches of the genome with the maximal LOD score of 
2.38, on chromosomes 1 and 10. On chromosome 1, the stretch was 9.5Mb in length, and 
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was bordered by the markers rs6425457 and rs4607826, whilst the stretch on chromosome 
10 was 5.42 Mb long, between rs11201179 and rs12265445 (figure 5.4). These two stretches 
were considered to be identical by descent in the two affected individuals.  
In tandem, whole exome sequencing was performed on the affected female. 
Insertion/deletion variation analysis of this exome sequencing data was performed by Dr. 
Vincent Plagnol (University College London, London) and revealed the presence of a 
homozygous 4 base-pair deletion (g.155574_77delGTAA) in the PLA2G4A gene, located in the 
splice donor site directly following exon 17 (the penultimate exon) of the gene. PLA2G4A 
(Accession Number: NG_012203.1) maps within the common region of homozygosity found 
on chromosome 1, at 1q25. 
 
Figure 5.4: Homozygosity mapping revealed the presence of two regions of the genome (on 
chromosomes 1 and 10) with the maximum possible LOD score of 2.383, which were shared by 
the affected individuals identically by descent. These same two regions were identified by 
homozygosity mapping as being homozygous between the two affected individuals. SNP array 
analysis was performed by Dr. Franz Rüschendorf (Max-Delbrück Center for molecular medicine, 
Berlin, Germany).  
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5.2.3 Confirmation of mutations in PLA2G4A 
To confirm the presence of the g.155574_77delGTAA mutation in both affected siblings, and 
its segregation with disease, PCR and Sanger sequencing was performed, using primers 
designed to amplify the mutated region of PLA2G4A (primer sequences are shown in 
appendix 1). Sequencing was performed on the DNA of the two affected individuals, their 
mother, father and brother (all of whom are unaffected by the disease), and an unrelated, 
otherwise normal control. 
Sequencing confirmed the homozygous presence of the four base-pair deletion in both of the 
affected individuals, with the mother, father and brother of the siblings all found to be 
heterozygous carriers of the mutation (figure 5.5), which was absent in an unrelated control. 
This deletion has never been described before, and is not present in either the dbSNP or 
1000 Genomes databases of genetic variation. Although one individual has been identified 
who carries two compound heterozygous mutations in PLA2G4A which result in disease 
(Adler et alet al., 2008), this represents the first identification of a deletion mutation being 
associated with disease in PLA2G4A, and only the second identification of any disease-
associated mutation in that gene.  
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Figure 5.5: Confirmation of PLA2G4A mutations segregating with disease in the affected family. 
A: Sanger sequence traces of the g.155574_77delGTAA mutation site in the affected individuals, 
their immediate family members, and an unrelated control. B: A family pedigree based on the 
presence of the g.155574_77delGTAA mutation illustrates that this mutation segregates with 
disease in this family (white: unaffected individuals; grey: affected individuals) 
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5.2.4 Characterisation of PLA2G4A mutations 
To predict the consequences of the g.155574_77delGTAA mutation in humans, bioinformatic 
analysis was performed. The mutation is located in the splice donor site that directly follows 
exon 17 (the penultimate exon) of PLA2G4A, the gene encoding cPLA2α, and is predicted to 
result in the loss of the affected splice donor site, and introduce a frameshift predicted to 
encode 10 amino acids before a premature stop codon (p.V707fsX10). This would result in 
the loss of 43 codons from the C-terminus of cPLA2α mRNA, and the loss of 24 amino acids 
(residues 707-732) from the mature cPLA2α protein product (figure 5.6, A). The deleted area 
makes up part of the large region known as the cPLA2α catalytic domain, though it does not 
lie directly adjacent to any of the active site residues, or the ‘funnel-shaped’ cavity which 
defines the substrate selectivity of the enzyme. The loss of the deleted region would 
however be expected to affect the shape of the enzyme. Furthermore, the deleted region is 
highly conserved between species (figure 5.6, B).  In addition to this, the deleted region 
contains a key regulatory site (serine-727) at which phosphorylation is required for cPLA2α 
activity (Tian et alet al., 2008). Taken together, this analysis suggests that this region would 
be expected to play an important role in the correct functioning of the enzyme, and its 
deletion would negatively impact enzymatic activity.  
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Figure 5.6: Analysis of the consequences of cPLA2α mutation. A: Space-filling model of cPLA2α, 
with the C2 domain in pink, and catalytic domain in blue. The yellow highlighted region 
represents the region deleted as a result of the g.155574_77delGTAA mutation. Note that some 
deleted residues are inside the protein structure and thus are not visible. The cPLA2α structure 
was retrieved from the NCBI Conserved Domains database (accession number: cd07200) and 
visualised using Cn3D software. B: Conservation of amino acids residues in part of the cPLA2α 
catalytic domain across species. The region predicted to be deleted is highlighted in red. The 
lower yellow graph illustrates the degree of conservation of each residue, a full-height yellow bar 
indicating complete conservation between species. 
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5.2.5 Expression of cPLA2α in affected individuals and controls 
To examine how the detected g.155574_77delGTAA mutation affected the expression of 
cPLA2α, immunohistochemical staining of paraffin-embedded small intestine sections was 
performed, using an antibody against cPLA2α which targets the protein at a site around 
serine-505 (i.e. in a location upstream the region predicted to be deleted, and distant from it 
in the tertiary structure of the enzyme). This staining revealed the presence of high levels of 
cPLA2α staining in the intestinal epithelium of an unrelated control individual, particularly 
along the apical membrane of enterocytes. However, no cPLA2α expression could be 
detected in the small intestine of the affected female or male, with the pattern of staining 
indistinguishable from the background autofluorescence observed when staining the tissue 
in the absence of an anti-cPLA2α primary antibody (figure 5.7, A).  
Next, expression of cPLA2α was examined by western blotting, in protein lysates derived 
from the peripheral blood mononuclear cells (PBMCs) of the two affected individuals, and 
their unaffected father (a heterozygous carrier of the g.155574_77delGTAA mutation). This 
revealed a complete absence of cPLA2α protein in both affected individuals, whilst the father 
displayed robust expression (figure 5.7, B).  
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Figure 5.7: cPLA2α expression. A: Immunofluorescence of cPLA2α in paraffin-embedded small 
intestinal sections from an unrelated control and the affected individuals. B: Western blotting of 
cPLA2α in the PBMCs of both affected individuals and their unaffected father.  
 
5.2.6 Thromboxane A2 as a measure of cPLA2α function 
Thromboxane A2 (TxA2) is an eicosanoid produced primarily in platelets, which is synthesised 
from arachidonic acid by the sequential actions of COX-1 or -2 and thromboxane-A synthase 
1 (as shown in figure 5.3). As such, its synthesis is dependent on the actions of cPLA2α. TxA2 
generated by platelets acts in an autocrine manner on the TxA2 receptor (TP) (Smyth et alet 
al., 2009), a G-protein coupled receptor expressed on platelets, as well as a variety of other 
cell types, such as macrophages, vascular endothelial cells and smooth muscle cells (Nisar et 
alet al., 2014). Activated platelets secrete TxA2, which in turn activates other platelets via 
binding to the TP, which when activated predominantly couples to the G-proteins Gq and 
G12/13. Respectively, these G-proteins facilitate platelet aggregation (via protein kinase C-
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dependent pathways), and platelet shape changes (via Rho/Rho kinase-dependent 
signalling). TxA2 is therefore a potent stimulant of platelet aggregation. Aggregation of 
platelets can be induced in plasma in vitro by the addition of stimuli such as collagen and 
adrenaline. Collagen is a strong stimulant of platelet activation in vivo, typically in cases 
where vascular damage exposes collagen in the sub-vasculature to platelets, inducing 
platelet activation mediated (particularly at lower collagen concentrations) through the 
production of TxA2 (Roberts et alet al., 2004). This makes measuring the aggregation of 
platelets in the plasma a good measure of TxA2 production, and therefore of cPLA2α function.  
A second advantage to this method is that inhibition of TxA2 production can be artificially 
induced in serum via the use of NSAIDs, in particular aspirin. As with all NSAIDs, aspirin 
inhibits COX activity; however, aspirin is unique in that it covalently acetylates serine 
residues in the COX enzymes (ser-529 in COX-1, ser-516 in COX-2) to inhibit enzyme activity 
irreversibly (Smyth et alet al., 2009). Irreversible COX inhibition, combined with platelets’ 
limited capacity for de novo protein synthesis, means that aspirin inhibits TxA2 production in 
a sustained manner. This sustained COX inhibition – and therefore inhibition of platelet 
aggregation – contributes to aspirin’s cardioprotective activity. The addition of aspirin to 
plasma can therefore act as a control, to study how platelets incapable of TxA2 production 
would be expected to act in response to aggregating stimuli.  
 
5.2.7.  Platelet aggregation and thromboxane A2 production in affected individuals and 
controls 
Platelet aggregation was measured in the plasma of the two affected individuals and 
unrelated controls by light transmission aggregometry, a method by which the amount of 
light passing through a sample of platelet-rich plasma over time gives an indication of the 
degree of platelet aggregation in response to a given stimulus. These experiments were 
performed in collaboration with the laboratory of Prof. Tim Warner (William Harvey 
Research Institute, Barts and The London School of Medicine and Dentistry, London). 
Examples of light transmission over a time course are shown in figure 5.8, in which platelet 
aggregation in response to collagen in the plasma of a healthy volunteer is represented by a 
large fall in light transmission. However, the response in the plasma of the affected male is 
significantly abrogated, and follows almost exactly the pattern of a healthy volunteer treated 
with 30µM aspirin (figure 5.8, A). Note that, in addition to its function as a stimulant of TxA2 
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production, collagen acts as a direct physical substrate for platelet aggregation (platelets can 
directly adhere to it, independent of the influence of TxA2 [(Roberts et alet al., 2004, Morton 
et alet al., 1989)]) meaning that some degree of platelet aggregation would be expected 
when stimulating with collagen, even in cells completely incapable of producing TxA2.  
Next, the effect of arachidonic acid on platelet aggregation was examined. In this case, the 
addition of 1mM arachidonic acid potently induced the aggregation of platelets in both 
healthy controls and the affected male, whilst no aggregation was observed in healthy 
controls treated with aspirin (figure 5.8, B). This result is consistent with a fully functional 
TxA2 synthesis pathway being present downstream of arachidonic acid in the affected male’s 
platelets, suggesting that a lack of arachidonic acid production is the limiting factor in the 
reduced aggregation observed. Conversely, aspirin inhibits the COX enzymes that are 
immediately downstream of arachidonic acid in the TxA2 synthesis pathway (see figure 5.3), 
meaning that arachidonic acid supplementation would not be expected to increase TxA2 
production (and therefore aggregation) in plasma treated with aspirin. Note that collagen 
was not used as an aggregation stimulant in this case, so no degree of platelet aggregation 
dependent on platelets adhering directly to collagen would be expected.  
 
 
Figure 5.8: Light transmission aggregometry of platelet-rich plasma A: Platelet aggregation 
measured by light transmission through platelet-rich plasma against time. Light transmission 
changes in response to 1µg collagen are shown in a healthy volunteer, a healthy volunteer 
treated with 30µM aspirin, and the affected male. B: Platelet aggregation in response to 1mM 
arachidonic acid in the same individuals. Experiments were performed in collaboration with the 
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group of Prof. Tim Warner (William Harvey Research Institute, Barts and The London School of 
Medicine & Dentistry, London).  
 
In addition to measuring aggregation in platelet-rich plasma, secretion of TxA2 was also 
measured indirectly, by measurement of levels of its stable and inactive hydration 
metabolite thromboxane B2 (TxB2; to which TxA2 is converted with a half-life of 
approximately 30 seconds ([Hamberg et alet al., 1975)]). As shown in figure 5.9, stimulation 
with increasing concentrations of collagen resulted in increasing levels of TxB2 production in 
healthy control platelets, whilst TxB2 could not be detected in the plasma of either the 
affected female or male. The addition of 1mM arachidonic acid led to greatly increased TxB2 
production in the healthy controls, whilst high levels were also produced by the platelets of 
both affected individuals (higher than many healthy controls). As with the light transmission 
aggregometry results, this suggests that the thromboxane synthesis pathway remains intact 
and functional in the affected individuals, with TxA2 production abolished as a result of a lack 
of arachidonic acid.  
 
 
Figure 5.9: TxB2 levels in platelet-rich plasma of healthy controls (n=4) and the two affected 
individuals, measured by ELISA, in response to stimulation with increasing levels of collagen and 
1mM arachidonic acid. Nd = not detected. Experiments were performed in collaboration with the 
group of Prof. Tim Warner (William Harvey Research Institute, Barts and The London School of 
Medicine & Dentistry, London). 
 
Platelet aggregation was next measured using a standardised optical multichannel 
absorbance-based method (‘Optimul’), in which platelet-rich plasma was added to 96-well 
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microplates containing lyophilised agonists, following which absorbance was read at 595nm 
to measure aggregation. Once more, aggregation was measured in healthy controls (n=4) 
with and without aspirin treatment, and both affected individuals. As shown in figure 5.10, 
platelet aggregation in the two affected individuals’ plasma was markedly reduced in 
response to stimulation by both collagen (3µg/ml) and adrenaline (10µM); with levels of 
aggregation again comparable to that seen in healthy individuals treated with aspirin, 
compared to healthy controls. Once more, treatment with 1mM arachidonic acid restored 
levels of platelet aggregation in both affected individuals to levels comparable to those seen 
in healthy volunteers, whilst aggregation in healthy volunteers treated with aspirin remained 
very low.  
The addition of a synthetic analogue of TxA2 (U46619, at 40 µM) resulted in comparable 
levels of platelet aggregation in all four groups, illustrating that no dysfunction exists in 
either the thromboxane receptor (TP), or its downstream, G-protein-dependent signalling 
pathway. Finally, stimulation with ristocetin – an antibiotic compound that stimulates the 
agglutination (as opposed to aggregation) of platelets in a manner dependent on adhesion 
between the platelet glycoprotein (GP)Ib/IX complex and the blood glycoprotein Von 
Willebrand Factor (Coller, 1978, Takata et alet al., 2012), and which is thus thromboxane-
independent – also produced agglutination which was very similar between healthy 
volunteers with or without aspirin and the two affected individuals. 
 
 
Figure 5.10: Platelet aggregation in healthy volunteers with and without aspirin treatment (both 
n=4), and the two affected individuals, measured by standardised optical multichannel 
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(‘Optimul’) platelet aggregometry. Aggregation was measured as absorbance at 595nm, and is 
displayed as absorbance relative to that seen in healthy controls with no aspirin treatment, as a 
percentage. Experiments were performed in collaboration with the group of Prof. Tim Warner 
(William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, 
London). 
 
 
These results were consistent with the hypothesis that cPLA2α activity is absent or 
significantly reduced in the affected individuals, and that defects in platelet aggregation 
result from a lack of arachidonic acid production owing to this abrogated activity.  
 
5.2.8. Genetic investigations in other individuals with CMUSE-like disease 
Subsequent to the association of the disease described above in the two siblings of Serbian 
origin, genetic investigations have taken place in two other candidate families (one from 
Bosnia-Herzegovina, the other from Turkey), whose gastrointestinal symptoms appeared 
similar to those described previously.  
To investigate these cases, PCR primers were designed to separately amplify each of the 18 
exons of PLA2G4A, all of which were then sequenced in the individuals suspected to harbour 
the disease, and the mother and father of both. Primer sequences are shown in appendix 
one. This strategy allowed for the successful sequencing of every exon, and the splice sites 
immediately preceding and following each, in each individual tested. No novel or potentially 
disease-causing mutations were observed in the PLA2G4A genes of any of these individuals, 
making it unlikely that the conditions they suffer from share the same aetiology as the one 
described above.  
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5.3 DiscussionSummary of chapter 
These data describe a pair of siblings with a catastrophic 40 year clinical history of intestinal 
and extra-intestinal disease. A combination of genome SNP homozygosity mapping and 
whole exome sequencing revealed the siblings to be homozygous for a 4 base pair deletion in 
the PLA2G4A gene, which encodes the enzyme cytosolic Phospholipase A2-α (Phospholipase 
A2 Group IV-A, cPLA2α) (Adler et alet al., 2008), which is predicted to entirely eliminate 
enzymatic activity.  No expression of cPLA2α could be observed in the affected individuals’ 
small intestine or PBMCs. Functional studies revealed absent production of the eicosanoid 
thromboxane A2, and severely impaired platelet aggregation in response to collagen, which 
was restored by the addition of exogenous arachidonic acid - cPLA2α’s enzymatic product.  
As such, it would be expected that these two affected individuals would have a global defect 
in the production of arachidonic acid, and therefore of eicosanoid synthesis. It is 
straightforward to hypothesise how a complete lack of prostanoid production that would 
follow from ablated cPLA2α activity would be expected to cause gastrointestinal disease, as 
this would be expected to be analogous to NSAID mediated enteropathy. The 
pathophysiology of this enteropathy and of many of the extra-intestinal conditions observed 
can reasonably be expected to be a consequence of a lack of cPLA2α function, and will be 
discussed in more detail in chapter 6.  
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6. Discussion 
 
6.1. An ADAM17 loss-of-function syndrome 
The third chapter of this thesis describes investigations into a neonatal-onset inflammatory 
skin and bowel disease, which was associated to a homozygous deletion mutation in 
ADAM17. This deletion was associated with severely reduced or absent ADAM17 protein 
expression and activity, and would therefore be expected to result in the abolition of the 
shedding of its many substrates in vivo.  
The clearest manifestations of ADAM17 loss-of-function mutations in the two affected 
individuals described in chapter 3 are inflammatory disease of the skin and bowel, 
accompanied by clear abnormalities in the nails, hair and heart. Considering the wide variety 
of ADAM17 substrates that can be assumed to be affected by loss-of-function mutations in 
ADAM17, a number of pathophysiological processes could plausibly lead to the different 
aspects of the phenotype that was observed. One of the most notable aspects of the disease 
described here is its relative lack of severity compared with an equivalent Adam17-knockout 
mouse model. Mice lacking ADAM17 expression die perinatally, with a phenotype involving 
severe developmental defects that can be shown to result from the absence of signalling by 
one or more of the five EGFR ligands that ADAM17 sheds (TGFα, amphiregulin, HB-EGF, 
betacellulin and epiregulin). Phenotypes of these mice are described in detail in section 
1.1.15. Notably, the syndromes observed in these mice included severe defects in epithelial 
development (including that of the skin) that resembled TGFα-knockout mice (Peschon et 
alet al., 1998), lungs, and heart (resembling amphiregulin ([Luetteke et alet al., 1999)] and 
HB-EGF ([Jackson et alet al., 2003, Shi et alet al., 2003)] null mice respectively). Knockouts of 
the mouse Eger Egfr produce an even more severe phenotype, with severely impaired skin 
development and differentiation (Miettinen et alet al., 1995), as well as heavily defective 
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development of numerous other tissues. Interestingly however, when a novel gene-targeting 
strategy was used to generate a mouse model expressing severely reduced (but not absent) 
levels of Adam17 (hypomorphic Adam17 mice), skin development was observed to be 
relatively normal, but an obvious skin inflammatory phenotype was observed (Chalaris et alet 
al., 2010), among other defects.  
In attempting to better understand pathophysiology of the skin disease observed in the 
ADAM17 mutation-affected individuals, keratinocyte-restricted Adam17 knockout 
(Adam17ΔKC) mice have provided interesting insights into a potential disease mechanism. 
These Adam17ΔKC mice display relatively normal skin architecture, but suffer from a 
pronounced chronic inflammatory dermatitis, a phenotype which superficially resembles the 
inflammatory skin phenotype seen in the ADAM17 mutation-affected individuals described 
here (Franzke et alet al., 2012). This dermatitis is accompanied by an epidermal barrier 
defect, shown to result from significantly reduced transglutaminase 1 (TGM1) activity in the 
upper layers of the epidermis, accompanied by a reduction in the expression of TGM1 mRNA. 
This reduction in TGM1 activity was itself a result of reduced EGFR signalling activity due to 
absent (ADAM17 substrate) EGFR ligand shedding, closely resembles the phenotype seen in 
keratinocyte-restricted Egfr knockout mice, and could be rescued by the application of 
topical TGFα (Franzke et alet al., 2012). Mirroring this mouse phenotype, the affected 
individual described in chapter 3 was found to have substantially reduced TGM1 expression 
in the granular layer of his skin, and virtually undetectable in situin situ TGM1 activity. In 
addition, the skin of the ADAM17 mutation-affected individual displayed a notable 
infiltration of T lymphocytes (of both CD4+ and CD8+ lineages) (Blaydon et alet al., 2011a), 
which was also seen in Adam17ΔKC mice. Given that shedding of ADAM17 substrates from the 
keratinocytes of the affected individual was shown to be virtually absent, it can be 
hypothesised that a lack of EGFR ligand shedding, and a downregulation of TGM1 expression 
and activity that results from it, may therefore make a substantial contribution to the 
inflammatory skin phenotype seen in the affected individuals, and as such that this 
phenotype is analogous to that seen in Adam17ΔKC mice. Furthermore, the fact that topical 
treatment with recombinant TGFα was sufficient to rescue the inflammatory dermatitis 
phenotype observed in Adam17ΔKC mice offers the intriguing suggestion that a treatment for 
the inflammatory skin disease observed in this individual may already exist, in the form of 
topical EGFR ligand supplementation.  
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As well as offering a plausible mechanism for the inflammatory skin disease observed, it is 
also interesting to note that, in common with the affected humans described here, the 
development and differentiation of Adam17ΔKC mouse skin appears otherwise normal. This 
may serve to illustrate the differing requirements for EGFR signalling in development, 
compared to the requirement for it in normal epidermal homeostasis. In each of the affected 
male individual described here, Adam17ΔKC mice, hypomorphic Adam17 mice, and mice with 
a spontaneous Adam17 mutation (waved with open eyelids mice (Hassemer et alet al., 
2010)([Hassemer et alet al., 2010)]), skin development and differentiation appears to 
proceed normally, whilst EGFR activity in each of these models was insufficient to maintain 
epidermal homeostasis, in terms of TGM1 activity and epidermal barrier maintenance.  
Related to the skin phenotype seen in these individuals was a clear abnormality in the hair: 
the eyebrows, eyelashes and scalp hair being found to be wiry, disorganised and easily 
broken, with hair follicles appearing severely weathered and abnormal under microscopic 
examination. These features bear a similarity to those seen in mice with knockouts of the 
tgfa (TGFα) gene, whose hair is disorganised (follicles are unaligned, and point in random 
directions), kinked and curly, giving an overall ‘wavy’ appearance. Interestingly, this hair 
phenotype is present in mice with a knockout of tgfa (Luetteke et alet al., 1993), with 
spontaneous null mutations in tgfa (the waved-1 mouse ([Mann et alet al., 1993)]), and in a 
mouse that is spontaneously hypomorphic for Adam17 (the waved with open eyelids mouse 
([Hassemer et alet al., 2010)]). A deficiency of TGFα signalling would in this case therefore 
appear to be the most logical explanation for the hair phenotype seen. 
Recently, the first example of an inherited human disease associated with loss-of-function 
missense mutations in the EGFR gene has been identified, which was characterised by 
inflammatory skin disease that resembled that seen in patients treated with EGFR-inhibiting 
drugs, as well as bowel and lung inflammation (Campbell et alet al., 2014). The skin and 
bowel disease observed in the single individual affected by this condition bore a resemblance 
to that seen in the ADAM17-null individual described in this thesis, lending credence to the 
suggestion that reduction in EGFR ligand shedding, and therefore of EGFR signalling, may be 
a highly important pathological process in the disease resulting from ADAM17 mutations. In 
contrast to ADAM17-null individuals, the child affected by EGFR mutation died at around 2.5 
years old (Campbell et alet al., 2014). This lethality may reflect the fact that EGFR loss-of-
function mutations would result in a reduction in signalling mediated by the binding of all 
EGFR ligands, whilst ADAM17 loss-of-function mutations would adversely affect signalling 
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mediated only by ADAM17-specific substrates (TGFα, HB-EGF, amphiregulin, epigen and 
epiregulin), whilst EGF and betacellulin signalling would be unaffected, as these are shed 
under the control of ADAM10.  
As well as inflammatory disease, the skin and nails of the individuals affected by ADAM17 
mutations were also noticeably susceptible to infection, by organisms such as Staphylococcus 
aureus, Psuedomonas and Candida species. The defective epidermal barrier function that 
would be expected to result from the reduced expression and activity of TGM1 in the upper 
epidermal layers, can plausibly be expected to result in reduced resistance to bacterial 
infection in the epidermis, which may contribute to the increased infection susceptibility. 
Further, an inability to shed TNFα, a cytokine with numerous important roles in the innate 
inflammatory response, would also be expected to result in reduced resistance to bacterial 
infection. This latter point is clearly illustrated by the example of iRhom2 knockout mice, 
whose macrophages cannot produce mature ADAM17, and thus cannot shed TNFα. Although 
viable, these mice fail to adequately control the replication of inoculated bacteria (Listeria 
monocytogenes), and as such succumb to infection as a direct consequence of impaired TNFα 
shedding (McIlwain et alet al., 2012).  
In addition to its functions in the maintenance of an effective skin (and gut, to be discussed 
below) barrier, the functions of ADAM17 at the level of individual cells may also be important 
in the response to infection. Work by Dr. Charlotte Simpson (Blizard Institute, London) has 
shown that knockdown of ADAM17 in keratinocytes results in increased susceptibility to 
infection by S. aureus bacteria, which are able to both adhere to and invade keratinocytes at 
a higher rate in the absence of ADAM17. Conversely, keratinocytes derived from TOC 
patients (which appear to have upregulated ADAM17 activity) demonstrate significantly 
increased resistance to bacterial invasion and adherence, which can be abolished by 
knockdown of ADAM17 in the same way as normal control keratinocytes (Brooke et alet al., 
2014a). 
In a fashion similar to the skin disease observed, complete abrogation of ADAM17 could 
plausibly be expected to result in an inflammatory gut disease through a number of different 
pathophysiological processes. Signalling through the EGFR is important in the development 
of the intestinal epithelium, with efgr null mice found to have fewer, shorter intestinal villi 
and reduced epithelial proliferation, though all of the four intestinal epithelial cell types do 
develop (Miettinen et alet al., 1995). The intestines of egfr null mice are fragile and strongly 
susceptible to damage, with numerous intestinal haemorrhages and disintegration of the villi 
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visible a few days after birth. As well as in development, EGFR signalling is required in the 
response to damage to the intestinal epithelium (McElroy et alet al., 2012, Dvorak et alet al., 
2002), suggesting that abrogated EGFR ligand shedding in ADAM17 null individuals would be 
expected to adversely affect both the development of, and the response to injury in, the 
intestinal epithelium. 
This is borne out by the severe gut sensitivity seen in mice expressing severely reduced levels 
of ADAM17 (hypomorphic for Adam17). In contrast to Egfr egfr knockout mice, the 
gastrointestinal tract in these mice appears superficially normal. They were however strongly 
susceptible to inflammatory colitis following challenge with dextran sulphate, with this 
sensitivity found to result from defective regeneration of intestinal epithelium due to an 
inability to shed EGFR ligands (Chalaris et alet al., 2010). High levels of EGFR ligands, in 
particular TGFα, were generated in the enterocytes of these mice following challenge, but 
remained at the plasma membrane due to the inability to effectively shed them, whilst 
treatment with soluble TGFα was sufficient to restore normal intestinal epithelial function. It 
is however worth noting that the gut inflammation observed in hypomorphic Adam17 mice 
was observed only after challenge with dextran sulphate (Chalaris et alet al., 2010), whereas 
diarrhoea was seen in affected humans within hours of birth, without any obvious challenge 
to the gut epithelium. Therefore, whilst the gut disease observed in hypomorphic Adam17 
mice may offer a good model of the intestinal inflammation seen in the ADAM17 null 
individual, further investigation is required to understand the precise pathology of this 
condition.  
Interestingly, much of the stimulus for regeneration after damage to the intestinal 
epithelium is mediated through the signalling actions of prostaglandins, particularly 
prostaglandin E2 (PGE2). PGE2 stimulates intestinal epithelial cell proliferation via 
transactivation of the EGFR (as described in section 1.2.6), a process which is dependent on 
the cleavage of TGFα, and therefore on the activity of ADAM17 (Pai et alet al., 2002). This 
therefore offers the intriguing possibility that the otherwise entirely unrelated gut diseases 
that are described in the individual in chapter 3 (affected by loss-of-function mutation in 
ADAM17) and the two individuals described in chapter 5 (affected by loss-of-function 
mutations in PLA2G4A, and who therefore cannot synthesise prostaglandins) may share 
some degree of common pathophysiology, in that proliferation of the intestinal epithelium 
cannot be stimulated by the actions of PGE2 in either disease, which would be assumed to 
result in defective regeneration of the gut epithelium and breakdown of the intestinal 
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barrier. It is also worth noting that the intestinal epithelium also expresses a 
transglutaminase enzyme, TGM2, which is notable for the fact that it is the main target for 
autoantibodies in the autoimmune inflammatory bowel condition coeliac disease (Dieterich 
et alet al., 1997). EGFR signalling has been shown to upregulate TGM2 activity in some cell 
types (Li et alet al., 2010, Li et alet al., 2011b), meaning that reduced EGFR signalling in the 
intestinal epithelium may also plausibly lead to barrier defects, in a fashion analogous to 
depleted TGM1 activity in the skin.  
Another important aspect of the disease observed in the ADAM17 null individuals is a 
notable heart phenotype. In the male individual, this consists of moderate left ventricular 
dilatation and borderline-dysfunctional systolic function (an ejection fraction of 55%, where 
45% is regarded as dysfunctional). The female sibling died suddenly at 12 years of age from 
fulminant myocarditis associated with Parvovirus B19 infection (Blaydon et alet al., 2011a). 
Given the lack of material available from the female child, it is impossible to investigate 
whether or not her heart displayed any abnormality prior to this infectious disease; however, 
the presence of heart dysfunction in these individuals is particularly interesting in the light of 
the phenotype of Adam17 knockout mice, who die perinatally as a result of severe heart 
abnormalities (Peschon et alet al., 1998). Intriguingly, mice hypomorphic for ADAM17 are 
also affected by an obvious heart dysfunction, which primarily takes the form of massive left 
ventricular hyperplasia (i.e. affecting the same part of the heart as in the human affected 
individual). Despite this, these mice remain viable. Whilst the wide variety of potential 
ADAM17 substrates makes it difficult to pinpoint precisely whether or not a shedding defect 
may underlie this observed cardiomyopathy, a number of potential mechanisms could 
plausibly underlie the development of cardiac disease in these individuals.  
The first of these is that the cardiomyopathy represents a developmental defect in the heart, 
analogous to the lethal failure of proper heart development in knockout mice. In these mice, 
the cardiac developmental defect closely resembles that seen in mice which cannot express 
the growth factor HB-EGF, which is required in heart development for the proper 
development and morphogenesis of the ventricles and the semilunar and atrioventricular 
valves (Iwamoto et alet al., 2003, Jackson et alet al., 2003), with mice lacking HB-EGF 
developing grossly enlarged and dilated ventricular chambers and cardiac valves, resulting in 
severe heart failure (Iwamoto et alet al., 2003). Similarly, mice that express an un-sheddable 
mutant form of HB-EGF develop severe heart defects analogous to those seen in HB-EGF-null 
mice, rather than the milder cardiomyopathy seen in mice expressing severely reduced 
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Adam17 (Yamazaki et alet al., 2003); this illustrates that a degree of active HB-EGF shedding 
is required for proper heart development. Therefore, it is interesting to note that a degree of 
functional redundancy has been shown between ADAM17 and the related sheddase 
ADAM19, in which ADAM19 can contribute to HB-EGF shedding in the heart in the absence 
of functional ADAM17 (Horiuchi et alet al., 2005). Although it was not directly studied, there 
is no reason to expect that ADAM19 levels would be different in the individuals described 
here compared to normal controls, suggesting that the relatively minor heart defects 
(compared to knockout mice) observed in the affected male may reflect only a partial 
abrogation of HB-EGF signalling in heart development. 
The second possibility chiefly concerns ADAM17’s substrate Desmoglein 2 (DSG2), a cadherin 
component of desmosomes, intercellular junction complexes which serve to robustly link 
adjacent cells (Brooke et alet al., 2012). ADAM17’s functions in the regulation of DSG2 are 
described in detail in section 1.2.9-10. Desmosomes are especially important in maintaining 
the integrity of tissues subject to high levels of mechanical stress, such as the skin, the 
bladder and the heart. The various desmosomal cadherins (desmogleins and desmocollins) 
are expressed in tissue- and differentiation-dependent patterns across numerous tissues; 
with DSG2 the primary cadherin present in the myocardium. The importance of DSG2 in the 
heart is illustrated by the association of mutations in DSG2 with arrhythmogenic right 
ventricular cardiomyopathy (ARVC) (Simpson et alet al., 2009), an inherited disorder causing 
cardiac arrhythmias and sudden cardiac death, (which can be associated with mutations in a 
variety of desmosomal components ([Brooke et alet al., 2012)]). Keratinocytes derived from 
the affected male were shown to have dysregulation in the processing of DSG2, and to 
accumulate DSG2 at their plasma membrane, suggesting that DSG2 dynamics were abnormal 
in this individual. However, the contribution of ADAM17-dependent DSG2 turnover to 
normal desmosomal homeostasis in the heart has not been extensively studied, and it is 
notable that the phenotype observed in the affected male does not exactly phenocopy ARVC 
(left- rather than right-ventricular dilatation, for example). Despite this, a cause of this heart 
disease dependent on desmosomal dynamics cannot be ruled out and bears further 
investigation. 
Thirdly, it remains possible that the infectious myocarditis observed in the affected female 
did not reflect a developmental or structural abnormality, but rather reflected an 
impairment in immune function resulting from ADAM17 loss-of-function. Notably, this is 
supported by evidence from TNFα-knockout mice, in which TNFα was shown to play a key 
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protective role in acute viral myocarditis (Wada et alet al., 2001), the very condition from 
which the affected female died. This hypothesis would not however explain the moderate 
cardiac defect observed in the affected male, making it most likely that some combination of 
the factors described here contribute to the cardiac disease seen.  
As previously described, Adam17 null mice die perinatally, and suffer from severe 
developmental defects which appear to be related to a lack of shedding of various EGFR 
ligands, and are analogous to complete knockouts of one or more EGFR ligands. However, in 
contrast to complete mouse knockouts of EGFR ligands, and despite the inflammatory 
disease and moderate hyperplasia, the overall structure of the skin in the human ADAM17 
loss-of-function individuals is relatively normal (though their hair did show obvious 
abnormality).  
Although loss-of-function mutations in ADAM17 would be expected to result in substantially 
reduced ADAM17-dependent EGFR ligand shedding in humans, the situation in these 
affected individuals cannot be considered to be analogous to a complete knockout of any of 
the EGFR ligands, or of the EGFR itself, for two reasons. Firstly, although these ligands cannot 
be  shed, interaction between cell surface-bound EGFR ligands and the EGFR on neighbouring 
cells (juxtacrine signalling) can be used to activate EGFR signalling; such as in signalling by 
membrane-bound TGFα through the EGFR in bone marrow stroma (Anklesaria et alet al., 
1990). Secondly, a degree of functional redundancy appears to exist in humans in the 
shedding of EGFR ligands by ADAMs. For example, in addition to ADAM17, HB-EGF can also 
be shed by ADAMs 9 (Izumi et alet al., 1998), 12 (Asakura et alet al., 2002), 15 (Hart et alet 
al., 2005) and 19 (with evidence having demonstrated a degree of mutual compensatory 
activity between ADAMs 17 and 19 in terms of HB-EGF secretion in heart development 
([Horiuchi et alet al., 2005)]), amphiregulin by ADAM15 (Schafer et alet al., 2004) and 
neuregulin by ADAM19 (Yokozeki et alet al., 2007). Whilst ADAM17 may act as the primary 
sheddase for these ligands under normal circumstances, shedding by these other ADAMs in 
the absence of ADAM17 may be sufficient for normal development in humans. This is in 
addition to the fact that two members of the EGFR ligand family (EGF and epigen) are shed 
by ADAM10,ADAM10; meaning that a degree of EGFR signalling would be expected to be 
activated even if no ADAM17 ligands could be shed at all. As such, although EGFR signalling 
can be expected to be reduced in the absence of ADAM17-mediated ligand shedding, it does 
not appear that this reduction in shedding is sufficient – in the context of normal skin 
 191 
 
development and differentiation – to produce the severe phenotypes associated with a 
complete lack of one or more EGFR ligands, or of the EGFR itself. 
The differences seen between Adam17-null mice and a human ADAM17-null individual could 
therefore plausibly be explained in a number of ways. The first of these is that some degree 
of residual ADAM17 activity can be found in the cells of the affected individuals. In support of 
this, it is notable that a small amount of TNFα could be shed by the PBMCs of the affected 
male, rather than none at all. Furthermore, the phenotype seen in the affected humans most 
closely resembles that seen in hypomorphic Adam17 mice, in that both have fully developed 
but inflammatory skin, significant intestinal inflammation, hair abnormalities, and left 
ventricular hyperplasia, without the lethal developmental defects that result from complete 
ablation of ADAM17. Second, the differences between human and mouse models of 
ADAM17 loss-of-function may plausibly represent subtle but significant differences in ADAM 
and EGFR ligand physiology between humans and mice. A less severe human disease may 
therefore reflect more effective compensation for ADAM17 loss by other ADAMs, which may 
or may not include other ADAMs having a broader spectrum of substrates in humans. 
Similarly, the various members of the EGFR ligand family may have slightly different roles in 
development and homeostasis in humans, such as the ability for EGF or epigen signalling to 
compensate for the loss of shedding of ADAM17 substrates, for example.   
These results illustrate the existence of a novel inherited genetic disease associated with 
ADAM17 mutations. In recent years, ADAM17 has emerged as an attractive pharmacological 
target for the potential treatment of inflammatory diseases, in particular those driven by 
TNFα (Saftig and Reiss, 2011, Arribas and Esselens, 2009). However, the dramatically 
deleterious phenotype seen in Adam17 null mice dampened enthusiasm for this therapeutic 
approach. The results seen in the individuals affected by ADAM17 loss-of-function mutations 
however illustrate that loss of ADAM17 activity is not incompatible with human survival, and 
therefore suggest that pharmacological treatment of this pathway should be considered 
plausible in humans.  
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6.2. Tylosis with oesophageal cancer, and the iRHOM2-ADAM17 axis 
The fourth chapter of this thesis described investigations into the pathophysiology of tylosis 
with oesophageal cancer (TOC), a dominantly inherited disease characterised by 
palmoplantar keratoderma, oral and oesophageal leukoplakia, and a striking susceptibility to 
oesophageal squamous cell carcinoma. TOC was associated in three large family groups 
(from the UK, USA and Finland) to dominantly inherited, notably clustered mutations in the 
gene RHBDF2 (Blaydon et alet al., 2012), the gene encoding iRHOM2; an association which 
was subsequently confirmed by analysis of another TOC-affected family in Finland (Saarinen 
et alet al., 2012). The linkage of iRHOM2 mutations to TOC represents the first and only 
linkage of inherited oesophageal cancer susceptibility to any gene. 
Subsequent to the association of RHBDF2 mutations to TOC, the role of iRHOM2 in regulating 
the maturation and activity of ADAM17 was revealed. In chapter 4, studies on immortalised 
keratinocytes, skin sections and PBMCs derived from TOC sufferers showed that TOC-
associated iRHOM2 mutations result in an increase in the processing of ADAM17, increased 
localisation of mature ADAM17 to its major site of activity (the plasma membrane), and 
increased constitutive and stimulated shedding of ADAM17 substrates (and other pro-
inflammatory cytokines), notably including the EGFR ligands amphiregulin, TGFα and HB-EGF. 
These changes were accompanied by the presence of desmosomes lacking electron dense 
midlines (in an immature, calcium dependent state), increased desmosome processing and 
increased epidermal transglutaminase 1 activity. TOC keratinocytes displayed a marked 
increase in their migration compared to controls, which was independent of exogenous EGFR 
ligand supplementation. This increase on migration was found to be associated with factors 
released by TOC keratinocytes (which could increase the migration of control keratinocytes), 
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and could be blocked via the inhibition of ADAM17-dependent EGFR ligand shedding by the 
small molecule ADAM17 inhibitor GW280264X.  
The finding that TOC-associated iRHOM2 mutations are associated with an increased rate of 
ADAM17 maturation implies that these mutations can be classified as gain-of-function in 
nature, and result in increased processing and activity of ADAM17. This hypothesis is 
supported by a number of factors. Firstly, gain-of-function mutations are consistent with the 
dominant pattern of inheritance observed for TOC, in that only one copy of the mutated 
gene would be required to increase iRHOM2’s function in ADAM17 maturation beyond the 
background level provided by wild-type iRHOM2. Secondly, the iRHOM2 mutations 
associated with TOC display a remarkable degree of clustering, with all three mutations 
described (in four entirely unrelated families) resulting in amino acid substitutions within the 
space of only four residues (see figure 4.2), strongly implying that these mutations affect a 
particular function in which the mutated motif is intimately involved. Importantly, these 
three TOC-associated iRHOM2 mutations are found within a long N-terminal loop domain 
that is unique to the two iRHOM proteins, and is very highly conserved between species and 
across large evolutionary distances (the mutated residues in iRHOM2 are conserved 
identically in humans, finches, toads and pufferfish, for example), implying that its function is 
subject to strong selection pressure. The fact that this domain is found only in the two 
iRHOM proteins in also revealing, as iRHOM1 has also been shown to share the ability of 
iRHOM2 to support ADAM17 maturation, with a large degree of functional redundancy 
having been observed between the two iRHOMs in tissues where they are co-expressed 
(Christova et alet al., 2013). The residues affected by TOC-associated mutations are 
expressed identically in iRHOM1. In fact, this N-terminal domain has been shown to be 
absolutely required for iRHOM2 to function correctly in regulating ADAM17 maturation: 
shedding of ADAM17 substrates in iRhom2-null mouse embryonic fibroblasts can be rescued 
by the addition of wild-type mouse iRHOM2, but not by a mutant iRHOM2 lacking the N-
terminal domain where TOC-associated mutations are found (Maretzky et alet al., 2013). 
Therefore, since the TOC-associated mutations affect extremely highly conserved residues in 
a domain that is absolutely required for ADAM17 maturation, and that is found only in those 
proteins capable of supporting ADAM17 maturation, it is reasonable to hypothesise that 
these mutations would influence the process of ADAM17 maturation. Furthermore, siRNA 
knockdown of iRHOM2 specifically abolished the increased level of mature ADAM17 in TOC 
keratinocytes, illustrating that – although both iRHOMs are expressed in skin, and both can 
 194 
 
effectively support the maturation of ADAM17 – the increased level of mature ADAM17 
observed is iRHOM2-dependent.  
As well as providing evidence that ADAM17 maturation in keratinocytes is strongly 
influenced by iRHOM2, siRNA knockdown experiments also suggested that reciprocal 
regulation of iRHOM2 by ADAM17 may exist. Knocking down expression of ADAM17 by 
siRNA led to noticeable downregulation of iRHOM2 expression, in TOC keratinocytes as well 
as controls. Although not expected, this corresponded with the observation of reduced 
iRHOM2 staining in the epidermis of the ADAM17-null individual described in chapter 3, and 
suggests that expression of iRHOM2 may depend on the activity of ADAM17 in some form.  
 
The upregulation of mature ADAM17, and its increased localisation to the plasma 
membrane, was accompanied by increased constitutive and stimulated shedding of many 
ADAM17 substrates. As well as upregulation of stimulated TNFα shedding from both 
keratinocytes and PBMCs, there was a highly significant increase in shedding of the EGFR 
ligands dependent on ADAM17 for release.  
In culture, keratinocytes express high levels of amphiregulin,amphiregulin and much lower 
levels of TGFα and HB-EGF (Pastore et alet al., 2008). It was therefore especially interesting 
to note that shedding of all three of these growth factors was upregulated in TOC 
keratinocytes, even in unstimulated conditions. Amphiregulin – the growth factor known to 
provide by far the strongest degree of autocrine stimulation of keratinocyte growth 
(Piepkorn et alet al., 1994) - was shed at a particularly high level. It was noticeable that, 
although the level of mRNA expression of TGFα and HB-EGF was comparable to that of 
amphiregulin, the levels of these two proteins in the medium were much lower than 
amphiregulin. This may however represent the differing importance of EGFR ligands in 
transactivation of the EGFR by triple membrane pass signalling. As described in section 1.2.6, 
the ligand involved in EGFR transactivation is commonly HB-EGF (Prenzel et alet al., 1999), 
whilst a role for TGFα in EGFR transactivation has been described in some tissues (such as the 
intestine ([Pai et alet al., 2002)]). Conversely, a role for amphiregulin is not well described in 
EGFR transactivation. The relatively increased level of amphiregulin in the medium of TOC 
cells may therefore be representative of this growth factor being freely shed into 
keratinocytes’ surroundings, whilst shed HB-EGF and TGFα is bound by the EGFR in an 
autocrine fashion shortly after release, during EGFR transactivation.  
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Upregulation of EGFR ligands in vivo is characteristic of numerous benign and malignant 
hyperproliferative conditions of the skin. For example, hyperproliferative psoriatic lesions 
overexpress TGFα (Elder et alet al., 1989), HB-EGF (Zheng et alet al., 2003) and amphiregulin 
(Piepkorn, 1996) as well as the EGFR (Nanney et alet al., 1986). Amphiregulin is also known 
to be strongly upregulated in actinic keratoses, verrucas and squamous cell carcinomas 
(Piepkorn, 1996). Meanwhile, transgenic overexpression of TGFα in murine epidermis leads 
to cutaneous hyperplasia and hyperkeratosis, accompanied by the spontaneous formation of 
squamous papillomas at sites of wounding (Dominey et alet al., 1993). EGFR ligand signalling 
also underlies the hyperproliferative effects of retinoids (a class of chemical compounds 
related to vitamin A) on keratinocytes, with retinoid-induced hyperplasia mediated by the 
marked induction of HB-EGF and amphiregulin shedding (Rittie et alet al., 2006, Stoll and 
Elder, 1998). The highly significant increases in shedding of these factors by keratinocytes 
from TOC affected areas could therefore plausibly be expected to play a role in the epidermal 
hyperproliferation that characterises TOC, and may offer a rationale for the development of 
the palmoplantar keratoderma seen.  
As well as the direct detection of increased EGFR ligand shedding, and the finding of 
increased EGFR phosphorylation in three-dimensional culture models of TOC keratinocytes, 
evidence of upregulated EGFR signalling in TOC epidermis can also be inferred from the 
activity of transglutaminase 1 (TGM1) in TOC skin. As described previously for an ADAM17-
null individual (and Adam17ΔKC mice), TGM1 activity is regulated by EGFR signalling, and is 
dependent on shedding of ADAM17-substrate EGFR ligands (Franzke et alet al., 2012). Both 
TOC epidermis and three-dimensional culture models of TOC keratinocytes display increased 
TGM1 activity in their upper layers. As well as offering a stark contrast to ADAM17-null skin 
(where TGM1 activity is undetectable), this increased TGM1 activity implies antecedent 
upregulation of EGFR activity, and suggests that individuals affected by TOC may display 
increased epidermal barrier function.  
As well as functioning to increase epidermal barrier function, upregulation of ADAM17 
activity may also have a direct effect on cells’ susceptibility to infection. As described 
previously, work by Dr. Charlotte Simpson has shown a direct role for ADAM17 in regulating 
individual keratinocytes’ susceptibility to attachment and invasion by Staphylococcus aureus 
bacteria. TOC keratinocytes have displayed a natural resistance to S. aureus attachment and 
invasion, which was found to be dependent on the activity of ADAM17 (Brooke et alet al., 
2014a). Combined with the finding of increased epidermal barrier function, this raises the 
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intriguing possibility that the skin of TOC-affected individuals may display a naturally 
heightened resistance to infection. Rates of infection in TOC patients have never been 
examined in detail, though it would undoubtedly be interesting to investigate this aspect of 
the phenotype resulting from TOC-associated iRHOM2 mutations.  
Signalling through the EGFR is also known to play an important role in cutaneous wound 
healing – particularly in the early phase response to wounding – by increasing keratinocyte 
proliferation and migration (Barrientos et alet al., 2008). The importance of this response is 
illustrated in mice with egfr-null epidermis, whose skin lesions heal at a slower rate 
compared to controls (Repertinger et alet al., 2004). ADAM-mediated shedding of EGFR 
ligands is required for keratinocyte migration during wound healing and is immediately 
induced upon wounding (Tokumaru et alet al., 2000), with factors upregulated in wounded 
skin including amphiregulin, TGFα and HB-EGF (but not EGF or betacellulin) (Barrientos et 
alet al., 2008). In particular, TGFα is responsible for approximately 80% of keratinocyte 
migration activity during wound healing (Li et alet al., 2006) and also promotes proliferation 
(Cha et alet al., 1996); whilst HB-EGF promotes re-epithelialisation (Hashimoto et alet al., 
1994) and accelerates cutaneous wound healing when applied topically (Tolino et alet al., 
2011, Shirakata et alet al., 2005).  
As such, it may be plausible to consider that the significant, constitutive upregulation of EGFR 
ligand shedding by TOC keratinocytes can be thought of as representing a constitutive 
‘wound healing-like’ state in the epidermis and keratinocytes of TOC sufferers. This 
hypothesis is supported by other lines of evidence, such as the presence in TOC skin of 
desmosomes lacking the electron-dense midline that characterises mature, ‘hyperadhesive’, 
calcium-independent desmosomes. This immature desmosomal state is associated with 
keratinocyte motility (Brooke et alet al., 2012), and is especially prominent in skin 
undergoing wound healing (Garrod et alet al., 2005). Secondly, in addition to high levels of 
EGFR ligands, TOC keratinocytes also secrete particularly high levels of IL-6 and IL-8, both of 
which are correlated with, and important for, wound healing processes (Werner and Grose, 
2003). For example, IL-6 is strongly upregulated at sites of wounding (Grellner et alet al., 
2000), persists in chronic wounds (Barrientos et alet al., 2008, Finnerty et alet al., 2006), and 
is strongly reduced in glucocorticoid treated mice, which display significant impairment in 
wound healing (Grose et alet al., 2002). IL-6-knockout mice heal wounds significantly more 
slowly than controls, a phenotype which can be rescued by topical IL-6 application (Gallucci 
et alet al., 2004, McFarland-Mancini et alet al., 2010). Meanwhile, IL-8 is also upregulated in 
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wounded tissue (Werner and Grose, 2003) and may enhance keratinocyte proliferation and 
wound healing (Rennekampff et alet al., 2000, Jiang et alet al., 2012), though high IL-8 levels 
have conversely been associated to impaired wound healing (Iocono et alet al., 2000).   
As with rates of infection in TOC patients, wound healing in TOC patients has also never been 
directly studied. No mouse model of TOC-associated iRHOM2 mutation is available at the 
time of writing, but any differences in wound healing in the epidermis that arise as a 
consequence of these mutations would be an extremely interesting aspect of the TOC 
phenotype that would benefit from closer examination.  
As well as the skin phenotype, by far the most prominent aspect of TOC – and the primary 
cause of mortality amongst TOC-affected individuals – is the striking susceptibility to 
oesophageal squamous cell carcinoma (OSCC) that has been described. Oesophageal cancer 
(of which OSCC is the predominant type) is the eighth most common cancer worldwide and 
the sixth leading cause of cancer related mortality, with overall 5-year survival rates ranging 
from 15 to 25% (Pennathur et alet al., 2013). Environmental risk factors for OSCC 
prominently include tobacco smoking, alcohol and caustic injury, whilst TOC is the only 
known syndrome of highly penetrant inherited OSCC susceptibility (Blaydon et alet al., 2012, 
Enzinger and Mayer, 2003). An affected individual belonging to a large, TOC-affected family 
in the UK has been calculated as having a 92% probability of dying from oesophageal cancer 
by the age of 70 (Ellis et alet al., 1994).   
The observed excessive secretion of EGFR ligands may offer clues to this OSCC susceptibility 
observed in TOC patients. In sporadic OSSCOSCC, EGFR overexpression has been observed in 
45.6-72.1% of primary tumours (Gibault et alet al., 2005, Abedi-Ardekani et alet al., 2012), 
88% of OSCC lymph node metastases, and 90% of oesophageal squamous dysplasias (Itakura 
et alet al., 1994) – suggesting that signalling through the EGFR may make a substantial 
contribution to tumour initiation. Direct EGFR gene amplification is seen in 12-28% of OSCC 
(Kitagawa et alet al., 1996, Itakura et alet al., 1994, Hanawa et alet al., 2006) and is 
associated with significantly reduced cumulative survival (Kitagawa et alet al., 1996), whilst 
EGFR overexpression has been shown to correlate with poor prognosis (Okines et alet al., 
2011). Increased levels of EGFR ligand secretion have been associated with the development 
and progression of squamous cell carcinomas in the oesophagus, where upregulation of 
TGFα is associated with poor OSCC prognosis (Yamabuki et alet al., 2006), and numerous 
other tissues, including the epidermis (Rittie et alet al., 2007, Cataisson et alet al., 2012), lung 
(Fujimoto et alet al., 2005), mouth (Tsai et alet al., 2006), and head and neck tissues (Rubin 
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Grandis et alet al., 1998). Independently of the EGFR, expression of ADAM17 itself has also 
been recently shown to correlate with progression of OSCC (Liu et alet al., 2013). 
Upregulation of ADAM17 activity in TOC, and the increased EGFR ligand shedding that 
accompanies it, may therefore plausibly play a role in the initiation of OSCC in TOC patients.  
Together, the data presented here illustrate that TOC-associated iRHOM2 mutations affect 
the process of iRHOM2-regulated ADAM17 maturation, leading to upregulation of ADAM17 
activity. The consequences of this demonstrate that the iRHOM2-ADAM17 axis plays a key 
role in epidermal proliferation, skin barrier maintenance, inflammation and migration, and 
represents a novel oncogenic pathway in the oesophagus. This pathway may therefore have 
important roles in normal epidermal homeostasis, the response to injury in the skin, and 
oesophageal oncogenesis, and represents an attractive target for further research.  
 
6.3. PLA2G4A mutations in cryptogenic multifocal ulcerative stenosing enteritis 
In the fifth chapter of this thesis, genetic mutations underlying an inherited syndrome of 
severe intestinal disease, whose symptoms corresponded to cryptogenic multifocal 
ulcerative stenosing enteritis (CMUSE) accompanied by multiple extra-intestinal 
complications, were investigated. This condition was associated, in two affected siblings from 
a consanguineous family, with homozygous deletion mutations (g.155574_77delGTAA) in 
PLA2G4A, the gene encoding cytosolic phospholipase A2-α (cPLA2α), an enzyme responsible 
for the production of arachidonic acid from membrane phospholipids, and which therefore 
catalyses a rate-limiting reaction in the production of eicosanoids. No expression of cPLA2α 
could be observed in the affected individuals’ small intestine or PBMCs. Functional studies of 
platelet aggregation demonstrated that both individuals were unable to synthesise the 
eicosanoid thromboxane A2, a situation which could be rescued by the addition of exogenous 
arachidonic acid.  
The intestinal disease observed in the two affected individuals bore a striking resemblance to 
the enteropathy that results from long-term use of high dose non-steroidal anti-
inflammatory drugs (NSAIDs), which function to block synthesis of prostaglandins (a class of 
eicosanoid) by their actions as cyclooxygenase (COX) inhibitors (see section 5.1.3). In 
particular, gastro-duodenal and small intestinal ulceration and concentric strictures of the 
small bowel are known consequences of high-dose, long-term NSAID use (Bjarnason et alet 
al., 1988, Matsuhashi et alet al., 1992, De Petris and Lopez, 2008, Fellows et alet al., 1992), 
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and (but for the greater severity of the disease) closely resemble the phenotype of the 
affected individuals described here. As such, it seems likely that the enteropathy affecting 
these two siblings is a direct consequence of their inability to produce prostaglandins and 
other eicosanoids.  
As described in section 5.1.5, prostaglandins, particularly PGE2 and PGI2, play especially 
important roles in gastrointestinal defence, by stimulating the secretion of mucus (and 
bicarbonate in the stomach), increasing blood flow to the intestinal epithelium and 
accelerating cellular proliferation in the intestinal epithelium following damage, via EGFR 
transactivation. As mentioned previously, cell proliferation stimulated by prostaglandins 
(especially PGE2) requires transactivation of the EGFR, in a process dependent on ADAM17 
shedding of TGFα (Pai et alet al., 2002), meaning that the intestinal disease described in the 
two cPLA2α-deficient individuals can be expected to share, in part, a common 
pathophysiology with that seen in the ADAM17-deficient individual described in chapter 3. In 
addition to the roles of PGE2 and PGI2, other prostaglandins have been shown to have 
important gastro-protective effects, including PGD2, and its derivative 15-deoxy-Δ12,14-PGJ2, 
which has a potent anti-inflammatory role that results from its ability to specifically inhibit 
the NF-κB signalling pathway (a key activator of inflammatory response genes) (Straus et alet 
al., 2000). PGD2 has meanwhile been shown to be specifically upregulated in the long-term 
remission of ulcerative colitis (Vong et alet al., 2010), illustrating a gastro-protective effect 
which would presumably also be lacking in cPLA2α-deficiency. As well as the absence of these 
prostaglandins, the increased severity of the enteropathy seen in the two individuals 
described here (relative to that seen in NSAID-associated enteropathy) may reflect the wider 
spectrum of eicosanoids that cannot be produced by the cPLA2α-deficient individuals. For 
example, lipoxins are a class of eicosanoid produced by the sequential actions of two or more 
lipoxygenase enzymes from arachidonic acid; lipoxins can therefore be produced in NSAID-
treated individuals, whilst the cPLA2α-deficient individuals described here will be unable to 
synthesise them. Lipoxins A4 and B4 have potent anti-inflammatory and pro-resolution 
functions, and have been shown to have gastro-protective actions (Serhan, 2005, Pajdo et 
alet al., 2011), as well as anti-inflammatory roles in other tissues.  
A single case of ileo-jejunal ulceration, accompanied by gastrointestinal blood loss, anaemia, 
and impaired eicosanoid biosynthesis, has previously been reported to be associated with 
compound heterozygous single base-pair mutations in PLA2G4A.  Interestingly, this patient 
only developed disease requiring surgery in the 4th decade of life, although milder symptoms 
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of gastrointestinal ulceration were described as having been lifelong. In addition, unlike the 
cPLA2α-deficient siblings described here, who have severe duodenal, gastric and oesophageal 
disease, this compound heterozygous individual had a normal upper bowel.  Although the 
mutations observed in the compound heterozygote were expected to affect the 
conformation of cPLA2α, a reasonable (though reduced) degree of protein expression could 
be observed in this individual. Furthermore, although also significantly reduced, expression 
of multiple eicosanoids was observed in the compound heterozygote (TxA2, PGI2 and PGE2 
were found at 16, 30 and 43% of normal expression levels respectively, for example) (Adler 
et alet al., 2008). This is in contrast to the pair of individuals carrying the 
g.155574_77delGTAA mutation, who demonstrated no cPLA2α expression in the small 
intestine or PBMCs, and no detectable production of TxA2 in the absence of arachidonic acid, 
although metabolites of other eicosanoids were not examined. Moreover, aggregation of 
platelets in the plasma of the two affected individuals was identical to that of healthy 
volunteers treated with aspirin, a drug which irreversibly blocks TxA2 production. It is 
therefore reasonable to assume that cPLA2α activity is completely absent in these two 
individuals (carrying the g.155574_77delGTAA mutation), in contrast to the previously 
described compound heterozygote, whose cPLA2α deficiency is clearly less marked, and 
whose associated disease is consequently of a much less severe nature.  
As well as the pronounced and severe enteropathy, both cPLA2α-deficient individuals were 
affected by multiple extra-intestinal complications. Considering the lifelong nature of their 
disease, it is in some cases difficult to determine whether these systemic complications were 
secondary to their severe enteropathy, or represent separate phenomena.  Both siblings 
have shown clear pathologies of the biliary tree, such as fibrosis and ulceration of the 
common bile duct, accompanied variously by liver abscesses, evidence of fibrosis in the liver 
and gall stones. Due to the intimate connection between the GI tract and biliary tree, these 
pathologies may most likely represent mechanical damage, arising from the increased 
susceptibility of the bile duct and related tissues to stress and injury in the absence of 
eicosanoid-mediated protection.  However, cPLA2α also plays an important role in the direct 
protection of hepatocytes from Fas-induced apoptosis (mediated through upregulation of 
EGFR activity), illustrating another potential mechanism of liver injury in the absence of 
cPLA2α (Li et alet al., 2011a). The female sibling has meanwhile developed pernicious 
anaemia, which could be hypothesised to result from a deficiency of vitamin B12 absorption 
as a consequence of the extensive gastrointestinal damage. This possibility is supported by 
the fact that vitamin B12 deficiency has also been previously noted in the male sibling. 
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However, the pathogenesis of other extra-intestinal disease developed by the siblings, 
including bladder fibrosis, endometrosis, infertility and cardiac ventricular hypertrophy in the 
female, and diabetes in the male, cannot be obviously be explained as secondary 
complications of severe enteropathy. Many of the symptoms seen in the cPLA2α-deficient 
individuals do however bear similarities to those seen in Pla2g4a-null mice, which do 
demonstrate defects in reproduction (Bonventre et alet al., 1997) and parturition (Uozumi et 
alet al., 1997) and exaggerated cardiac muscle growth (Haq et alet al., 2003), as well as 
ulcerative small intestinal lesions (Takaku et alet al., 2000). In addition, a naturally occurring 
genotypic variant of PLA2G4A has been strongly associated with the development of type-2 
diabetes in the Pima Native American population, a population with an extremely high 
prevalence of that disease (Wolford et alet al., 2003).  
The female sibling in particular has also suffered repeatedly from infectious diseases, 
including infections by Candida albicans, Campylobacter and Salmonella species, as well as 
repeated, severe Staphylococcus infections. This susceptibility to infection may be related to 
the role cPLA2α is known to play in innate immunity. For example, cPLA2α has been shown to 
be required for the efficient killing of bacteria by neutrophils (Rubin et alet al., 2005), which 
some reports have suggested may be related to a requirement for cPLA2α in the activation of 
NADPH oxidase, an enzyme necessary for the generation of reactive oxygen species, in a 
process known as respiratory burst (Shmelzer et alet al., 2003, Murakami et alet al., 2011). 
Abscesses of the skin and other tissues are frequently seen in diseases such as chronic 
granulomatous disease, which are related to an inability to generate such reactive oxygen 
species in immune cells, frequently as a result of mutations in the NADPH oxidase-2 gene 
CYBB (Holland, 2010). The presence of multiple abscesses in the cPLA2α-deficient individuals 
described here could thus plausibly be related to deficiencies in this pathway. Furthermore, 
immunity to intracellular pathogens such as Chlamydia trachomatis requires cPLA2α, since in 
its absence production of type I interferon is deficient (Vignola et alet al., 2010); whilst 
Candida albicans has been shown to rapidly upregulate cPLA2α in macrophages, suggesting 
that its absence may compromise innate immunity to that yeast (Parti et alet al., 2010). 
Lastly, cPLA2α is involved in the induction, by pro-inflammatory cytokines, of expression of 
the intercellular adhesion molecule ICAM-1 on the surface of endothelial cells, suggesting 
that cPLA2α-deficient individuals may be affected by impaired mobilisation and 
transmigration of leukocytes from the bloodstream into tissues to deal with infectious agents 
(Hadad et alet al., 2011). 
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In conclusion, mutations in PLA2G4A were found to segregate with the severe CMUSE-like 
syndrome observed in two affected individuals over a 40-year period. CMUSE remains a very 
rarely diagnosed condition, despite its severe consequences, and has until now never been 
associated with any inherited mutations. As such, investigations of PLA2G4A offer a novel 
diagnostic strategy in cases of otherwise unexplained gastrointestinal ulceration and 
stricturing.  
 
 
 
 
 
 
6.4. Future work 
The findings presented in this thesis offer specific insights into the pathophysiology of the 
inherited diseases studied, but also into the wider biology of the particular proteins affected 
by mutations in each instance. As such, these findings could be used as the basis for further 
investigations in numerous fields.  
In the first instance, the most immediate potential impact of understanding these genetic 
disorders is in informing the treatment of patients affected by them. To at least some extent, 
the inflammatory skin phenotype described in chapter 3 could plausibly result from 
downregulation of transglutaminase 1 (TGM1) activity in the upper epidermal layers of the 
affected individual studied. As described in section 6.1, the TGM1-dependent inflammatory 
skin phenotype seen in mice with a keratinocyte restricted Adam17 knockout could be 
reversed by the application of topical TGFα; this suggests that EGFR ligand supplementation, 
for example by topical creams, may offer a route to treatment of this skin condition. 
However, the epidermis of this individual is already notably hyperproliferative, meaning that 
further growth factor supplementation would have to be carefully monitored, to avoid 
exacerbating this phenotype.  
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Next, the finding that the pathology of tylosis with oesophageal cancer (TOC) is associated 
with upregulation of ADAM17 activity suggests that direct pharmacological targeting of this 
pathway may prove useful in the treatment of at least the skin manifestations of this 
condition. Targeting of ADAM17 has in the past been considered as a potential strategy in 
treatment of inflammatory diseases driven by TNFα (Saftig and Reiss, 2011, Arribas and 
Esselens, 2009), until the severe phenotype of Adam17 knockout mice dampened 
enthusiasm for this approach. However, the relatively (in comparison to mouse models) 
minor phenotype seen in the individuals affected by ADAM17 loss-of-function mutations (as 
described in chapter 3) illustrates ADAM17 inhibition would not necessarily result in the 
same severe disease in adult humans, and suggesting that pharmacological treatment of this 
pathway should be considered plausible in future. Furthermore, the majority of the most 
serious defects observed in Adam17 null mice result from impaired shedding of EGFR ligands 
(and therefore of reduced EGFR signalling). It is therefore pertinent to note that therapeutic 
targeting of the EGFR is a widely used and proven strategy in cancer treatment; and although 
inflammatory skin disease is a consequence of this approach, the effects seen are by no 
means as severe as those in egfr-null mice, suggesting that ADAM17 inhibition need not be 
expected to result in the same effects.   
Treatment of the two individuals affected by CMUSE, as a result of PLA2G4A mutations, 
could also plausibly follow from the identification of cPLA2α mutations as the cause of their 
inherited disease. In this case, replacement of prostaglandins, the inability to synthesise 
which may contribute significantly to the disease observed, would appear to be the most 
obvious treatment strategy. Indeed, subsequent to the findings of PLA2G4A mutations as the 
causative factor in this disease, both affected individuals began to be treated with the 
synthetic PGE2 analogue misoprostol. Neither individual initially tolerated the treatment very 
well, complaining of gastrointestinal upset and an unusual ‘fuzzy’ feeling, which may reflect 
the fact that they were unaccustomed to having any circulating prostaglandins at all. 
However, in the female sibling at least, renal function has stabilised, the need for 
oesophageal dilatation has reduced, and there have been no severe, acute episodes of 
gastrointestinal disease since treatment began (Dr. Hilary Longhurst, personal 
communication). Notably, the previously described American individual with compound 
heterozygous PLA2G4A mutations improved only slightly when treated with misoprostol, but 
improved significantly when the nitric oxide donor sildenafil was added, suggesting a 
potential treatment strategy in future.  
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Other patient-focussed investigations could include the genetic screening of other individuals 
who have displayed symptoms similar to those seen in the three diseases described here. In 
the case of the diseases associated to ADAM17 and PLA2G4A mutations, investigation of 
other potentially-disease-affected individuals and families can and has been performed by 
direct sanger sequencing of those genes, as previously described. A number of potentially 
affected individuals have already been screened by this method, without the finding of any 
potentially disease-causing mutations in these genes, with the possible exception of a 
dutchDutch individual described in section 3.3. In these cases, further investigations into a 
genetic cause for these diseases could involve more general next generation sequencing 
techniques, such as whole exome sequencing.  
Beyond patient focussed investigations, the findings of TOC-associated iRHOM2 mutations 
having a significant effect on ADAM17 maturation can also form the basis of further 
experiments. The particular localisation of iRHOM2 mutations associated with TOC within the 
protein structure suggests that ADAM17 maturation is heavily influenced by interactions 
involving the iRHOM2 N-terminal domain generally, and the highly-conserved motif affected 
by TOC-associated mutations in particular. This association could be further investigated by 
the knock-in of these mutations into animal models. No mouse model of TOC yet exists, but 
the effects of TOC-associated iRHOM2 mutations on epidermal and oesophageal 
homeostasis in this system would be very interesting, and could also be used to shed light on 
the cancer susceptibility that is a key feature of TOC. Conversely, the finding that these three 
very specific residues are intimately involved in ADAM17 maturation would make studies 
into the particular iRHOM2 residues necessary for ADAM17-iRHOM2 of particular interest. 
For example, targeted knock out of, or the introduction of deleterious mutations to, the 
specific residues involved could be used to establish which particular features of the iRHOM2 
N-terminal domain are necessary for ADAM17 maturation. Similarly, the introduction of TOC-
associated mutations into iRHOM1 (which shares the function of iRHOM2 in ADAM17 
maturation, and in which the TOC-associated residues are identical) in cell or animal models 
could be used to further investigate the iRHOM-ADAM17 interaction, and its importance in 
cellular signalling.  
Similarly, the finding in TOC epidermis of many features associated to epidermal wound 
healing make the function of iRHOM2 in skin regeneration an aspect of TOC that bears 
further scrutiny. As well as wound healing studies in any potential TOC mouse model, 
zebrafish have in recent years emerged as valuable models of cutaneous wound healing 
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(Richardson et alet al., 2013), and could be used to investigate wound healing in TOC. 
Zebrafish do express a single iRHOM protein, meaning that a model of TOC wound healing 
could be generated either by mutation of the zebrafish iRHOM, or by engineering zebrafish 
to express human TOC-associated-mutant iRHOM2.  
Further investigations of iRHOM biology could focus on their roles beyond the regulation of 
ADAM17 maturation. It is interesting to note that a mouse double knockout of both iRHOMs 
results in a phenotype that does not exactly phenocopy that seen in Adam17-null mice. This 
double iRHOM knockout phenotype is both more severe than Adam17 knockout, in that it 
leads to lethality at a much earlier stage, but also results in effects that are not obviously 
related to ADAM17 dysfunction, such as brain haemorrhages and dysfunctions in multiple 
organs (Christova et alet al., 2013). This therefore implies that iRHOMs regulate processes 
other than ADAM17 maturation, and that investigation of other iRHOM functions would 
provide fruitful insights into the development and homeostasis of numerous tissues.  
Returning to the particular disease phenotype of TOC, the particular effects of TOC-
associated iRHOM2 mutations in oesophageal carcinogenesis would be of particular interest. 
In particular, considering the specific upregulation of EGFR ligand shedding in TOC, 
investigating the ADAM17-EGFR axis in oesophageal squamous cell carcinoma (OSCC) 
further, by histological, genetic and functional analyses of TOC-associated OSCC cells and 
tissue samples, as well as samples of the oesophageal precursor lesions that develop in TOC 
patients, would be a priority in further research. This would provide meaningful insights into 
the biology of both TOC-associated and sporadic oesophageal tumours, a cancer type which 
remains severely under-researched, despite its high incidence and rate of mortality.  
At a wider level, investigations into TOC highlight the potential utility of the skin in 
investigating syndromic disease. In a similar fashion to TOC, and as described in section 1.3.2, 
numerous inherited syndromes exist that feature skin disease as only one of a number of 
pathologies, accompanied by other conditions such as the oesophageal cancer susceptibility 
in TOC. Because of the high visibility and accessibility of the skin, investigations of skin cells 
affected by a disease can provide useful insights into the pathophysiology of conditions 
affecting otherwise inaccessible tissues. For example, examination of the effects of 
mutations in desmosomal components in keratinocytes could be used to understand the 
desmosomal defect that could cause the cardiac condition arrhythmogenic right ventricular 
cardiomyopathy (ARVC), which would otherwise be intensely difficult due to the 
unavailability of heart tissue. Taken further, the availability of skin cells that carry a particular 
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inherited mutation could be exploited by harvesting these cells and reprogramming them 
into induced pluripotent stem cells (iPS cells), which could then be differentiated into other 
cell types and used to investigate syndromic diseases affecting other, non-skin tissues.  
 
 
 
 
 
 
 
 
 
 
6.5. Concluding remarks 
This thesis has focussed on investigations into the pathophysiology of three rare, inherited 
diseases, and has sought to offer physiological explanations as to the mechanisms by which 
mutations in the associated genes – ADAM17, RHBDF2 and PLA2G4A – result in the various 
phenotypes that characterise these conditions. It is particularly interesting to have observed 
that two distinct diseases, an ADAM17 loss-of-function-associated syndrome and tylosis with 
oesophageal cancer, have pathophysiologies that essentially reflect the down- and 
upregulation of the same gene (ADAM17), with entirely different consequences.  
Taken together, the data presented here underscore both the power of next-generation 
genotyping technologies, and the utility of combining these with well-understood cell and 
molecular biology techniques, in the investigation and understanding of rare and complex 
inherited diseases. 
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7. Appendices 
 
7.1. Appendix 1: Primers and probes used in genotyping and qPCR studies 
Table A1.1: Primers used for ADAM17 genotyping 
ADAM17 
Exon (s) Forward Primer Reverse Primer 
Product 
Size (bp) 
1 CTGCTCTTCCCTCAAACGAG CTTCCGGCTGTGGGTGG 411
2 CCCAAGATTTCAGTAGATACCCTT GTCTGGCACTCTCATTTTAACGA 302
3 CTGCACCAGAAAAGAATATGCA TGAGACTTAAAATTTGTGTGCTT 271
4 CTGAGCAGCTTTTTGAAAATCAG TTGAGAGTAATGCATAGTTTCTTAT 221
5 AAGAACAAGCAAAGAATGTTAGAAGA GGAACAAACCTCTTATTTTCATGC 306
6 CATGGAATGTACCCACCCAA ACTCCTTGTTTTGGTGAATTTTGA 246
7 AGGTTTTGAATACAAGTGACAAA CAGGAGAGGTAAAGAGTTACAT 217
8 TCCTTCATTAAAACACATACAATCC GAGCCTTCTGACTTATTTTGGA 250
9 & 10 ACTGAGGTTCTACTACAATAAACT CATCTTTTAGTCTGATGTAATTGTT 477
11 TGATCATTATACACAGCCTCTTTCC TTTAAGACAGCATAGGCCCAAC 294
12 CCTGCAAGTTCAGTCTTCTCTTA ATTGCATGGGAATACATTTTTATGA 340
13 TCATCTGAACAAAACATAATCTTGT CGTTTGATTTGATATGGGGCC 253
14 GCAGACAAAGGCCATGTTTTC GCACCTGTAGAACTGGTGGA 252
15 ACTTCCTATCTGGCTGTTACA AGAGGCAGGTCTCAGAACAA 228
16 TCATCACAGAAATTGACTCAGCT TGCTTCTGAATACATTGTGTTTGG 189
17 CCAGAGATTACATGGTTGGAGT TTTGTGAAGTACTTGGTCAAGA 209
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Table A1.2: Primers used for PLA2G4A (cPLA2α) genotyping 
PLA2G4A 
Exon (s) Forward Primer Reverse Primer 
Product 
Size (bp) 
1 AAAGCGCAAGGAGACCAGCCC GAGGGTGGGAGAGAGAAGTGGAGC 190
2 ACTGCATCCAAGAGGAAGCTTAACA AGCAACACCCGCAATATTCACAGA 224
3 GTTTCTGGTATGCATGCTACTTGTT AGGCAGAACCTCCGATTTGTCA 288
4 ACCTCCTTCTTGTTTGTGTTTACT GGACAAACTCAAGCATGTCTCTCA 249
5 TCCATGGGAAATTTTATTTTTGTGC CCAAGTGTTAAACCCAACTTCCC 239
6 AGGGTCTTCATGGAGCTGTGT AGTGGATCACTCACAATATTTCTCA 239
7 AAACCAGACCACTGGGAGCA TTGGGGAAATTGTCCAAGCTAAA 261
8 GTGTACAAATCTCTCTGTTGCATCG TCCCCTTTTCTCTTCTAGTGCTTG 251
9  ACAGAGTGTGCCTTCTTTCTTTGG ACGCATAGTTGGACAAATAAGTAGA 437
10 TGAATAGCATTCTTTCTGTGTCTGT TGCAATTCAGAGGTTCCAGGAAGT 229
11 & 12 TAATTGTGCACACCATGCCA AGCAAGATTTGTATCAATGTAAGCA 431
13 GATCTCACTCTGTGGTTTTGCTCA ATCCTTTCCTCATGGATCTGGGC 220
14 TTTGGAGTCTGTATGGTGACCTTTT TCTCCTGCATTAGCTCCCACT 321
15 GTCTCCAAAGCCTGAGGGCCTA AAGGCAAGCAAGAGAATGTGGT 362
16 TGCTGGCACACAGTAGACACCT GCTGGTACAGCAGTGACAGAGTGA 394
17 TGGGGACTCCCACTGCTGTCT AGTGGCATATTTTGGGTGGTGTCAT 392
18 GCAGCGCTAATTATACAACTTCTGT GGGATTGCAAACTGCCTCAGC 222
 
Table A1.3: Primers used for TaqMan qPCR 
Gene Forward Primer Reverse Primer Product Size (bp) 
ADAM17 GGTTCCTTTCGTGCTGGCGC AAGCTTCTCGAGTCTCTGGTGGG 73
GAPDH TGGCCCCTCCGGGAAACTGT CCTTGCCCACAGCCTTGGCA 92
AREG AAGGACCAATGAGAGCCCCG TAATGGCCTGAGCCGAGTATC 82
TGFA AGCATGTGTCTGCCATTCTG TGTGATGATAAGGACAGCCAGG 96
HBEGF TTCTGGCTGCAGTTCTCTCG TGGATACAGTGGGAGGGTC 105
TNF GCCCATGTTGTAGCAAACCC TATCTCTCAGCTCCACGCCA 97
IL6 CAGTTCCTGCAGAAAAAGGCAA CTGCAGCCACTGGTTCTGT 108
IL8 ACCACCGGAAGGAACCATCT GGCAAAACTGCACCTTCACAC 111
 
Table A1.4: Fluorescently-labelled probes used for TaqMan qPCR 
Gene Probe 5’ Modification 3’ modification
ADAM17 CGCGACCTCCGGATGACCCGGGCT 6-FAM BHQ-1
GAPDH GCGTGATGGCCGCGGGGCTCTCCA HEX BHQ-1
AREG GCCGGCGCCGGTGGTGCTGT 6-FAM BHQ-1
TGFA TGGCCGTGGTGGCTGCCAGCCA 6-FAM BHQ-1 
HBEGF GGCGAGAGCCTGGAGCGGCTTCGG 6-FAM BHQ-1 
TNF CGCCGGGCCAATGCCCTCCTGGCC 6-FAM BHQ-1
IL6 GCCAGCCTGCTGACGAAGCTGCAGGC 6-FAM BHQ-1
18 CTAACAGGGCCTCAGACCA CTGAATTGTATTTGTAGGGAATGAC 152
19 ACAAGCTGTGATTGATTTGTAGG TGAGGACCTCCGATTCATCTT 476
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IL8 GCTGGCCGTGGCTCTCTTGGCAGCC 6-FAM BHQ-1
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